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chaPter 1 General introduction










Rheumatoid arthritis (RA) is a systemic inflammatory disease with a potentially chronic and 
disabling disease course. It is characterised by a symmetric poly-arthritis most commonly 
affecting small joints in hands and feet.1 Chronic inflammation causes damage of bone and 
joint tissues, potentially resulting in functional disability, work disability and social and 
mental problems.2-5 Extra-articular manifestations such as cardiovascular disease, interstitial 
lung disease and rheumatoid vasculitis may shorten life expectancy, although with current 
treatment strategies their occurrence is declining.1
RA affects approximately 0.5-1% of the population of industrialized countries and most 
often women. The onset of symptoms often lies between 40 and 60 years.6 It is an auto-
immune disease, partly caused by genetic factors and partly by environmental factors, such 
as smoking.1
The classic auto-antibody in RA is rheumatoid factor (RF), consisting of immunoglobulins 
of all isotypes directed against the Fc fragment of IgG.7 The most important auto-antibodies 
for clinical practice nowadays are those directed against anti-citrullinated proteins (ACPA). 
With a specificity of about 90-97%, ACPA have a higher specificity than RF. Their presence has 
been shown years before symptoms of arthritis develop.8 In patients with undifferentiated 
arthritis (UA), presence of ACPA has shown to be predictive for the development of RA,9,10 and 
in UA as well as established RA, presence of ACPA is associated with worse disease outcomes 
such as functional disability and joint damage progression.11
classification of ra
In 2010 new American College of Rheumatology (ACR)/European League Against Rheuma-
tism (EULAR) classification criteria for RA are proposed to substitute the 1987 ACR classifi-
cation criteria.12,13(table 1) As many studies have shown that RA patients benefit from early 
introduction of disease modifying anti-rheumatic drugs (DMARDs)14-17, these new criteria 
were designed with the aim to identify and consequently treat RA patients earlier in the 
disease course. Recent data have shown that the 2010 criteria indeed classify more patients 
as RA in an earlier phase of the disease than the 1987 criteria, and their sensitivity seems to be 
higher. The potential downside is that their specificity is lower, meaning that more patients 




During the last decades, dramatic changes have taken place in the treatment of RA. Treating 
patients earlier in disease course, using combination treatment, using tight control treatment 
strategies and the introduction of biological agents have resulted in spectacular improve-
ments in disease outcomes.
Many trials in patients with recent-onset RA, often defined as a symptom duration of less 
than two years, have shown that early introduction of DMARDs more effectively suppresses 
disease activity, preserves functional ability and slows down radiological damage progres-
sion than delayed start of treatment.14,17 Even more studies suggest the benefit of starting 
DMARD combination therapy, in particular together with glucocorticosteroids, instead of 
monotherapy on similar disease outcomes.20-22 The concept of tight control treatment, tar-
geted at a predefined treatment goal such as a low disease activity, has also been shown to 
be superior to conventional non-targeted ways of treating patients.23 Finally, the introduction 
of biological agents in the 1990s has improved disease outcomes. Combining a DMARD with 
a biological agent has been shown to be more effective than DMARD-monotherapy 13,16,24,25 
table 1: The 2010 ACR/EULAR classification criteria for rheumatoid arthritis.13 
Target population: patients who
1) have at least 1 joint with definitive clinical synovitis
2) with the synovitis not better explained by another disease
A score ≥ 6/10 is needed for classification as RA
Score
Joint involvement
1 large joint 0
2-10 large joints 1
1-3 small joints 2
4-10 small joints 3
> 10 joints (at least 1 small joint) 5
Serology
Negative RF and negative ACPA 0
Low-positive RF or low-positive ACPA 2
High-positive RF or high-positive ACPA 3
Acute phase reactants
Normal CRP and normal ESR 0
Increased CRP or increased ESR 1
Symptom duration
< 6 weeks 0
≥ 6 weeks 1









 1or multiple DMARDs.26 The EULAR recommendations for the management of RA recommend 
to start DMARD-monotherapy as soon as RA is diagnosed, to steer treatment at low disease 
activity or even remission, to expand to combination therapy as soon as monotherapy seems 
to fail and to switch to combination therapy with a biological agent, anti-TNF alpha being 
first choice, as soon as the treatment target is not reached with multiple DMARDs.27 Although 
biological agents are very effective, they are also expensive and may have (infectious) side 
effects 28, making the need to search for less expensive alternatives ongoing. Treatment 
combinations including glucocorticosteroids may be one of those alternatives. Low dose 
glucocorticosteroids have previously been shown to suppress radiological joint damage 
progression when used as monotherapy and in combination with a DMARD.29-31 Adding a 
tapered high dose of prednisone to multiple DMARDs has even been shown to be equally ef-
fective as methotrexate (MTX) in combination with infliximab in terms of controlling disease 
activity and suppressing radiological progression.16 
Although both doctors and patients have concerns about the side effects of glucocorti-
costeroids, such as the enlarged risk of cardiovascular disease, diabetes and osteoporosis,32 
there is, at least on short term, no clear evidence that low doses of glucocorticosteroids cause 
more side effect than placebo treatment. There has even been a suggestion that low dose glu-
cocorticosteroids result in fewer side effects when given as part of combination therapy.33,34 
In the EULAR recommendations for the management of RA (2010) it is recommended to add 
low to moderate high doses of glucocorticosteroids to initial DMARD mono- or combination 
therapy, but it should be tapered as rapidly as clinically feasible.27
disease outcomes
Due to improving treatment strategies, treatment goals have changed over time and the bar 
has been set higher and higher. Nowadays we are not satisfied until total disease control has 
been achieved, by trying to rapidly lower disease activity aiming for remission and even drug 
free remission, trying to prevent radiological damage progression, to preserve functional and 
working ability and to normalize quality of life.
In clinical trials, remission and drug free remission have become attainable treatment 
goals, although not for all patients.35-37 Several definitions for remission have been used. The 
Disease Activity Score (DAS), a composite score including a swollen joint count, a tender joint 
count (using the Ritchie Articular Index), laboratory data (Erythrocyte Sedimentation Rate 
(ESR) or C-reactive protein (CRP)) and the patient’s opinion (Visual Analogue Scale (VAS) for 
global health) reflects low disease activity if the score is ≤ 2.4. A cut off point of 1.6 has been 
shown to correspond with the 1981 ACR preliminary criteria for clinical remission, which are 
less easy to apply.38,39 Other composite scores have their own cut offs to denote remission. In 
the hope to create a uniform definition for remission, a joint committee of the ACR, EULAR 
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and Outcome Measures in Rheumatology (OMERACT) proposed two new definitions for 
remission in 2011. The first so called ‘Boolean based definition’ is defined as a tender joint 
count, swollen joint count, CRP (mg/dl) and VAS global health (1 to 10 scale) all ≤ 1.(table 2) 
The second definition is defined as a Simplified Disease Activity Index is ≤ 3.3.40 In chapters 
3 and 4 of this thesis we used both the DAS-definition and the Boolean-based definition for 
remission to calculate remission rates after one year in the Induction therapy with Methotrex-
ate and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED) study.
The amount of joint damage progression in RA has declined last decades due to more 
adequate suppression of disease activity by improved treatment strategies. An often used 
method for assessing radiological damage is the modified Sharp-van der Heijde Score (SHS), 
in which the amount of erosiveness and joint space narrowing is scored in 44 joints of the 
hand and feet.41
Less has been published about so called ‘Patient Reported Outcomes’ (PROs), which 
represent health related quality of life (HRQoL). In RA, pain and functional limitations can 
cause impairment in social, emotional and psychological functioning, such as anxiety and 
depressive symptoms.4 PROs can be disease specific, such as the McMaster Toronto Arthritis 
questionnaire (MACTAR), or generic such as the Health Assessment Questionnaire (HAQ) 
and the Short Form (SF)-36. The BeSt study showed that patients with early RA suffer from 
impaired functional ability and HRQoL compared to the general population, and that current 
treatment strategies are able to improve, but not normalize HRQoL.42 In chapter 5 of this 
thesis the question whether HRQoL measures can be improved more or even be normalized 
with the proper treatment strategy, will be answered. In chapter 7 we investigate whether 
patients with early (rheumatoid) arthritis experience symptoms of depression, whether their 
disease affects their state of optimism and the effect of four months of remission induction 
therapy on depressive symptoms and optimism scores.43,44
undifferentiated arthritis
If no definitive diagnosis can be made in patients with an inflammatory mono-, oligo- or 
poly-arthritis, they are said to have undifferentiated arthritis (UA). Over time, this syndrome 
may naturally evolve into a chronic inflammatory disease or into remission. Several observa-
table 2: ACR/EULAR Boolean-based definition of remission in rheumatoid arthritis clinical trials.40
At any time point, patient must satisfy all of the following:
Tender joint count ≤ 1
Swollen joint count ≤ 1
C reactive protein (mg/dl) ≤ 1








 1tional cohorts of early arthritis patients have shown that, depending on the inclusion criteria, 
17-32% of the patients progress to RA,45 while 40-55% achieve spontaneous remission.46,47 
The remaining patients continue to have symptoms of UA or develop other inflammatory 
diseases. In those patients who over time develop a chronic poly-arthritis, UA can be seen as 
an early stage of RA.
treatment of ua
Major improvements achieved by starting treatment soon after RA has been diagnosed, have 
raised the question whether treating patients even earlier, already in the phase of UA, may 
be even more beneficial. It has been suggested that, as in other inflammatory diseases such 
as diabetes type I or Morbus Crohn,48,49 in an early stage of RA a time period exist in which 
appropriate treatment may reverse the auto-immune process and alter the disease course. It 
is hypothesized that intensive treatment in this so called ‘window of opportunity’ may result 
in long-term sustained benefits, may prevent RA from becoming a chronic disease and may 
even cure the disease.50,51
To date, only few placebo controlled randomized controlled trials (RCTs) have investigated 
whether treatment of UA patients is really beneficial. Also, definitions for UA, therapies tested 
and outcome measures vary considerably among these trials, which impedes making com-
parisons and drawing conclusions. However, these trials and a number of cohort studies 
indicate that treating patients in the phase of UA may indeed be advantageous.52-59 Chapter 2 
of this thesis gives an overview of trials a cohort studies, obtained from a systematic literature 
search on the treatment of UA patients.
The IMPROVED study is the first trial in which both UA and RA patients are included, en-
abling a head to head comparison of introducing therapy in patients who recently fulfilled 
the classification criteria for RA with introducing therapy in the phase of UA, when classifica-
tion criteria are not (yet) met. Data from this trial are used in most parts of this thesis. More 
details on the IMPROVED study are described below.
the imProVed study
The IMPROVED study, acronym for Induction therapy with Methotrexate and Prednisone 
in Rheumatoid Or Very Early arthritic Disease, is a multi-centre, randomized, single blinded 
clinical trial in patients with undifferentiated and early rheumatoid arthritis. The trial was de-




Previously, the PROMPT study had shown that in patients with UA the development of RA 
could be postponed but not prevented by one year of targeted treatment with MTX mono-
therapy.53,60 The BeSt study showed that in patients with early RA a combination of synthetic 
DMARDs with a tapered high dose of prednisone, earlier investigated in the COBRA trial,22 
was equally effective in suppressing disease activity and radiological damage progression 
as combination therapy including a biological agent.16,21 One question that had risen after 
these trials were done, was whether treating patients earlier, already in the phase of UA, and 
with combination therapy consisting of MTX and a tapered high dose of prednisone, would 
improve disease outcomes even more. Because starting treatment this early in disease course 
could lead to overtreatment of patients who might have achieved spontaneous remission, a 
second important question was if it would be possible to taper medication as soon as remis-
sion was achieved, and if drug free remission (DFR) was an attainable treatment goal. A third 
essential question was what would be the next best treatment in patients failing on initial 
combination therapy. Finally, as in the BeSt study and TICORA trial targeting treatment at 
low disease activity appeared to be very advantageous, 21,61 a last question was if steering at 
an even more stringent target, namely remission defined as a DAS <1.6, would lead to better 
disease outcomes.
To address these questions, the IMPROVED study was designed. Patients were treated ac-
cording to a tight controlled protocol and treatment was steered at remission, defined as 
a DAS <1.6. As soon as remission was achieved, medication was tapered, if remission was 
not achieved medication was restarted or intensified. The trial started with an open label 













































figure 1: Study flow chart and main results of the first year of the IMPROVED study.








 1remission induction phase, in which all patients were treated with MTX in combination with 
a high dose of prednisone, tapered in 7 weeks from 60 mg/day to 7.5 mg/day, continued up 
to 4 months. Patients in remission after 4 months of this initial combination treatment (early 
remission) started tapering medication, if possible to drug free. Patients not in early remission 
were randomized to either combination therapy with MTX, sulfasalazine, hydroxychloroquine 
and low dose prednisone (7.5 mg/day) or to MTX in combination with adalimumab.(figure 1)
Patients were recruited between March 2007 and September 2010 in 12 hospitals in the 
Western part of the Netherlands. Patients were included if they fulfilled the 1987 criteria for 
RA with a symptom duration of less than 2 years (RA patients), or if they had at least one 
arthritic and one other painful joint regardless of symptom duration but not fulfilled the 1987 
criteria for RA (UA patients). As in 2010, after inclusion was closed, new classification criteria 
for RA were proposed,62 we reclassified all patients according to the new criteria. UA was now 
defined as having at least one arthritic and one other painful joint but not fulfilling the 2010 
criteria for RA.
Primary outcomes are percentages achieved remission (defined as a DAS <1.6) and drug 
free remission, functional ability (measured by HAQ) and progression of joint damage (as-
sessed by SHS) in UA and RA patients, in patients achieving early remission and in random-
ized patients, after one, two and five years of follow up. Secondary outcomes were, among 
others, DAS and PROs such as MACTAR and SF-36.
Predicting disease outcome
As we now tend to treat RA patients earlier, already in the stage of UA, and more intensively, 
we face the risk of overtreatment of those patients who would have achieved remission 
spontaneously or with a less intensive treatment strategy. Predicting disease outcome in RA, 
or even better in UA patients, can distinguish patients with a more severe disease course 
needing progressive treatment strategies from those with less severe disease. Up to now, we 
can only partly predict disease outcome and there is a need for new predictors to improve 
existing prediction models.63-66 A new potential predictor is early metacarpal bone mineral 
density loss.
bone loss and digital X-ray radiogrammetry
The earliest radiological manifestation present in patients with RA is peri-articular bone loss, 
which has been shown already in the phase of UA and precedes erosions.67-69 A higher disease 
activity is associated with more peri-articular bone loss.70,71 It is hypothesized that inflamma-
tory cytokines such as TNF alpha, IL-1, IL-6 and IL-17 induce bone resorption by stimulating 
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osteoclasts through up-regulation of receptor activator of nuclear factor κB ligand (RANKL). 
It is also thought that inflammatory cytokines suppress bone formation by suppressing 
osteoblast activity through blocking the Wnt pathway by inducing dickkopf-1 (Dkk-1) and 
sclerostin.72
Peri-articular bone loss can be measured in metacarpal bones by Digital X-ray radiogram-
metry (DXR). This is a computerised method to estimate metacarpal bone mineral density 
on digital X-rays of the hands. In the middle three metacarpals, three regions of interest are 
automatically identified. Per region, multiple measurements contribute to an average cortical 
thickness and bone width, and from these the final metacarpal bone mineral density (BMD) 
is calculated.73
Metacarpal BMD loss is present in (early) RA and shown to be associated with disease activ-
ity.71,74,75 Also, metacarpal BMD loss after 1 year has previously been shown to be predictive 
for radiological damage up to five years in patients with RA.68,76-78
aims and outline of thesis
This thesis focuses on improving disease outcomes in patients with undifferentiated and early 
rheumatoid arthritis by new treatment strategies. For all analyses, data from the IMPROVED 
study were used. Important questions are addressed, such as ‘do patients benefit from early 
treatment, even before they fulfill classification criteria for RA?’ and ‘is it possible to taper 
medication as soon as remission is achieved, with the ultimate goal of achieving sustained 
drug free remission?’ and one of the most challenging questions ‘can we alter the disease 
course of RA by early introduction of treatment?’.
Chapter 2 gives an overview of all literature published on drug therapy in patients with 
undifferentiated arthritis until February 2012. In chapter 3 main outcomes after 4 months of 
remission induction therapy in patients with early (rheumatoid) arthritis in the IMPROVED 
study are given. Both in chapters 4 and 5 outcomes after one year of early remission steered 
treatment in the IMPROVED trial are analysed. In chapter 4 primary outcomes and in chapter 
5 patient reported outcomes are evaluated. In chapter 6 determinants of drug free remission 
are explored in those IMPROVED patients who achieve early remission. Chapter 7 addresses 
the questions whether patients with early RA have depressive symptoms, either as a side 
effect of medication or as response to changes in (symptoms of ) disease activity. In chapter 
8 the predictive value of metacarpal bone mineral density loss after 4 months for future joint 
damage is evaluated. Chapter 9 describes changes in metacarpal bone mineral density dur-
ing the first year of remission steered treatment in the IMPROVED study. Finally, an overview 
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Undifferentiated arthritis (UA) is defined as an inflammatory oligo- or polyarthritis in which 
no definitive diagnosis can be made. We performed a systematic literature review to assess 
the efficacy of various drug therapies in patients with UA.
methods
The systematic literature search was conducted using electronic databases Pubmed, EMBASE 
and MEDLINE in adults with undifferentiated or early arthritis (not fulfilling the ACR 1987 or 
ACR/EULAR 2010 criteria for RA). Drug therapy consisted of disease modifying anti-rheumatic 
drugs (DMARDs), biological agents and oral, intra-muscular (IM) or intra-articular corticoste-
roids.
results
Nine publications on 8 randomized controlled trials (RCTs), 2 publications on 2 uncontrolled 
open-label trials and 7 publications on 3 cohort studies were included. Temporary treatment 
with methotrexate (MTX), abatacept and IM corticosteroids were demonstrated in RCTs with 
12 months to 5 years follow up to be more effective than placebo in suppressing disease 
activity or radiologic progression. One study suggests that DMARD combination therapy is, at 
least after 4 months, superior to MTX monotherapy in UA patients at high risk of developing 
persistent arthritis. The open label uncontrolled trials and cohort studies also suggested that 
early treatment may provide immediate suppression of inflammation. The long term benefit 
of early treatment in UA remains unclear.
conclusions
UA patients benefit from early treatment with MTX. Combining multiple DMARDs or DMARDs 
with corticosteroids and biological agents may be even more beneficial. However, which 
treatment may provide the best results or may alter the disease course still has to be deter-
mined. More randomized clinical trials with longer follow up time are needed.
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Undifferentiated arthritis (UA) is defined as an inflammatory oligo- or polyarthritis in which 
no definitive diagnosis can be made, and which over time may naturally evolve into a chronic 
inflammatory disease or into remission. Several observational cohorts of early arthritis pa-
tients have shown that, depending on the inclusion criteria, 17-32% of the patients progress 
to rheumatoid arthritis (RA),1 while 40-55% achieve spontaneous remission.2,3
Since many studies have proven that early treatment of RA improves clinical, functional 
and radiological outcomes,4-6 the question has risen if treatment in the stage of UA may be 
even more beneficial. The so called ‘window of opportunity theory’ hypothesizes that in an 
early stage of RA, possibly in the stage of UA, a period may exist in which the disease course 
can be altered by the appropriate treatment, preventing it from becoming a chronic and 
disabling disease.7 In 2010, new classification criteria have been published to enable earlier 
diagnosis and treatment of RA patients.8 Recent data have shown that patient indeed are 
diagnosed earlier,9 but the benefit of the new criteria in terms of long term disease outcome 
still needs to be elucidated. Furthermore, also with these new criteria part of the patients 
with inflammatory oligo- or polyarthritis cannot (yet) be classified as RA.
To investigate whether early initiation of disease modifying anti-rheumatic drugs (DMARDs) 
is beneficial for patients with UA, we performed a systematic literature review to identify all 
articles on disease outcomes of drug treatment in patients with UA, and aimed to assess the 
efficacy of the different drug therapies.
methods
The systematic literature search was conducted using electronic databases Pubmed, EMBASE 
and MEDLINE and restricted to adults with UA or early arthritis (not fulfilling the ACR 1987 or 
ACR/EULAR 2010 classification criteria for RA). The following definitions were searched for up 
to February 2012: undifferentiated or early or unclassified or probable (inflammatory) arthritis 
or oligo- or polyarthritis. Drug treatment was restricted to glucocorticosteroids, DMARDs and 
biological agents. Articles were only included if they concerned disease outcomes of drug 
therapy. All types of publications were included and no language restrictions were used.
Using predefined inclusion criteria, titles and abstracts were screened by one researcher 
and checked up by a second researcher. Disagreements were solved by discussion. Of the 
selected articles, full texts were screened for final selection in the review. Reference lists of 
included review articles were hand searched for additional relevant articles. Data extraction 
was performed by one researcher. Methodological quality of included randomized con-
trolled trials (RCTs) was assessed by two independent researchers following the Guidelines 
for Cochrane Musculoskeletal Group Systematic Reviews, using the Cochrane Collaboration’s 
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tool for assessing risk of bias.10 For each study, the risk of several types of bias (selection, per-
formance, detection, attrition and reporting bias and ‘other sources of bias’) was judged and 
summarized in an overall risk as low, high or unclear. Also, the Jadad score was performed, a 
quality score assessing randomization, blinding, withdrawals and drop outs.11 Scores range 
from 0-5 with higher scores indicating better methodological quality.
Because of the large heterogeneity in types of patients, drug therapies and outcome mea-
sures no meta-analysis was performed.
results
After screening 3608 titles and abstracts, 67 articles were screened full text.
In total 30 articles were selected: 11 on 10 clinical trials of which 8 were RCTs and 5 placebo 
controlled, 7 on 3 cohort studies, and 10 review/opinion articles and 2 recommendations 
which were disregarded for this analysis.(figure 1)
Electronic database searching n=3608
Exclusion on titles and abstracts n=3541
(3223 concerning RA)
Fulltext articles screened n=67
Exclusion on full text n=35:
(28 not concerning UA, 7 not concerning 
outcomes of drug treatment)
Total inclusion n=32:
RCT’s n=9
Open label uncontrolled trials n=2





Open label uncontrolled trials n=2 
Observational cohort studies n=7
Reviews and recommendations excluded after 
screening reference lists n=14
figure 1: Flow diagram of systematic literature search for publications on drug treatment of patients with 
undifferentiated arthritis.
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Characteristics of clinical trials are shown in table 1. Three trials included both UA and RA 
patients.12-14 Drug therapies studied were intra-muscular (IM) or intra-articular (IA) corticoste-
roids (3 RCTs, 2 placebo controlled, 1 open label trial), DMARDs with or without oral gluco-
corticoids (GCs) (2 RCTs, 1 placebo controlled, 1 open label trial), biological agents (2 placebo 
controlled RCTs) and one RCT comparing tight control with ‘routine DMARD’ treatment. On 
one placebo controlled RCT two articles with different follow up duration were published.
Characteristics of observational studies are shown in table 2. Five of 7 publications were 
based on the Norfolk Arthritis Register (NOAR), a primary care-based cohort in adults with 
≥2 swollen joints for at least 4 weeks, of which 46% at baseline fulfilled the 1987 criteria for 
RA.15 Four studies compared treated and untreated patients and/or early versus delayed start 
of treatment. Adjustments for differences in disease severity or time dependent confounders 
between groups were made using propensity scores or marginal structural models (MSM). 
One publication comparing anti-citrullinated protein antibodies (ACPA) positive and nega-
tive patients and two publications without comparisons between treated and/or untreated 
patients are not further mentioned.
Main outcomes of all included clinical trials are shown in table 3. Seven clinical trials in-
vestigated temporary treatment and 3 trials continuous tight controlled treatment. Follow 
up varied between 3 months and 5 years. Many different outcome measures were used for 
assessing response to treatment in terms of disease activity state, achieving remission, joint 
damage or progression to RA.
results of synthetic dmards
Van Dongen et al 16 and van Aken et al 17 compared a 12 months course of methotrexate 
(MTX) with placebo after 30 months and 5 years follow up. After 30 months 22 (40%) in the 
MTX group and 29 (53%) in the placebo group had progressed to RA(1987 criteria) (p value 
not published), after 5 years 25 (45%) and 29 (53%) did (p=0.45). Remission was achieved 
in comparable numbers after 30 months and 5 years (after 30 months 15 (27%) and 13 
(24%) and after 5 years 20 (36%) and 15 (27%) in the MTX and placebo group respectively 
(p-values not published)). All patients in the placebo group who progressed to RA did so 
within one year compared to half of the patients in the MTX group (p=0.04), suggesting that 
progression to RA was at least postponed by one year of MTX treatment. After 30 months, 
more patients showed radiological progression in the placebo group (14 versus 6, p=0.046), 
but after 5 years median SHS progression did not differ between groups (p=0.78). Up to 30 
months, fewer adverse events (AE) were reported in the placebo group, serious AE (SAE) were 
reported similarly in both groups.
De Jong et al 14 compared MTX monotherapy with MTX+sulphasalazine (SSZ)+ hydroxy-
chloroquine (HCQ) in early arthritis patients at high risk for developing persistent arthritis 
according to the prediction model of Visser et al.18 All patients received GC bridging therapy 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































had a lower mean Disease Activity Score (DAS) than the monotherapy group (difference (95% 
CI) 0.39 (0.67-0.11)). No significant difference was seen between oral and IM GC bridging 
therapy. AE and SAE were reported in 67 (75%) and 50 (56%) in the combination therapy and 
the monotherapy group. Fewer medication changes were made in the monotherapy group 
(14 (16%) versus 18 (20%), p=0.006).
In an open label trial in patients with UA or recent onset RA(2010 criteria),13 MTX was com-
bined with a tapered high dose of prednisone for 4 months. Remission after 4 months was 
achieved in 79 (65%) UA and 291 (61%) RA patients (p=0.5). Median (IQR) SHS progression 
was 0 (0-0) in both UA and RA patients (p=0.9). AE were reported in 341 (56%) and SAE in 16 
(3%) of all patients.
These studies indicate that synthetic DMARDs suppress disease activity in UA patients. MTX 
monotherapy may postpone but not prevent the development of RA and may slow down 
radiological progression. It appears that initial combination therapy with MTX and multiple 
DMARDs or corticosteroids (oral or parenteral) results in better short term clinical outcomes. 
No long term data are available.
results of biological dmards
Two trials have investigated biological agents in UA patients. Saleem et al 19 compared a 14 
week course of infliximab with placebo in UA patients who had relapsed after a single cor-
ticosteroid injection. If clinical inflammation was persistent after week 14, MTX was started. 
Independent safety monitors halted recruitment ‘because of poor outcomes in all subjects’ 
before inclusion was completed, after inclusion of 17 patients (10 randomized to infliximab, 
7 to placebo) Clinical remission at 26 weeks was achieved in 1 patient and 2 patients in the 
placebo and infliximab group respectively. After 1 year, all patients in the infliximab group 
had progressed to RA (1987 criteria) compared to 5/7 in the placebo group, in which this 
occurred earlier (after a median of 14 compared with 26 weeks, respectively). Data on (S)AE 
were not reported.
Emery et al 20 compared a six months course of abatacept with placebo. After 1 year, re-
spectively 12 (46%) and 16 (67%) of the abatacept and placebo group progressed to RA(1987 
criteria) (difference (95% CI) -21% (-47% to 8%)). Radiologic progression (Genant-modified 
Sharp score) after one year was significantly less in the abatacept group (difference in total 
score -1.10 (95% CI -2.05 to -0.15)). Remission (DAS28 definition) after 1 year was achieved in 
9 (47%) and 5 (39%) in the abatacept and placebo group respectively. Numbers of reported 
AE and SAE were similar.
These trials suggest that a biological agent may slow down progression to RA in UA pa-
tients. Early treatment with abatacept appears to suppress radiological damage progression. 
Long term benefits remain uncertain.
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results of corticosteroid injections
Green at al 21 performed an open label pilot with IA GC injections in all arthritic joints in 
51 patients. Clinical synovitis was absent in 23 (45%) and 26 (51%) after 12 weeks one year 
respectively.
Marzo-Ortega et al 22 injected all inflamed joints with GC (early intervention (EI) group) and 
compared this with ‘conservative treatment’ (CT group) with a nonsteroidal anti-inflammatory 
drugs (NSAID). In case of progression to polyarthritis SSZ was started. Clinical synovitis was 
absent in 25 (81%) and 16 (57%) patients after 52 weeks in the EI and CT group respectively 
(p=0.05), but more patients in the EI group started DMARD treatment (14 (45%) versus 4 
(14%), p=0.012). The EI group reported a significantly lower mean Visual Analogue Scale 
(VAS) pain after 4 weeks than the CT group, but not after 12 and 52 weeks. Data on (serious) 
AE were not reported.
Machold et al 23 compared a single IM injection of GC with placebo. Respectively 32 (16%) 
and 33 (18%) in the GC and placebo group achieved persistent remission without additional 
treatment after 1 year (p=0.68). Initiation of a DMARD and core set variables were compa-
rable. AE generally were mild and comparable between groups.
Verstappen et al 24 compared a three week course of IM GC injections with placebo. When 
patients met ≥2 of 4 predefined criteria (≥3 swollen joints, ≥6 painful joints, morning stiffness 
≥45 minutes or erythrocyte sedimentation rate ≥28 mm/h), they were referred for DMARD 
treatment. After 6 months, patients in the placebo group were more often referred for DMARD 
treatment than the GC group (96 (76%) versus 77 (61%), adjusted OR (95% CI) 2.11 (1.16-3.85), 
p=0.015). After 1 year, remission without DMARD use was less often achieved in the placebo 
group (11 (10%) versus 22 (20%), adjusted OR (95% CI) 0.42 (0.18-0.99), p=0.048). Sixty seven 
(60%) and 54 (49%) in the placebo and GC group were classified as RA(1987 criteria) (adjusted 
OR (95% CI) 1.58 (0.85-2.93), p=0.15). AE were comparable between groups.
These studies indicate that a single corticosteroid injection probably has no long term 
benefit. Repeated IM corticosteroid injections may postpone the need to start DMARDs but 
not prevent progression to RA, and in one study possibly encourage remission. No long term 
follow up data exist.
results of tight control and treat to target strategies
Van Eijk et al 12 compared tight control treatment (TC group) with conventional care (CC group) 
in early arthritis patients. The TC group (n=42) started with MTX monotherapy, medication 
was intensified in case of no remission (19 patients changed to adalimumab, 15 increased 
adalimumab, 11 switched to multiple DMARDs , 3 added prednisone and 1 switched to leflu-
nomide). The CC group (n=40) used conventional DMARDs without treatment target (24, 14 
and two patients started HCQ, MTX and SSZ respectively). No prednisone or biologics were 
allowed. After 2 years, respectively 66% and 49% in the TC and CC group were in remission 
(numbers and p-value not published). Median SHS progression was 0 (0-1.0) and 0.25 (0-2.5) 
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in the TC and CC group (p=0.17). Over two years, no significant differences in DAS and Health 
Assessment Questionnaire (HAQ) levels were seen. The number of reported AE was higher in 
the TC group (62 versus 35, p=0.03). The number of SAE was comparable.
In conclusion, this trial shows no benefit to patients with UA of tight control treatment over 
conventional care in terms of radiological and clinical outcomes and achieving remission.
early versus delayed treatment
No RCTs compared early versus delayed start of treatment in patients with UA. In an open 
label study 13 no difference in proportions remission was found between UA and RA (2010 
criteria) patients after a four months of MTX and a tapered high dose of prednisone. But 
although UA patients had a lower baseline DAS, baseline symptom duration was similar 
between UA and RA patients.
In an observational study in the ESPOIR cohort, Lukas et al 25 compared early versus delayed 
treatment, adjusted for selection bias using propensity scores. The estimated marginal mean 
(SE) SHS progression was 0.8 (0.37) and 1.7 (0.19) in patients who respectively started DMARD 
therapy within and after 3 months (p=0.03). Stratification in propensity quintiles showed 
that only patients with high baseline disease activity starting DMARD therapy after 3 months 
showed more progression than patients starting within 3 months.
Bukhari et al 26 found a similar result in the NOAR cohort, also using propensity scores. 
Starting treatment within 6 months after symptom onset was associated with less radiologic 
damage after 5 years than starting after 6-12 months and >12 months (OR (95% CI) 1.5 (0.9-
2.3) versus 2.3 (1.4-3.9) and 2.2 (1.4-3.5) respectively, with untreated patients as reference 
(1.0)).
Wiles et al 27 compared early versus delayed treatment in the NOAR cohort using propen-
sity scores, with functional ability after 5 years as outcome. Starting treatment early (within 
6 months of symptom onset) was not associated with a HAQ score ≥1.0 (OR 0.71 (0.34 to 
1.44), but starting treatment after 6-12 and >12 months was (OR (95% CI) 1.98 (0.86 to 4.54) 
and 2.03 (1.10-3.75) respectively, with untreated patients as reference (1.0)). Farragher et al 15 
used functional ability after 10 years as outcome and adjusted for time dependent confound-
ers using MSM. Patients treated within 6 months after symptom onset improved more in 
functional ability than untreated patients, although not significantly (difference (95% CI) in 
change from baseline HAQ -0.24 (-0.58-0.09)). In patients treated after 6-12 months and >12 
months functional ability improved less than in untreated patients (difference (95% CI) in 
change from baseline of respectively 0.12 (-0.13;0.37) and 0.18 (-0.06;0.41)). For each month 
that treatment was started earlier within 6 months, a significant additional benefit was found 
(difference (95% CI) in change from baseline HAQ -0.10 (-0.19 to -0.02) per month).
In conclusion, results from these observational cohort studies may indicate that disease 
outcomes improve if treatment is started within at the most six months after symptom onset, 
and starting sooner may even be better.
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This systematic literature review shows that to date, few placebo controlled RCTs have been 
done to answer the question if early treatment in patients with undifferentiated arthritis is 
beneficial and which treatment might be the best. To compare results is difficult because of 
inconsistent outcome measures. Five clinical trials, two open label studies and four obser-
vational studies suggest that starting treatment early may provide symptom relief, improve 
functional ability and suppress radiological progression. It may also postpone progression to 
classifiable RA or the need for other therapies. The strongest evidence of a potential benefit 
is present on early treatment with MTX, possibly in combination with other DMARDs or corti-
figure 2a: Remission percentages after one year 24,20,23 and 30 months 16 follow up of the four completed 
placebo controlled trials on temporary treatment of patients with undifferentiated arthritis * significant 
difference.
figure 2b: Percentages of patients who progressed to rheumatoid arthritis after one year 24,20,23 and 30 




costeroids. Observational studies, which by using propensity scoring and minimal structural 
models try to partially compensate for indication bias, suggest that other DMARDs than MTX 
may be used. Data from these cohorts also suggest that starting treatment in UA may be 
a case of ‘the earlier the better’. The benefit of earlier treatment has been previously dem-
onstrated for patients with RA.4,5,28,29 But contrary to what is recognized and recommended 
for patients with classifiable RA,30,31 one study suggests that patients with UA may not gain 
additional benefit from tight controlled targeted treatment.12
The ultimate goals in the treatment of UA would be to prevent progression to destruc-
tive RA or even induce permanent remission. Achieving these goals would mean that the so 
called ‘window of opportunity’, in which appropriate treatment can alter the disease course, 
does exist. The closest evidence for the presence of the window of opportunity possibly 
comes from a study in 253 UA patients,24 where after a three week course of IM corticosteroid 
injections more patients achieved remission (20% versus 10%), fewer required initiation 
of DMARDs (61% versus 76%) and possibly fewer progressed to classifiable RA than in the 
placebo group (49% versus 60%). Also 6 months abatacept appears to suppress progression 
to RA, at least over 1 year follow up, although no statistically significant difference was found 
possibly due to small numbers.20 Similarly, a one year course of MTX suppressed progression 
to RA and radiological progression, but after discontinuation of MTX the disease appeared 
to rerun its course.16,17 None of the articles included data on sustained drug free remission.
Over diagnosing as ‘early RA’ followed by overtreatment is a serious concern when treating 
patients with UA, or even patients who according to the new 2010 criteria would now be 
classified as RA. Patients may have another illness that may go into spontaneous remission. 
The solution may lay in predicting disease outcome, such as persistent arthritis or radiologic 
progression, or response to treatment. Prediction models for disease outcome have been 
developed.18,32 However, to predict disease outcome and response to treatment in individual 
patients is not yet possible.
In conclusion, there are limited trials and observational studies exploring the possibility of 
inducing remission and/or permanently altering the disease course in UA patients. Long term 
follow up data are mostly not available. During treatment with MTX monotherapy, combina-
tion therapy with multiple DMARDs or corticosteroids, biological agents and intra-muscular 
corticosteroid injections, active inflammation and ensuing radiographic damage may be 
suppressed. Early initiation of treatment may be better than delayed initiation, in particular 
if disease activity appears to be high. Thus, we should optimize strategies for early referral 
and early identification of patients with arthritis. In addition, any new randomized clinical 
trials in UA patients should include a short term placebo arm to investigate if early treatment 
can induce (drug free) remission and a long term follow up period to demonstrate if early 
treatment can alter the disease course.
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Classifying more patients as rheumatoid arthritis (2010 ACR/EULAR criteria for RA) may 
improve treatment outcomes but may cause overtreatment in daily practice. We determined 
the efficacy of initial methotrexate (MTX) plus prednisone treatment in patients with 1987 or 
2010 classified RA and undifferentiated arthritis (UA).
methods
Six-hundred-ten patients with recent onset RA or UA started with MTX 25 mg/week and pred-
nisone 60 mg/day tapered to 7.5 mg/day in 7 weeks. Percentages remission after 4 months 
were compared between RA (1987 or 2010 criteria) and UA. Predictors for remission were 
identified.
results
With the 2010 criteria 19% more patients were classified as RA than with the 1987 criteria, 
but similar remission rates were achieved: 291/479 (61%) 2010 classified RA and 211/365 
(58%) 1987 classified RA patients (p=0.52), and 79/122 (65%) UA (p=0.46). ACPA positive RA 
patients achieved more remission (66%) than ACPA negative RA patients (51%, p=0.001), but 
also had a lower mean baseline DAS (3.2 versus 3.6, p<0.001). ACPA negative RA patients 
who achieved remission had a shorter median symptom duration. Independent predictors 
for remission were male sex, low joint counts, DAS and HAQ, low Body Mass Index (BMI) and 
ACPA positivity.
conclusions
Initial treatment with MTX and a tapered high dose of prednisone results in similarly high 
remission percentages after four months (about 60%) in RA patients, regardless of fulfilling 
the 1987 or 2010 criteria, and UA patients. Independent predictors indicate that initiating 
treatment while disease activity is relatively low results in more remission.
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Starting treatment earlier in the disease course of Rheumatoid Arthritis (RA) has improved 
functional and radiological outcome as compared to delayed treatment.1-6 New RA classifica-
tion criteria support this trend,7 but have triggered concerns that some patients may now be 
misclassified and overtreated as a result.8
Remission has increasingly become a treatment goal in clinical trials, resulting in remission 
rates that vary between 26% and 42%.9
It is hypothesized that starting treatment already in the phase of Undifferentiated Arthritis 
(UA) may prevent progression to classified RA and increase permanent remission rates. How-
ever, methotrexate (MTX) monotherapy for patients with probable RA postponed but did not 
prevent progression to RA. Similar drug free remission rates (about 25%) were achieved in the 
MTX group and the placebo group.10
Since in RA initial combination treatment with prednisone leads to a more rapid clinical 
improvement and less radiological progression of joint damage than disease modifying 
anti-rheumatic drugs (DMARD) monotherapy,3,11-14 treatment with combination possibly in 
the phase of UA may increase remission and drug free remission rates, as well as improve 
short-term functional outcome and long-term joint damage progression.
To investigate this, we designed the IMPROVED (Induction therapy with Methotrexate 
and Prednisone in Rheumatoid Or Very Early arthritic Disease) study, the first clinical trial in 
patients with UA and early RA, with an induction phase with MTX and a tapered high dose 
of prednisone, aimed at achieving remission. This trial allowed us to evaluate the effect of 
classifying patient groups according to the old and the new RA classification criteria and to 
identify predictors of remission.
methods
study design
The IMPROVED-study is a multicenter, clinical trial in recent onset RA and UA patients. All 
patients were initially treated for four months with MTX 25 mg/week and a tapered high 
dose of prednisone, starting with 60 mg/day, tapered in 7 weeks to 7.5 mg/day, continued 
in this dose up to four months. Later, this introduction phase will be followed by a single 
blind randomized controlled trial, where those patients who did not achieve remission will 
be treated according to two treatment strategies; one starting with a combination of MTX, 
sulfasalazine, hydroxychloroquine and low dose prednisone, the other with a combination of 
MTX with adalimumab.
Rheumatologists participating in the Foundation for Applied Rheumatology Research 
(FARR) designed and conducted the study. Patients were recruited between March 2007 and 
CHAPTER 3
42
September 2010 in 12 hospitals in the Western part of the Netherlands. The Medical Ethics 
Committee of each participating centre approved the study protocol and all patients gave 
written informed consent. The IMPROVED trial was registered in the ISRCTN Register (number 
11916566) and the EudraCT (number 2006-006186-16).
Patients
Patients with RA classified according to the 1987 American College of Rheumatology (ACR) 
criteria 15 with a symptom duration of < 2 years and UA, defined as likely to have early RA ac-
cording to the treating rheumatologist, with at least one arthritic joint and one other painful 
joint, regardless of symptom duration, were included in the trial. All patients had a disease 
activity score (DAS) ≥1.6.16
Exclusion criteria included previous therapy with DMARDs or corticosteroids, pregnancy 
or pregnancy wish during the study, malignancy within the last five years, bone marrow 
hypoplasia, elevated liver enzyme levels (alanine transaminase (AST) and/or aspartate 
transaminase (ALT) >3 times normal value), serum creatinine level >150 umol/l or estimated 
creatinine clearance of <75%, uncontrolled diabetes mellitus, uncontrolled hypertension, 
heart failure (NYHA class III/IV), alcohol or drug abuse, serious infections in the previous 3 
months or chronic infectious disease, opportunistic infections within previous 2 months, 
active or latent hepatitis B infection, documented HIV infection or AIDS, lymphoproliferative 
disease and multiple sclerosis. All patients with active tuberculosis (TB) were excluded, as 
well as UA patients with latent TB. RA patients with latent TB could be included if they started 
adequate anti-tuberculous therapy (according to local TB specialists) prior to initiation of 
high dose prednisone.
reclassification according to the 2010 acr/eular classification criteria
After inclusion was complete the new classification criteria were published. Unless specified 
otherwise (by adding the year of classification criteria between brackets), ‘RA’ in the text 
denotes RA classified according to the 2010 criteria, and ‘UA’ denotes not fulfilling the 2010 
criteria.
outcomes
Primary outcomes after four months were percentage clinical remission, defined as a DAS 
<1.6,16 disease activity measured by DAS, functional ability measured by the Health Assess-
ment Questionnaire (HAQ)17 and radiological progression using the Sharp/van der Heijde 
scoring method (SHS).18
Radiological damage was assessed by two independent readers using SHS, blinded for 
patient identity and time order of the radiographs.18 Progression was defined as an increase 
in SHS score of ≥0.5 points. Due to the small distribution of SHS scores, caused by a large 
proportion of patients without progression, the inter-observer and intra-observer intraclass 
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correlation coefficients (ICC) were not suitable for measuring reliability.19 In 91.5% of patients 
both readers scored the same progression. In the others, the median (IQR) difference in pro-
gression score between readers was 2 (2-3). A consensus score was reached for radiographs 
with inter-reader differences ≥ median difference in progression score (n=41).
Percentages remission according to ACR/EULAR preliminary definition 20 were compared 
with percentages remission based on the DAS.
statistical analysis
All outcomes were calculated according to the intention-to-treat (ITT) principle. Percentages 
remission in the RA and the UA group were compared using Chi-square test. Categorical vari-
ables were compared between groups using Chi-square test, normally distributed outcome 
measures using Independent Samples t-test and skewed outcome measures using Mann-
Whitney U-test.
Independent predictors for remission were identified using univariate followed by multi-
variate logistic regression with achieving or not achieving remission as binominal dependent 
variable. All available clinical variables were entered in a univariate regression analysis. Using 
a P-value <0.10, significant variables were then entered in the multivariate regression analysis.
results
study profile
Between March, 2007 and September, 2010, 730 patients signed informed consent and were 
screened for inclusion.(figure 1) We included 610 patients; 364 RA patients (1987 classification 
criteria) or 479 RA patients (2010 classification criteria) and 122 UA patients (i.e. not fulfilling 
the 2010 classification criteria).(table 1)
During 4 months 12 patients left the trial: 2 patients because of a revised diagnosis (1 
osteoarthritis, 1 lupus), 2 because of comorbidity, 6 withdrew consent and 2 died.(figure 1)
table 1: Classification of patients according to the 1987 ACR and the 2010 ACR/EULAR criteria for RA.
Inclusion 1987 criteria, no (%) RA (1987): 364 (60%) UA: 246 (40%)
Reclassification 2010 criteria, no (%)* RA (2010): 479 (79%) UA (2010): 122 (20%)
RA (2010) UA (2010)
RA (1987), no (%) 324/364 (89%) 34/364 (9%)
UA, no (%) 155/246 (63%) 88/246 (36%)
*9 patients could not be classified because of insufficient data.
no, number; RA (1987), RA according to the 1987 classification criteria for RA; UA, at least one swollen and 
one painful joint, at risk for developing RA according to the rheumatologist; RA (2010), included in trial as 
RA (1987) or UA, reclassified as RA according to the 2010 classification criteria for RA; UA (2010), included 




RA (1987) patients had a higher mean DAS based on more affected joints, higher erythrocyte 
sedimentation rate (ESR) and higher serum C-reactive protein (CRP) than RA (2010) patients. 
UA patients included fewer females, were less often RF and ACPA positive, had lower disease 
activity and HAQ. There was no significant difference between RA (1987 or 2010 classified) 
and UA patients in baseline damage scores or erosiveness.(table 2)
After four months, DAS <1.6 was achieved in 58% of the RA (1987), 61% of the RA (2010) 
(p=0.52) and 65% of the UA patients (p=0.46 compared to RA 2010).
DAS improved more in the RA (2010) group than in the UA group and similar as in the RA 
(1987) group, resulting in comparable mean (SD) DAS levels after 4 months: 1.4 (0.9) in UA, 
1.6 (0.9) in RA (1987) and 1.5 (0.9) in RA (2010) patients. Also HAQ improved more in the RA 
patients than the UA patients, resulting in HAQ levels of 0.44 both in UA and RA patients 
(p=0.96) after 4 months.
Baseline and 4 months radiographs of hands and feet were available for 546 patients. 
After four months, 61 patients (10%) showed radiological progression, without a difference 
between UA and RA patients. In those with progression the median (IQR) SHS progression 
was 1(1-1) points.
Patients who did not achieve remission after 4 months treatment had a higher baseline 
DAS, and higher DAS components, and were more often ACPA negative than patients who 
did achieve remission (table 3). Of the ACPA positive RA patients, 66% achieved remission 
compared to 51% of the ACPA negative RA patients (p=0.001). ACPA positive RA patients had 
730 screenings
610 patients included for baseline visit
598 patients included for follow up
120 screening failures
- 30 positive PPD
- 18 contra-indications to treatment
- 11 DAS <1.6
- 3 revised diagnosis
- 58 withdrawal of consent
12 early terminations
- 2 revised diagnosis
- 2 comorbidity
- 2 lost to follow up
- 4 withdrawal of consent
- 2 died
figure 1: Flow chart of screenings failure and early terminations 
PPD, purified protein derivative; DAS, disease activity score.
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a lower baseline DAS (mean (SD) 3.19 (0.89)) than ACPA negative RA patients (mean (SD) 3.64 
(0.94), p<0.001). ACPA negative RA patients who achieved remission had a shorter median 
(IQR) symptom duration (12 weeks (8-26)) than those who did not (20 weeks (10-31), p=0.02). 
In the whole study population, there was a trend for more remission in patients with shorter 
symptom duration.
The distribution of joints was different in patients with RA and UA. All RA patients had 
involvement of small joints (wrists, hands and feet), compared to 94% of the UA patients 
table 2: Baseline characteristics and clinical outcomes after 4 months of patients classified as rheumatoid 
arthritis either by 1987 or 2010 criteria and of patients with undifferentiated arthritis.
RA (1987) RA (2010) UA
Baseline N= 364 N= 479 P-value N= 122 P-value*
Age, years (mean, SD) 53.5 (14) 52 (13) 0.08 52 (16) 0.90
Female, no (%) 256 (70) 333 (70) 0.8 74 (61) 0.06
Symptom duration, weeks (median, 
IQR)
17 (8-32) 18 (9-34) 0.25 16 (8-28) 0.14
RF positive, no (%) 245 (67) 330 (69) 0.59 5 (4) <0.001
ACPA positive, no (%) 228 (63) 324 (68) 0.15 4 (3) <0.001
ESR mm/hr (median, IQR) 29 (15-45) 26 (12-41) 0.04 16 (9-38) 0.01
CRP mg/l (median, IQR) 13 (6-35.5) 11 (5-28) 0.046 10 (4-24) 0.25
DAS (mean, SD) 3.50 (0.9) 3.34 (0.9) 0.02 2.70 (0.65) <0.001
Swollen Joint Count (median, IQR) 8 (4-12) 7 (3-11) 0.02 3 (2-6) <0.001
Tender Joint Count (median, IQR) 7 (5-11) 7 (4-10) 0.18 5 (3-8) <0.001
HAQ (mean, SD) 1.26 (0.65) 1.19 (0.67) 0.11 1.03 (0.62) 0.02
BMI (mean, SD) 25.5 (4.1) 25.9 (4.5) 0.18 25.8 (4.0) 0.88
Total SHS (median, IQR) 0 (0-1) 0 (0-0.5) 0.33 0 (0-0.4) 0.98
Erosive, no (%) 49 (13) 60 (13) 0.62 12 (9) 0.46
4 months follow up
DAS (mean, SD) 1.56 (0.89) 1.52 (0.89) 0.56 1.43 (0.85) 0.30
HAQ (mean, SD) 0.45 (0.51) 0.44 (0.53) 0.81 0.44 (0.51) 0.96
Improvement DAS (mean, SD) 1.93 (1.04) 1.82 (1.04) 0.11 1.26 (0.88) <0.001
Improvement HAQ (mean, SD) 0.80 (0.64) 0.74 (0.66) 0.16 0.59 (0.61) 0.03
Total SHS (median, IQR) 0 (0-1) 0 (0-0.5) 0.37 0 (0-0) 0.85
Erosive, no (%) 48 (13) 64 (13) 0.98 11 (9) 0.22
SHS progression (median, IQR) 0 (0-0) 0 (0-0) 0.75 0 (0-0) 0.93
Remission (DAS <1.6), no (%) 211 (58) 291 (61) 0.52 79 (65) 0.46
* P-value based on difference between RA (2010) and UA (2010)
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CRP, C-reactive protein; DAS, disease 
activity score; erosive, defined as having ≥1 erosions; ESR, erythrocyte sedimentation rate; HAQ, 
health assessment questionnaire; IQR, inter quartile range; no, number; RA (1987), RA according to the 
1987 classification criteria for RA; RA (2010), RA according to the 2010 classification criteria for RA; RF, 
rheumatoid factor; SD, standard deviation; SHS, Sharp-van der Heijde Score; UA, undifferentiated arthritis.
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(p<0.001). Large joint (all other joints) involvement was found in similar percentages of RA 
and UA patients (73% versus 68%, p=0.22). Patients with large joint involvement had more 
affected small joints (median (IQR) 10 (6-17) versus 7 (4-11), p<0.001) and achieved less often 
remission than patients without large joint involvement (57% versus 76%, p<0.001).
Predictors for remission
Significant univariate clinical predictors for achieving remission in the total study population 
were baseline DAS, HAQ, symptom duration, male sex, ACPA positivity, number of affected 
table 3: Baseline characteristics and clinical characteristics after 4 months of patients achieving remission 
versus patients not achieving remission.
Remission No remission
Baseline N=375 N=221 P-value
DAS (mean, SD) 2.99 (0.85) 3.57 (0.92) <0.001
Swollen joint count 5 (2-9) 7 (3-12) 0.001
Tender joint count 5 (3-8) 8 (6-14) <0.001
VAS global health, mm (mean, SD) 42 (24) 52 (21) <0.001
ESR mm/hr (median, IQR) 23 (10-38) 25 (13-41) 0.20
HAQ (mean, SD) 1.03 (0.65) 1.37 (0.62) <0.001
Small joints* (median, IQR) 8 (4-13) 12 (7-18) <0.001
Large joints** (median, IQR) 1 (0-2) 2 (1-4) <0.001
Age, years (mean, SD) 52 (14) 51 (14) 0.54
Symptom duration, weeks (median, IQR) 16 (9-30) 21 (9-37) 0.08
Female no (%) 231 (62) 172 (78) <0.001
RF positive no (%) 219 (58) 111 (50) 0.09
ACPA positive no (%) 220 (59) 106 (48) 0.007
Diagnosis RA(2010) no (%) 291 (78) 177 (80) 0.46
BMI 25.4 (3.9) 26.6 (5.1) 0.001
4 months follow up
DAS (mean, SD) 0.94 (0.36) 2.45 (0.65) <0.001
Swollen joint count 0 (0-0) 1 (0-4) <0.001
Tender joint count 0 (0-1) 4 (3-8) <0.001
VAS global health, mm (mean, SD) 13 (14) 36 (21) <0.001
ESR mm/hr (median, IQR) 6 (3-13) 11 (6-22) <0.001
HAQ (mean, SD) 0.23 (0.33) 0.82 (0.59) <0.001
*number of swollen and/or tender small joints (metacarpophalangeal joints, proximal interphalangeal 
joints, thumb interphalangeal joints, wrists, second through fifth metacarpophalangeal joints)
** number of swollen and/or tender large joints (shoulders, elbows, hips, knees, ankles)
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; DAS, disease activity score; ESR, 
erythrocyte sedimentation rate; HAQ, health assessment questionnaire; IQR, inter quartile range; no, 
number; RF, rheumatoid factor; RA (2010), RA according to the 2010 classification criteria for RA; SD, 
standard deviation; VAS, visual analogue scale.
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small joints, number of affected large joints and body mass index (BMI).(table 4) Fulfilling the 
1987 or 2010 classification criteria for RA was not a predictor of remission. In a multivariate 
regression analysis including baseline DAS and excluding number of affected small and large 
joints, independent predictors were baseline DAS, HAQ, symptom duration, ACPA positivity, 
male sex and BMI. In a model including the baseline numbers of affected small and large 
table 4a: Univariate logistic regression analyses with remission after 4 months (yes/no) as dependent 
variable.
Univariate regression Odds ratio 95% CI
Classified RA (2010) 0.85 0.56 - 1.30
Baseline DAS 0.49 0.40 - 0.60
Baseline HAQ 0.43 0.33 - 0.57
Small joints* 0.93 0.90 - 0.95
Large joints** 0.72 0.65 - 0.79
Symptom duration (weeks) 0.99 0.99 - 1.00
ACPA positivity 1.59 1.14 - 2.23
Age (years) 1.00 0.99 - 1.02
Male sex 2.19 1.50 - 3.20
BMI (kg/m2) 0.94 0.90 - 0.98
*number of swollen and/or tender small joints (metacarpophalangeal joints, proximal interphalangeal 
joints, thumb interphalangeal joints, wrists, second through fifth metacarpophalangeal joints)
** number of swollen and/or tender large joints (shoulders, elbows, hips, knees, ankles)
BMI, body mass index; CI, confidence interval; DAS, disease activity score; HAQ, health assessment 
questionnaire; RA (2010), RA according to the 2010 ACR/EULAR classification criteria.
table 4b: Multivariate logistic regression analyses with remission after 4 months (yes/no) as dependent 
variable.
Multivariate regression Analysis with DAS Analysis with small
and large joints
Odds ratio 95% CI Odds ratio 95% CI
Baseline DAS 0.61 0.47-0.78 - -
Small joints* - - 0.96 0.93-0.99
Large joints** - - 0.81 0.72-0.90
Baseline HAQ 0.66 0.46-0.94 0.63 0.46-0.88
Symptom duration (weeks) 0.99 0.98-0.997 0.99 0.98-0.997
ACPA positivity 1.59 1.09-2.33 1.44 0.98-2.12
Male sex 2.03 1.34-3.08 2.01 1.32-3.07
BMI (kg/m2) 0.94 0.90-0.98 0.94 0.90-0.98
*number of swollen and/or tender small joints (metacarpophalangeal joints, proximal interphalangeal 
joints, thumb interphalangeal joints, wrists, second through fifth metacarpophalangeal joints)
** number of swollen and/or tender large joints (shoulders, elbows, hips, knees, ankles)
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; CI, confidence interval; DAS, disease 
activity score; HAQ, health assessment questionnaire.
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joints instead of the DAS, the number of affected small and large joints were both predictive, 
independently of each other. In this analysis, ACPA positivity was not an independent predic-
tor.(table 4)
acr/eular preliminary definition of remission
According to the preliminary ACR/EULAR definition 20 157/610 (26%) of the patients achieved 
remission after four months (34 patients could not be defined because of missing data), with-
out a difference between UA and RA patients (29/122 (24%) versus 126/479 (26%), p=0.45).
Mean (SD) DAS after four months of patients in ACR/EULAR remission is 0.82 (0.41).
206/610 (34%) patients did achieve DAS remission but were not in ACR/EULAR remission. 
They had a median (IQR) TJC of 0 (0-1), a median (IQR) SJC of 0 (0-0), a median (IQR) CRP of 5 
(3-9) and a mean (SD) VAS general health of 21(14).
table 5: Numbers of adverse events reported during 4 months of treatment with MTX and a tapered high 
dose of prednisone.
Numbers of adverse events
Gastro-intestinal symptoms 98
Nausea 47/98
Liver enzyme elevations 45
Infectious 80




























152/610 (25%) patients achieved remission by both criteria, 201/610 (33%) did not achieve 
remission according to either and 5/610 (0.8%) patients were in ACR/EULAR remission but 
not DAS remission, based on arthritis in the feet (not included in the ACR/EULAR remission 
definition).
The data suggest that the ACR/EULAR definition of remission is more stringent than DAS-
remission, resulting in lower remission percentages. Clinical and radiological follow-up is 
needed to show which definition is most adequate.
adverse events
During 4 months of treatment 341/610 (56%) of the patients reported one or more adverse 
events (table 5). There were 16 serious adverse events in 16 (3%) of 610 patients (8 per 100 pa-
tient years). Two patients died: a 70 year old female from a myocardial infarction later found to 
be caused by giant cell arteriitis (incorrect inclusion due to alternative diagnosis), and an 85 
year old female after refusing treatment for pneumonia. Fourteen hospital admissions were 
reported for patients with bacterial coxarthritis, Pneumocystis Carinii Pneumonia (a patient 
with pre-existing Non-Specific Interstitial Pneumonia), other pneumonia (3 patients), viral 
pneumonitis, urothelial cell carcinoma, surgery for carcinoma of the cecum, diverticulitis, 
bleeding from a benign intestinal polyp, supraventricular tachycardia, hypertension, periph-
eral arterial occlusion and pulmonary embolism.
discussion
Initial treatment with MTX and a tapered high dose of prednisone results in similar remission 
rates in 2010 classified and 1987 classified RA patients and in UA patients after four months. 
The majority (90%) of the patients showed no radiological progression after four months. 
Independent predictors for remission were low baseline DAS, low numbers of affected large 
and small joints, ACPA positivity, male sex and BMI.
The early remission rate of 61% is higher than previously reported in cohorts such as 
Combinatietherapie Bij Reumatoide Artritis (COBRA) and Behandel Strategieën (BeSt), where 
patients also received MTX and a tapered high dose of prednisone, combined with sulfasala-
zine.3,11 This is most likely explained by our intentional inclusion of patients with milder 
disease activity and not (yet) fulfilling the classification criteria for RA. Also, our patients had 
on average a shorter symptom duration. Thus, the higher remission rate in this study would 
support the window of opportunity theory. However, earlier inclusion may have over clas-
sified patients who possibly had self-limiting disease.8 Other possible explanations are the 
initial dose of methotrexate (25 mg/week compared to 7.5 mg/week in the other cohorts) 
and the absence of sulfasalazine in the initial drug combination.
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The 2010 ACR/EULAR classification criteria were formulated to classify patients earlier in 
disease course.7 In this study however, the symptom duration of patients classified as RA 
according to the 1987 or the 2010 criteria is comparable, which might explain why we found 
no difference in clinical response and remission rates between the groups, even though the 
2010 criteria classified 19% more patients.
Also, we found no difference in remission rates between RA and UA patients, although 
we hypothesized that UA patients, as presumably very early RA, would benefit more from 
early combination therapy, and despite the facts that UA patients had a lower mean baseline 
disease activity and were predominantly male. This may be explained by the comparable 
symptom duration in UA and RA patients. Of the UA patients 64% had a symptom duration 
>12 weeks, thus possibly missing the so called window of opportunity.21 Also, only a few UA 
patients were ACPA positive, compared to 68% in the RA group, and ACPA positivity in the 
total study population was found to be a predictor of achieving remission. ACPA negative 
RA and ACPA negative UA both may represent or include illnesses that do not sufficiently re-
spond to combination therapy with MTX and prednisone and require different treatments.22 
Previously, in the PRObable rheumatoid arthritis: Methotrexate versus Placebo Treatment 
(PROMPT) study ACPA negative UA patients did not benefit from treatment with methotrex-
ate monotherapy.10
The baseline characteristics in this study population suggest that classifying patients as RA 
by the new classification criteria rests predominantly on numbers of (small) joints involved 
and ACPA positivity, with UA patients having less joints involved and almost all UA patients 
being ACPA negative. ACPA negative patients who were still classified as RA had a higher 
disease activity and a longer symptom duration than ACPA positive RA patients. These char-
acteristics may explain why ACPA negative RA patients achieve less remission than ACPA 
positive RA patients. It is possible that they might have benefited more from treatment if 
they were treated earlier.
As shown in previous studies, male patients achieve more remission than female patients.23 
Our results show that male sex is an independent predictor of remission and not associated 
with a lower pain score or tender joint count. Also a lower body mass index (BMI) was found 
to be an independent predictor of remission, which may be related to relative under dosing 
of patients with a high BMI.
The early and intensive treatment with a high dose of methotrexate and a tapered high 
dose of prednisone in this study was accompanied by adverse events in more than half (56%) 
of the patients. Although most adverse events were mild, serious adverse events were re-
ported in 3% of patients. Two elderly patients died, one from pneumonia that may have been 
treatment related and on the patient’s request remained untreated, one of a vasculitis related 
cardiac event. This patient thus was misdiagnosed, and, since the lethal event occurred dur-
ing treatment with the tapered dose of prednisone, possibly under dosed.
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In conclusion, initial therapy with MTX and a tapered high dose of prednisone results in 
high remission percentages (about 60%) both in early RA patients (regardless of classification 
according to the 1987 or 2010 criteria) and in UA patients after four months of treatment. 
Independent predictors for remission, besides male sex and low BMI, indicate that initiation 
of treatment while disease activity is relatively low results in more remission, regardless of 
whether patients fulfil the classification criteria for RA. ACPA negative patients may benefit 
from early treatment, but on the whole achieve less remission on MTX with prednisone than 
ACPA positive patients. This may indicate that this subgroup of patients represents a different 
disease, for which the optimal treatment remains to be determined.
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To assess which treatment strategy is most effective in inducing remission in early (rheuma-
toid) arthritis.
methods
Six-hundred-ten patients with early rheumatoid arthritis (RA-2010 criteria) or undifferenti-
ated arthritis (UA) started with methotrexate (MTX) and a tapered high dose of prednisone. 
Patients in early remission (Disease Activity Score (DAS) <1.6 after 4 months) tapered 
prednisone to zero and with persistent remission after 8 months, tapered and stopped MTX. 
Patients not in early remission were randomized to either MTX plus hydroxychloroquine plus 
sulphasalazine plus low dose prednisone (arm 1) or to MTX plus adalimumab (arm 2). In case 
of remission after 8 months both arms tapered to MTX monotherapy, if not, arm 1 changed to 
MTX plus adalimumab and arm 2 increased adalimumab. Remission rates were compared be-
tween arms and between RA and UA patients, as were functional and radiological outcomes.
results
Of all patients, 61% achieved early remission. After 1 year 68% of those were in remission 
and 32% in drug free remission. Of the randomized patients, 25% in arm 1 and 41% in arm 
2 achieved remission at year 1 (p<0.01). Outcomes were comparable between RA and UA 
patients.
conclusions
Initial MTX and prednisone resulted in early remission in 61% of patients with early (rheu-
matoid) arthritis. Of those, 68% are in remission and 32% were in drug free remission after 1 
year. In patients not in early remission, earlier introduction of adalimumab resulted in more 
remission at year 1 than first treating with DMARD combination therapy plus prednisone.
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The way patients with rheumatoid arthritis (RA) are treated has changed dramatically over 
the last decades. Early and tight controlled treatment with disease modifying anti-rheumatic 
drugs (DMARDs), targeted to low disease activity, suppresses inflammation better than ever 
before, resulting in improved functional ability and minimized radiological joint damage.1-6 
Even remission can be achieved. Early combination therapy with synthetic DMARD treatment 
plus prednisone or a tumor necrosis factor alpha (TNF-α) inhibitor is most effective in most 
patients.7-9
It is thought that there is a ‘window of opportunity’ during which initiation of effective 
treatment may prevent inflammatory symptoms to become chronic and damaging to bone 
and joint tissues. To enable earlier diagnosis and treatment initiation, classification criteria 
for RA were revised in 2010.10 Starting anti-rheumatic treatment already in the stage of undif-
ferentiated arthritis (UA), when RA is still unclassifiable, might be useful.7
Treatment of UA patients with methotrexate (MTX) was successful in postponing but 
not preventing progression to RA.12 It is possible that, as in RA patients, initial combination 
therapy with MTX and prednisone is more effective.8,13 If patients do not achieve remission 
on initial combination therapy, the best follow up strategy needs to be determined: either 
expansion of DMARDs or switching to MTX with a TNF-α inhibitor, both proven effective in 
established RA.6,9
We designed a two-step treatment strategy study (remission induction therapy followed by 
randomization for patients who did not achieve remission) in patients with recent onset RA 
or UA, to determine how often remission or even drug free remission (DFR) can be achieved. 
Here we report clinical and radiological outcomes after 1 year.
methods
study design and patients
The IMPROVED-study (acronym for Induction therapy with Methotrexate and Prednisone in 
Rheumatoid Or Very Early arthritic Disease, ISRCTN Register number 11916566 and EudraCT 
number 2006-006186-16) is a multicentre, randomized, single-blinded clinical trial designed 
by Dutch rheumatologists participating in the Foundation for Applied Rheumatology 
Research (FARR). Patients were recruited between March 2007 and September 2010 in 12 
hospitals in the Western part of the Netherlands. Medical Ethics Committees of each partici-
pating centre approved the study protocol and all patients gave written informed consent.
Patients with both UA and early RA were included. Detailed in- and exclusion criteria were 
previously published.8 Recent onset RA was defined according to the American College of 
Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 classification 
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criteria 10 with symptom duration ≤2 years. UA patients had at least 1 joint clinically assessed 
as ‘arthritis’ and at least 1 other tender joint, in the opinion of the rheumatologist clinically 
suspected to represent early RA but not fulfilling the 2010 ACR/EULAR criteria.
intervention
The treatment target was clinical remission, defined as a DAS <1.6.11 Four-monthly DAS 
assessments were performed by trained nurses who were blinded for allocated treatment. 
Patients and doctors were not blinded for practical reasons. All patients started with four 
months of open-label MTX 25 mg/week (dose escalated from 7.5 mg/week in 4 weeks) and 
prednisone tapered in 7 weeks from 60 mg/day to a stable dose of 7.5 mg/day. Patients in 
‘early DAS-remission’ (defined as DAS <1.6 at 4 months) tapered prednisone to zero in 3 weeks 
and when still in remission at 8 months, also tapered MTX to zero in 9 weeks. In case of a DAS 
≥1.6 after stopping prednisone, it was restarted at 7.5 mg/day.(figure 1)
Patients not in early remission at 4 months were randomized either to MTX 25 mg/week 
plus hydroxychloroquine (HCQ) 400 mg/day, sulphasalazine (SSZ) 2000 mg/day and predni-
sone 7.5 mg/day (arm 1) or to MTX 25 mg/week plus adalimumab 40 mg/2weeks (arm 2). If 
in remission at 8 months, patients in arm 1 started tapering prednisone and subsequently 
SSZ and HCQ to MTX monotherapy, patients in arm 2 tapered adalimumab to MTX mono-
therapy. If not in remission at 8 months, patients in arm 1 switched to MTX+adalimumab (40 
mg/2weeks), patients in arm 2 increased adalimumab to 40 mg/week.(figure 1)













































figure 1. Study flow chart with percentages DAS-remission after the first study year.
DAS, disease activity score; HCQ, hydroxychloroquine; MTX, methotrexate; Remission, DAS ≤1.6; SSZ, 
sulfasalazine.
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Patients who did not regain remission after restarting prednisone, were also randomized 
(‘delayed randomization’) as described above.
Variable block randomization stratified per centre and diagnosis ensured numerical equality 
of the two randomization arms. Randomization sequence was obtained by computer. At the 
local centres, allocation was performed by the rheumatologists drawing opaque envelops.
study outcomes and assessments
Primary outcomes after 1 year were percentages of clinical and DFR based on a DAS <1.6.11 
A provisional Boolean based remission definition published by the ACR/EULAR 12 based on 
the 44 joint count was used to recalculate remission percentages at 4, 8 and 12 months. 
Secondary outcomes collected 4 monthly were DAS, functional ability measured with the 
Health Assessment Questionnaire (HAQ, ranging from 0 (best) to 3 (worst), ≥0.2 points 
change is clinically relevant)13, radiological damage progression measured with Sharp-van 
der Heijde score (SHS, ranging from 0-448, progression was defined as an increase in SHS ≥0.5 
point)14 and toxicity. Radiographs of hands and feet, blinded for patient identity, were scored 
for the presence of erosions and joint space narrowing in time random order by 2 trained, 
independent readers (KW and LH). Since 88% of patients showed no progression, intra-class 
correlation coefficients were not suitable for measuring reliability.15 In 83% of patients both 
readers scored the same progression. In 54 patients with inter-reader differences ≥2 (the 
median difference in progression score of patients in which both readers scored different 
progression) a consensus score was reached.
Outcomes were reported separately for patients who achieved early DAS-remission and 
those randomized, and were compared between randomization arms. Additional compari-
sons were made between RA and UA patients. Patients who were not in early DAS-remission 
and who were not randomized according to the protocol were analysed in the Outside of 
Protocol group. Reasons for protocol deviation were not inventoried.
statistical analysis
With a power calculation we assessed the number of patients needed in each randomization 
arm to detect differences between arms of at least 50% in remission rates and 0.2 points in 
HAQ with a power of 80%. Based on previous studies 9,16,17 we estimated 30% of the patients 
would achieve early remission. We needed 535 patients to randomize at least 100 patients 
per arm. Because during the study early DAS-remission rates were higher, the inclusion 
number was extended to 610 patients.
We performed intention-to-treat analyses. Outcomes were analysed using students T tests, 
Mann Whitney U tests and chi square tests. DAS and HAQ over time were compared using 
linear mixed models, with treatment strategy (arm 1 and 2) and time (study visit) as fixed 
effects, in an unstructured covariance structure. Statistical analyses were conducted with 





In total 610 patients were included, 479 (79%) with RA and 122 (20%) with UA and 9 patients 
could not be classified because of missing values. Over the year 23 patients withdrew con-
sent, 3 discontinued because of a revised diagnosis and 6 because of co-morbidity. Twelve of 
these patients dropped out during the first 4 months.
After 4 months, 375/610 patients (61%) had a DAS <1.6 (early DAS-remission). Twelve other 
patients with a marginally high DAS at 4 months were by protocol reassessed after 1 month. 
All then had a DAS <1.6 and were included in the early remission group, bringing it to a 
total of 387 patients, 291/479 (61%) RA patients and 79/122 (65%) UA patients were in early 
remission (12 patients were lost to follow up and 5 were not classifiable because of missing 
data). One-hundred-forty-four/387 (37%) (114/291 (39%) with RA and 28/79 (35%) with UA, 2 
had missing data) also fulfilled the proposed ACR/EULAR remission definition.
In total, 161/610 (26%) patients not in DAS-remission were randomized, 83 patients into 
arm 1 and 78 to arm 2. None fulfilled the proposed ACR/EULAR remission definition. Two pa-
tients with a missing DAS at 4 months and 48 other patients with a DAS ≥1.6 at 4 months who 
did not follow the protocol were analysed in the Outside of Protocol (OP) group. Thirty-three 
of these patients tapered prednisone and in 17 patients various other treatment decisions 
were made.
clinical characteristics at baseline and 4 months
Patients who achieved early DAS-remission had lower mean baseline DAS, HAQ and DAS-
components, were more often male and anti-citrullinated protein antibodies (ACPA) positive 
and had a shorter symptom duration than randomized patients.8 Clinical characteristics at 
baseline and 4 months were comparable in arm 1 and 2.(table 1)
outcomes after 1 year
After 1 year, 328/610 (54%) patients achieved DAS-remission (253/479 (53%) RA patients 
versus 71/122 (58%) UA patients (p=0.10), 4 patients were not classifiable. Proposed ACR/
EULAR remission was achieved in 144/610 (24%). Drug free remission (DFR) after 1 year was 
achieved in 130/610 (21%) patients (93/479 (19%) RA patients, 36/122 (30%) UA patients, 1 
patient was not classifiable). In the early DAS-remission group patients most often achieved 
DAS-remission. Patients in arm 1 less often achieved DAS-remission than patients in arm 2 
(p=0.01) (table 1).
After 1 year, mean HAQ and DAS were lower in the early DAS-remission group than in arm 
1 and 2. Over time, no significant difference in DAS and HAQ between arms 1 and 2 was 
present (mean DAS difference of 0.03 (95%CI -0.16;0.22), mean HAQ difference 0.04 (95%CI 
0.01;0.29)).
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table 1. Baseline characteristics and clinical outcomes per treatment group.
Early DAS-remission Randomization Outside protocol treatment
Arm 1 Arm 2
Baseline characteristics n = 387 n = 83 n = 78 n = 50
DAS, mean + SD 3.0 ± 0.8 3.6 ± 0.9 3.6 ±1.0 3.6 ±0.9
HAQ, mean + SD 1.0±0.7 1.4±0.6 1.4±0.6 1.3 ±0.7
Swollen Joint Count, median (IQR) 5 (2-9) 6 (3-10) 8 (4-12) 7 (3-13)
Tender Jont Count, median (IQR) 5 (3-8) 8 (6-13) 9 (6-13) 8 (6-14)
Age in years, mean + SD 52±14 49±14 51±14 54±14
Female, no (%) 240 (62) 64 (77) 58 (74) 42 (84)
Symptom duration in weeks, median (IQR) 17 (9-30) 22 (9-41) 21 (8-31) 18 (9-42)
Symptom duration <12 weeks, no (%) 247 (64) 59 (71) 49 (63) 28 (56)
RF positive, no (%) 224 (58) 41 (49) 43 (55) 23 (46)
ACPA positive, no (%) 225 (58) 40 (48) 37 (47) 25 (50)
RA(2010), no (%) 298 (77) 66 (80) 66 (85) 40 (80)
Total SHS, median (IQR) 0 (0-0.5) 0 (0-0) 0 (0-0) 0 (0-0)
Erosive, no (%) 63 (16) 10 (12) 13 (17) 3 (6)
4 months follow up
DAS, mean + SD 1.0±0.4 2.5±0.6 2.6±0.7 2.3±0.6
HAQ, mean + SD 0.2±0.3 0.9± 0.6 0.9±0.6 0.8±0.7
Swollen Joint Count, median (IQR) 0 (0-0) 1 (0-4) 2 (1-5) 0 (0-2)
Tender Joint Count, median (IQR) 0 (0-1) 4 (3-7) 5 (3-9) 4 (2-6)
ESR mm/hr, median (IQR) 6 (3-12) 13 (7-22) 11 (6-19) 15 (9-28)
VAS global health in mm, mean + SD 14±14 37±21 38±21 30±21
1 year follow up
DAS, mean + SD 1.3±0.8 2.1±0.9 1.8±0.9 2.1±0.8
HAQ, mean + SD 0.4 ±0.5 0.9±0.6 0.8±0.7 0.8±0.6
Swollen Joint Count, median (IQR) 0 (0-1) 0 (0-3) 0 (0-1) 1 (0-2)
Tender Joint Count, median (IQR) 0 (0-2) 3 (1-7) 3 (0-6) 4 (1-8)
ESR mm/hr, median (IQR) 8 (4-15) 9 (5-18) 9 (4-16) 14 (7-31)
VAS global health in mm, mean + SD 20±21 33±23 27±20 33±24
Total SHS, median (IQR) 0 (0-0.5) 0 (0-0.5) 0 (0-0) 0 (0-0)
Erosive, no (%) 65 (17) 12 (15) 12 (16) 2 (4)
DAS-Remission, no (%) 263 (68) 21 (25) 32 (41)* 12 (24)
Drug free remission, no (%) 124 (32) 1 (1) 0 (0) 5 (10)
ACR/EULAR remission, no (%) 122 (32) 9 (11) 13 (17) 4 (8)
SHS progression, median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
*p-value <0.05 between arm 1 and arm 2. After 4 months 12 patients were lost to follow up and 598 
patients were categorized a described in this table.
ACPA, anti-citrullinated protein antibodies; DAS, disease activity score; DAS-remission, DAS <1.6; ACR/
EULAR remission, provisional Boolean based remission definition published by the American College of 
Rheumatology and the European League Against Rheumatism based on a 44 joint count; Erosive denotes 
the presence of at least 1 erosion on radiographs of hands and feet; ESR, erythrocyte sedimentation rate; 
HAQ, Health Assessment Questionnaire; IQR; interquartile ranges; no, number; Progression, increase in 
SHS ≥0.5 points; RF, rheumatoid factor; RA(2010), rheumatoid arthritis according to the 2010 classification 
criteria; SD, standard deviation; SHS, Sharp- van de Heijde Score; VAS, visual analogue scale.
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Median (IQR) SHS progression score in all groups was 0 (0-0) without a difference between 
UA and RA patients. Of the total study population, 33/610 (5%) had radiological progression 
defined as an increase in SHS ≥0.5 point, 20/387 (5%) in the early remission group, 5/83 (6%) 
in arm 1, 6/78 (8%) in arm 2 and 2/50 (4%) in the OP group. Only 1 patient, categorized in the 
early DAS-remission group and losing remission at 8 months, had rapid radiological progres-
sion (defined as a progression score of ≥5 points in 1 year) of 18 points.
loss of early das-remission after prednisone discontinuation
Fifteen of 387 patients who achieved early DAS-remission did not taper and stop prednisone. 
Of the other 372 patients, 109 (29%) lost DAS-remission at 8 months of which 67 restarted 
prednisone at 7.5 mg/day. In 40 patients the protocol was not followed and various other 
steps were taken. Two patients had missing data. After 1 year, 48/67 (72%) of the patients re-
treated according to protocol and 22/40 (55%) of those treated otherwise had again achieved 
remission.
results at 8 months
DAS-remission at 8 months was achieved in 30/83 (36%) in arm 1 and 27/78 (35%) in arm 2 
(p=0.99). In arm 1, 30 patients tapered to monotherapy, 33 switched to adalimumab and in 19 
patients other steps were taken (1 patient had missing data). In arm 2, 26 patients tapered to 
monotherapy, 28 increased adalimumab and in 21 patients other steps were taken (3 patients 
had missing data). More patients in arm 2 who increased adalimumab achieved DAS-remission 
after 1 year, than patients in arm 1 who switched to adalimumab (8/28 (29%) versus 6/33 (18%) 
(p=0.29)). In addition, more patients in arm 2 retained DAS-remission after tapering to MTX 
monotherapy than in arm 1 (17/26 (65%) versus 11/30 (37%) respectively, p=0.02).
subgroups
During the first year of the study 96/610 (16%) patients never achieved DAS-remission, 
462/610 (76%) achieved DAS-remission at least once and 52 patients had one or more 
missing DAS-values during the first year. Compared to those who achieved DAS-remission 
at least once, patients who never achieved DAS-remission had a higher mean baseline DAS 
(mean (SD) 3.7 (0.9) versus 3.1 (0.9), p<0.001), a longer median symptom duration (median 
(IQR) 24 (12-44) versus 17 (8-31) weeks, p=0.002) and included more females (85/96 (89%) 
versus 291/462 (63%), p<0.001) and fewer ACPA-positives (45/96 (47%) versus 265/462 (57%), 
p=0.047).
adverse events
During the first 4 months there were 471 adverse events (AE) in 341/610 (56%) patients, 
including 2 deaths and 14 other serious adverse events (SAE) in 14 patients.8
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table 2. Number of adverse events reported between 4 months and 1 year for patients in the early DAS-









Patients with AE*, no (%) 205/387 (53%) 61/83 (74%) 52/78 (68%) 28/50 (56%)
Total number of AE
Type of AE
298 101 88 40
Cardiovascular 9 5 6 1
Pulmonary 11 - 2 1
Gastrointestinal 62 18 20 8
Nausea/emesis 15 6 5 2
Increased liver 
enzymes
33 5 9 3
Other 14 7 6 3
Neuropsychiatric 22 17 2 4
Headache 2 7 - -
Dizziness 10 1 - 2
Mood disorders 6 5 1 -
Other 4 4 1 2
Urogenital 5 2 2 1
Skin/mucous membranes 51 6 13 3
Rash 20 5 6 2
Hair thinning/loss 8 1 2 1
Sicca complaints 5 - 1 -
Stomatitis 4 - - -
Other 14 - 4 -
Infections 76 23 27 11
Upper airway tract 17 4 8 5
Gastro-intestinal 4 - 3 -
Skin/mucosa 11 2 1 1
Pneumonia / 
bronchitis
8 3 1 1
Urinary tract 9 6 5 1
Flu/unspecified fever 10 2 2 2
Other 17 6 7 1
Trauma/injury 15 3 - 2
Surgical procedures 
without hospitalization
9 3 2 2
Other 38 24 14 7
*One or more adverse events possible per patient.
AE: adverse event; no, number.
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From 4 months to 1 year, 346/610 (57%) patients reported 527 AE, 53% in the early DAS-
remission patients, 74% in arm 1, 68% in arm 2 (arm 1 versus arm 2 p=0.41) and 56% in the 
OP-group. The most common AE in all groups were increased liver enzymes, nausea, upper 
airway and skin/mucosa infections and skin rashes (table 2). In 26/610 (4%) patients, serious 
adverse events were reported. Three patients died: one of a squamous cell carcinoma of the 
tongue (early remission group), one of a cerebral tumor (arm 2, treated with adalimumab 
40 mg/2weeks for 4 months), and one patient of an ovarian carcinoma (OP-group; in the 
7 months prior to diagnosis the patient was treated with MTX and with prednisone for 4 
months). Three other malignancies were reported, all in the early remission group (breast 
carcinoma, basal cell carcinoma of the skin, malignant mesothelioma). Twenty-five hospital 
admissions were reported in 23/610 (3%) patients, 10 in the early remission group, 7 in arm 
1, 6 in arm 2 and 2 in the OP group. Reasons for hospitalization were: complications of malig-
nancy (3 patients, described above), pneumonia (4 patients; 2 in arm 1, 1 in arm 2 and 1 in the 
OP-group), suspicion of septic arthritis (arm 1, cultures remained negative), cellulitis of the 
lower leg (2 patients; early remission group and arm 1), percutaneous coronary intervention 
for cardiac ischemia (2 patients; early remission group and arm 2), cardiac arrhythmia (2 pa-
tients in the early remission group), urosepsis (arm 1), myocardial infarction (early remission 
group), femoral fracture (early remission group), total hip replacement for osteoarthritis (arm 
1), lower leg amputation for peripheral vascular disease due to diabetes mellitus (OP-group), 
exacerbation of chronic obstructive pulmonary disease (arm 2), surgery for cervical spinal 
disc herniation (early remission group), cerebrovascular accident (arm 2), Nissen fundoplica-
tion (arm 2), femural head necrosis (arm 2) and trauma due to a car accident (arm 1).
discussion
In patients with early arthritis, remission defined by DAS can be achieved in 54% after 1 year 
with initial treatment with MTX and a tapered high dose of prednisone followed by remission 
steered treatment adjustments. Radiological damage progression was effectively suppressed 
in almost all patients. Of the 61% of patients who started tapering medication after being in 
remission after 4 months, 68% were in remission and 32% in drug free remission (DFR) after 
1 year. These results suggest that combination therapy with MTX and a tapered high dose of 
prednisone can halt the potentially chronic disease course of rheumatoid arthritis, prevent 
damage and induce DFR.
Remission is more difficult to achieve if the initial treatment was unsuccessful. For those 
patients who did not achieve early remission, an early switch to a combination of MTX with 
adalimumab resulted in more remission (41% versus 25%) than treatment expansion with 
SSZ and HCQ, reserving adalimumab as possible next step. Functional ability, radiological 
damage progression and toxicity were similar.
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This study is the first to steer at remission in patients with early RA and taper and stop 
medication as soon and as long as this is achieved. The overall remission rate of 54% after 
1 year is high. Few other studies reported similar percentages, and there treatment was 
continued longer and none tapered medication or achieved early DFR.17-20
A possible explanation for the high (drug free) remission rates and the minimal radiological 
damage progression is that we included patients in a relatively early and possibly revers-
ible disease stage which may represent the ‘window of opportunity’.21 Maybe in this stage, 
chronicity and damage can be prevented or reversed. It is also possible that some patients 
with UA or even classified as RA might have had a self-limiting type of arthritis.22 A second 
explanation may be that we included patients with relatively low disease activity, who will 
more easily achieve the target of a DAS <1.6.8,23 The final explanation might be the treatment 
chosen, initially with a rapidly built up high dose of MTX and a high dose of prednisone 
tapered to 7.5 mg/day - a combination proven superior to DMARD monotherapy in patients 
with RA 6,24,25 - followed after randomization by progressive therapies either with multiple 
DMARDs or with a TNF-inhibitor, proven to be effective both in early and established RA.26-28
We used the DAS criteria to define remission, which are less stringent than the provisional 
remission criteria proposed by the American and European Rheumatology associations. 
Nonetheless, we have shown that our patients in DAS-remission have good functional ability 
and virtually no damage progression.
After 1 year significantly more patients in arm 2 had achieved DAS-remission than in arm 
1, although after 8 months the remission rates were similar. The 1 year difference is explained 
by more patients losing remission after tapering low dose prednisone and poly-DMARDs to 
MTX monotherapy and less patients achieving remission after switching from poly-DMARDs 
and prednisone to adalimumab (both in arm 1). This suggests that if remission is not achieved 
on initial combination therapy, it is better to introduce adalimumab early. It appears that 
patients who fail on prednisone and poly-DMARDs may respond less well to any other treat-
ment, as was previously demonstrated in a comparison of initial or delayed treatment with 
infliximab in patients with recent onset RA (1987 classification criteria).29
Although prednisone in the initial treatment combination appears to be very effective, it 
may also have several side effects and therefore our results may come at a price. Fourteen 
serious adverse events (infections, cardiovascular disease, femoral head necrosis, diabetic 
complications) might be related to the use of prednisone. Thirty-six % of our patients did not 
achieve DAS-remission on the initial treatment, and 16% did not achieve DAS-remission on 
any treatment step. Other (biologic) therapies may be more effective and less toxic.
In this trial, which integrated treatment adjustments by protocol with daily practice, the 
treating rheumatologist sometimes disagreed with required treatment steps based on DAS 
evaluations by nurses who were blind for treatment. In some cases the patients refused to 
take the next treatment step. Despite the protocol deviations that ensued, in general, treat-
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ment remained steered at DAS-remission or clinical remission, and follow up visits continued 
as before. Because we included all data in our analyses, no information was lost.
In conclusion, the majority of patients with early rheumatoid arthritis can achieve remis-
sion with initial combination therapy followed by treatment targeted at remission early in 
the disease course. Of the 61% of patients who achieve remission on initial treatment and 
start tapering medication, 68% are in remission and 32% are in drug free remission after 1 
year. For patients not in early remission, combination therapy including adalimumab resulted 
in significantly more remission after 1 year than combination therapy with poly-DMARDs. 
Overall, in all patients functional ability was preserved and radiographic damage progression 
was minimal. This study suggests that, if diagnosed and treated early, rheumatoid arthritis 
may not progress to the chronic and destructive autoimmune disease as we knew it.
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To investigate patient reported outcomes (PROs) of functional ability and health related 
quality of life (HRQoL) in patients with early (rheumatoid) arthritis during 1 year of remission 
steered treatment.
methods
Six-hundred-ten patients with early rheumatoid (RA) or undifferentiated arthritis (UA) 
were treated with methotrexate (MTX) and tapered high dose of prednisone. Patients in 
early remission (Disease Activity Score (DAS) <1.6 after 4 months) tapered prednisone to 
zero and when in persistent remission, also tapered MTX. Patients not in early remission 
were randomized to either MTX+hydroxychloroquine+sulphasalazine+prednisone (arm 1) 
or to MTX+adalimumab (arm 2). Every 4 months, patients filled out the Health Assessment 
Questionnaire (HAQ) and the McMaster-Toronto Arthritis Patients Preference Questionnaire 
(MACTAR), the Short Form 36 (SF-36) and visual analogue scales (VAS). Change scores were 
compared between treatment groups. The association with achieving remission was ana-
lyzed using linear mixed models.
results
During year 1, patients who achieved early remission had the most improvement in PROs with 
scores comparable to the general population. Patients in the randomization arms showed 
less improvement. Scores were comparable between the arms. There was a significant as-
sociation between achieving remission and scores of HAQ, MACTAR and physical HRQoL.
conclusions
In early arthritis, PROs of functional ability and HRQoL after 1 year remission steered treat-
ment reach normal values in patients who achieved early remission. In patients not in early 
remission who were randomized to two strategy arms PROs improved less, with similar scores 
in both treatment arms.
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In rheumatoid arthritis (RA) treatment with disease modifying anti-rheumatic drugs 
(DMARDs) is targeted at achieving optimal suppression of disease activity. With that, clini-
cal symptoms as well as radiological joint damage (progression) are prevented and patient 
reported outcomes (PROs) such as pain and health related quality of life (HRQoL), physical 
and mental wellbeing, improve.1 Earlier studies have suggested that the better disease ac-
tivity is suppressed, the better the outcomes of functioning and radiological joint damage 
progression.2,3 Achieving clinical remission would ideally be associated with achieving PROs 
comparable to those in the general population.
In the IMPROVED study, anti-rheumatic treatment was targeted at remission. Patients with 
early (rheumatoid) arthritis were treated with initial combination therapy of methotrex-
ate (MTX) and prednisone. If clinical remission (disease activity score (DAS) <1.6) was not 
achieved after 4 months, patients were randomized into two treatment arms: either starting 
with a combination of non-biologic DMARDs with low dose prednisone or with MTX and 
TNF-α inhibitor adalimumab. The aim of this sub-analysis was to measure change in func-
tional ability and HRQoL during the first year of remission-steered treatment, to compare 




The IMPROVED-study (acronym for Induction therapy with Methotrexate and Prednisone 
in Rheumatoid Or Very Early arthritic Disease) is a multicenter, randomized, single-blinded 
trial comparing two combination therapies in patients with recent onset arthritis aiming at 
clinical remission, defined as a DAS <1.6. The IMPROVED trial was designed and conducted by 
rheumatologists in the Foundation for Applied Rheumatology Research (FARR) and was regis-
tered in the ISRCTN Register (number 11916566) and the EudraCT (number 2006-006186-16).
Patients were recruited between March 2007 and September 2010 in 12 hospitals in the 
Western part of the Netherlands. The Medical Ethics Committee of each participating center 
approved the study protocol and all patients gave written informed consent. Patients with 
rheumatoid arthritis (RA) and patients with undifferentiated arthritis (UA) were included. RA 
was diagnosed according to the 2010 American College of Rheumatology (ACR) / European 
League Against Rheumatism (EULAR) classification criteria 4 with symptom duration of <2 
years. UA was defined as ‘arthritis’ in at least one joint and one other painful joint in which 
no definitive diagnosis could be made, considered to have very early RA according to the 
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treating rheumatologist, regardless of symptom duration. All patients were ≥18 years old 
with a DAS ≥1.6. Detailed inclusion and exclusion criteria were previously described.5
All patients were initially treated for 4 months with MTX 25 mg/week and a tapered high 
dose of prednisone, starting with 60 mg/day, tapered to 7.5 mg/day in 7 weeks. Patients in 
early remission (DAS <1.6 after 4 months) tapered prednisone to 0 and when still in remis-
sion after 8 months, also tapered MTX to 0. Patients not in early remission (DAS ≥1.6) were 
randomized using variable block randomization stratified per centre to ensure numerical 
equality of the two treatment groups. Randomization sequence was obtained by computer. 
At the local centres, allocation was performed by drawing opaque envelopes from separate 
boxes for UA and RA. Patients were randomized to either a combination of either MTX 25 
mg/week, hydroxychloroquine (HCQ) 400 mg/day, sulphasalazine (SSZ) 2000 mg/day and 
prednisone 7.5 mg/day (arm 1) or a combination of adalimumab 40 mg/2weeks and MTX 
25 mg/week (arm 2). When patients did not achieve remission after 8 months, patients in 
arm 1 switched to MTX+ adalimumab and patients in arm 2 increased adalimumab to 40 
mg/week. If patients achieved remission after 8 months, patients in both arms tapered to 
MTX monotherapy. Patients who did not achieve remission but were not randomized were 
analyzed in a separate group (outside of protocol (OP) group).6
outcomes
Functional ability was assessed every 4 months with the Health Assessment Questionnaire 
(HAQ).7 The HAQ score of a general (Finnish) population is 0.25.8
The McMaster-Toronto Arthritis Patients Preference Questionnaire (MACTAR) also mea-
sures functional ability. Patients have to rank five activities that are impaired because of their 
arthritis. Over time, improvement or deterioration of these five activities can be measured. 
The MACTAR is sensitive to change and useful to detect small differences. Compared to the 
baseline score, a higher score denotes improvement and a lower score means deterioration. 
The MACTAR interview from Canada was translated into Dutch in collaboration with the 
author of the original MACTAR. The translation was first used in the COBRA study, validated 
and judged as highly responsive.9-11
HRQoL was assessed using the Short-Form 36 (SF-36) focusing on 8 domains of health; 
physical functioning, role limitations due to physical or due to emotional functioning, bodily 
pain, general health, vitality, social functioning, mental health. The total score ranges from 0 
(worst) to 100 (best). Two summary components scores, the mental component score (MCS) 
and the physical component scores (PCS), can be calculated from the 8 domains. These 
component scores are standardized, based on the worldwide population norm, to a mean of 
50 and a standard deviation of 10.12,13 The minimum clinically important difference to assess 
improvement or deterioration is a 5-10 point difference from baseline for the subscales and 
2.5-5 points for the component scores.14
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Various visual analogue scales (VAS) were used and patients had to indicate on a scale from 
0 to 100 millimeters (0 means none, 100 means the worst) their appreciation of global health 
(VASgl), pain (VASpain), disease activity (VASda) and morning stiffness (VASms).
statistical analyses
All outcomes were calculated according to the intention-to-treat (ITT) principle. All mean 
outcomes after 4 months, 8 months and 1 year were tested between arms 1 and 2 using the 
students t-test and to test the difference in remission rates we used the χ2-test.
HAQ- and MACTAR scores, MCS, PCS and VAS measurements were reported separately for 
patients who achieved early remission and those randomized, and were compared between 
the randomization arms. The results of the study population were compared with those in 
the general population, if available.
Mean change scores over time were tested between the randomization arms using an 
independent Student’s t-test. Clinically relevant improvement or deterioration after 1 year in 
HRQoL was assessed per treatment group, using the minimum clinically important difference.
To assess the relationship between achieving remission and the PROs SF36-PCS, SF36-MCS, 
HAQ and MACTAR a linear mixed model (with an unstructured covariance structure) was used. 
The analyses were first performed with an interaction term for remission achievement and 
treatment (early remission, arm 1, arm 2, OP group) because the different treatment strate-
gies might influence remission achievement (as fixed effects were entered into the model: 
time (study visit at 4 months, 8 months and 1 year) and mean baseline score of the assessed 
PRO) In case of a significant interaction term, the analyses were stratified for treatment. The 
association between remission and PROs was assessed with and without adjustment for 
baseline variables anti-citrullinated protein antibodies (ACPA) status (positive/negative), sex 
(male/female), DAS at baseline, Tender Joint Count and Swollen Joint count. We used these 
determinants because they were identified as predictors for achieving remission after the 
first 4 months of the study.5 As fixed effects were entered into the model: time (study visit at 
4 months, 8 months and 1 year), mean baseline score of the assessed PRO and the determi-
nants for which the analyses were adjusted. After the initial analysis defining remission as a 
DAS <1.6 we re-analysed the association with remission defined according to the provisional 
Boolean based remission definition published by the ACR/EULAR with a 44 joint count.15
Statistical analyses were conducted with SPSS for Windows version 20.0 (SPSS Inc., Chicago, 
Ill).
results
In total, 610 patients were included. During the first year, 32 patients left the trial (23 with-
drew consent, 3 discontinued because of a revised diagnosis, 6 because of co-morbidity).
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After 4 months, 387 (63%) achieved early remission (DAS <1.6). Of the 221 patients who 
did not achieve early remission, 161 patients were randomized; 83 patients into arm 1 (poly-
DMARD), 78 to arm 2 (MTX+ adalimumab). Fifty patients did not achieve remission but were 
not randomized (outside of protocol (OP) group).6 Patients who achieved early remission had 
a lower mean baseline DAS, lower values of all DAS-components, a shorter median symptom 
duration and included fewer females and more ACPA positive patients.5(table 1)
After 1 year, remission was most often achieved by patients in the early remission group 
(68%). Fewer patients randomized to arm 1 achieved remission after 1 year than patients 
randomized to arm 2 (respectively 25% and 40%, p=0.01) (table 2).
functional ability
HAQ scores in the early remission group were lower, indicating better functional ability, 
than in the randomization arms, both at baseline and after 1 year.(figure 1) Functional ability 
table 1. Baseline characteristics per treatment group.
Early remission Arm 1 Arm 2 OP group
Baseline n = 387 n = 83 n = 78 n = 50
Age (years), mean ± SD 52 ± 14 48 ± 14 51 ± 14 54 ± 14
Female, n (%) 239 (62) 63 (76) 64 (82) 42 (84)
Symptom duration (weeks) 17 (9-30) 22 (9-40) 21 (8-29) 18 (9-42)
ACPA positive, n (%) 225 (58) 40 (48) 36 (46) 25 (50)
RA2010, n (%) 297 (77) 66 (80) 64 (82) 40 (80)
Erosive disease, n (%) 63 (16) 10 (12) 13 (17) 3 (6)
DAS, mean ± SD 3.0 ± 0.9 3.6 ± 0.9 3.6 ± 1.0 3.6 ± 0.9
Tender Joint Count, median (IQR) 5 (2-9) 6 (3-10) 8 (4-12) 7 (3-13)
Swollen Joint Count, median (IQR) 5 (3-8) 8 (6-13) 9 (6-13) 8 (6-14)
HAQ, mean ± SD 1.0 ± 0.7 1.4 ± 0.6 1.4 ± 0.65 1.3 ± 0.7
MCS, mean ± SD 51.2 ± 10.2 46.1 ± 12.4 48.8 ± 11.5 46.5± 13.3
PCS, mean ± SD 37.6 ± 9.3 33.0 ± 8.8 32.9 ± 8.9 35.2± 8.5
MACTAR, mean ± SD 50.1 ± 4.5 47.7 ± 4.6 48.1 ± 4.6 47.7 ± 5.2
VAS global (mm) , mean ± SD 43 ± 24 54 ± 20 54 ± 22 51 ± 22
VAS disease activity (mm) , mean ± SD 56 ± 25 66 ± 19 67 ± 22 66 ± 20
VAS pain (mm) , mean ± SD 50 ± 24 63 ± 19 61 ± 20 60 ± 24
VAS morning stiffness (mm) , mean ± SD 56 ± 27 69 ± 21 62 ± 25 54 ± 30
* p-value between arm 1 and 2. Data are presented as means and standard deviations (SD), medians and 
interquartile ranges (IQR), or numbers and percentages (%).
ACPA, anti-citrullinated protein antibody; DAS, disease activity score; HAQ, Health Assessment 
Questionnaire; MACTAR, McMaster-Toronto Arthritis Patients Preference Questionnaire; MCS, Mental 
Component Score; OP group, outside of protocol group; PSC, Physical Component Score; RA2010, 
rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria; VAS, visual analogue scale.
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table 2. Patient reported outcomes during 1 year follow up per treatment group.
Early remission Arm 1 Arm 2 p* OP group
n=387 n=83 n=78 n=50
4 months follow up
DAS 0.97 (0.40) 2.49 (0.63) 2.57 (0.68) 0.47 2.31 (0.63)
HAQ 0.23 (0.33) 0.86 (0.57) 0.88 (0.57) 0.77 0.73 (0.68)
MACTAR 58.2 (15.7) 52.8 (15.1) 48.9 (18.8) 0.14 51.6 (14.1)
MCS 52.4 (8.0) 48.8 (9.9) 50.7 (10.8) 0.26 49.8 (10.5)
PCS 51.7 (8.1) 39.4 (9.7) 38.1 (9.4) 0.44 42.5 (9.4)
VAS global (in mm) 14 (14) 37 (21) 39 (21) 0.61 28 (22)
VAS disease activity (in mm) 12 (15) 42 (24) 43 (24) 0.74 32 (25)
VAS pain (in mm) 10 (14) 39 (24) 38 (24) 0.79 27 (24)
VAS morning stiffness (in mm) 11 (17) 40 (27) 39 (27) 0.78 32 (30)
8 months follow up
DAS 1.29 (0.69) 1.97 (0.87) 2.01 (0.91) 0.77 2.02 (0.84)
HAQ 0.35 (0.44) 0.74 (0.61) 0.81 (0.64) 0.51 0.68 (0.59)
MACTAR 56.4 (15.7) 55.8 (14.7) 54.5 (16.1) 0.60 48.9 (19.9)
MCS 52.9 (8.4) 46.6 (17.9) 48.7 (10.3) 0.85 48.5 (13.0)
PCS 48.9 (9.1) 42.8 (10.9) 42.5 (11.0) 0.26 43.7 (9.5)
VAS global (in mm) 20 (20) 33 (23) 34 (21) 0.75 30 (23)
VAS disease activity (in mm) 22 (23) 39 (26) 33 (24) 0.20 35 (25)
VAS pain (in mm) 19 (23) 35 (26) 31 (25) 0.36 32 (24)
VAS morning stiffness (in mm) 24 (26) 34 (29) 37 (28) 0.51 40 (27)
1 year follow up
DAS 1.31 (0.78) 2.07 (0.89) 1.77 (0.90) 0.04 2.20 (0.83)
HAQ 0.38 (0.49) 0.87 (0.66) 0.81 (0.66) 0.60 0.77 (0.65)
MACTAR 63.0 (9.4) 59.2 (10.3) 60.4 (11.9) 0.54 59.7 (11.21)
MCS 53.1 (8.6) 50.5 (10.3) 50.5 (10.1) 0.97 50.4 (11.9)
PCS 48.6 (9.8) 39.9 (10.3) 43.0 (11.4) 0.10 42.6 (10.9)
VAS global (in mm) 20 (21) 33 (23) 27 (20) 0.10 33 (24)
VAS disease activity (in mm) 24 (26) 42 (29) 31 (26) 0.02 34 (27)
VAS pain (in mm) 21 (23) 38 (28) 28 (25) 0.02 28 (25)
VAS morning stiffness (in mm) 25 (26) 41 (31) 33 (27) 0.96 39 (30)
DAS-remission (DAS <1.6) 263 (68) 21 (25) 32 (41) 0.01 11 (22)
* p-value of the difference in mean scores and remission rates between arm 1 and 2. Data are presented as 
means and standard deviations (SD), medians and interquartile ranges (IQR), or numbers and percentages 
(%) when appropriate.
ACPA, anti-citrullinated protein antibody; DAS, disease activity score; HAQ, Health Assessment 
Questionnaire; MACTAR, McMaster-Toronto Arthritis Patients Preference Questionnaire; MCS, Mental 
Component Score; PSC, Physical Component Score; RA2010, rheumatoid arthritis according to the 2010 
American College of Rheumatology classification criteria; VAS, visual analogue scale.
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improved the most during the first 4 months in all patients.(figure 1) The mean improvement 
in HAQ during the first year was comparable between arm 1 and 2 (mean difference (95%CI) 
-0.005 (-0.3;0.2)). In the early remission group the mean HAQ score after 1 year of 0.38 was 
closest to the general population mean of 0.25 (compared to a mean HAQ of 0.87 in arm 1 
and 0.88 in arm 2).(figure 1, table 2)
Functional ability as measured by the MACTAR, which is more sensitive to change than the 
HAQ, improved in all groups together with continuous improvements in mean DAS.(table 
1, table 2) The mean change in MACTAR in year 1 was not significantly different between 
arm 1 and 2 (mean difference (95%CI) -1.1 (-5.2;3.1)). The outcomes of the OP group were 
comparable with those in arms 1 and 2.
health related Quality of life
At baseline, mental HRQoL measured with the mental component score (MCS) was higher 
than physical HRQoL measured by the physical component score (PCS) in all groups.(table 
figure 1. Functional ability as measured by the Health Assessment Questionnaire (HAQ) and the 
McMaster-Toronto Arthritis Patients Preference Questionnaire (MACTAR). Scores during the first year in 
the general population (only for HAQ), the early remission group, arm 1, arm 2 and the outside of protocol 
group.
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1, figure 2). Overall, the MCS at baseline was already close to the population average of 50, 
and improvement during the first year was minimal (table 1, figure 2), although clinically 
relevant in the randomization arms based on the minimal clinically important difference in 
component scores of 2.5-5 points (mean (SD) improvement arm 1: 3.8 (11.4), arm 2: 2.8 (10.0)). 
The mean improvement after 1 year was not significantly different between arm 1 and 2 
(mean difference 1.0 (95%CI) -2.8;4.7). The domains in which most improvement was seen, 
were role emotional and social functioning.(figure 3)
For the PCS, baseline scores in all groups were below the population average of 50 (table 
1, figure 2). The early remission group improved to the population average during the first 4 
months of treatment and stabilized, whereas the randomization arms also improved during 
figure 2. Summary components scores of health as measured by the Short-Form 36 (SF-36).
Mental component scores (MCS) and physical component scores (PCS) are calculated from the 8 domains 
(physical functioning, role limitations due to physical functioning, bodily pain, general health, vitality, social 
functioning, role limitations due to emotional functioning and mental health) of the SF-36. Scores during 




figure 3. The 8 domains of health as measured by the Short-Form 36 (SF-36; physical functioning, role 
limitations due to physical functioning, bodily pain, general health, vitality, social functioning, role 
limitations due to emotional functioning and mental health).
Scores range from 0 (worst) to 100 (best). Scores during the first year in the general population, the early 
remission group, arm 1, arm 2 and the outside of protocol group.  
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the first 4 months and stabilized, but below the population average (table 2, figure 2). The 
mean (SD) improvement in 1 year was clinically relevant in all groups based on the minimal 
clinically important difference of 2.5-5 points: in the early remission group 11.1 (11.7), in arm 
1 8.0 (10.9) and in arm 2 10.1 (12.8). The mean improvement in 1 year between patients who 
did and did not achieve early remission was significantly higher in patients who achieved 
early remission (mean difference (95%CI) -2.7 (-4.9;0.5)). There was no significant difference 
between arm 1 and 2 (mean difference (95%CI) -2.1 (-6.3;2.1)). The domains in which most 
improvement was seen, were physical functioning, role limitations due to physical function-
ing and bodily pain.(figure 3) Again, MCS and PCS in the OP group were comparable with 
those in arms 1 and 2.
Visual analogue scales
Patients who achieved early remission had at baseline and after 1 year lower VAS scores 
(indicating better outcomes) than the randomization arms.(table 1, table 2) Patients in arm 
2 reported lower VAS scores than patients in arm 1 after 1 year.(table 2) Only for VASda there 
table 3. Association between the patient reported outcomes and remission achievement during 1 year 
follow up for all patients and per treatment group.
All Early remission Arm 1 Arm 2 OP group
Crude beta (95%CI)
HAQ - -0.31 (-0.36;-0.26) -0.43 (-0.57;-29) -0.45 (-0.58;-
0.32)
0.18 (-0.33;-0.02)
MACTAR 7.8 (6.9;8.9) - - - -
PCS - 6.2 (5.1;7.4) 10.2 (7.5;12.9) 8.9 (5.8;12.0) 4.5 (0.6;8.4)
MCS 0.8
(0.01;1.6)
- - - -
Adjusted beta* 
(95%CI)
HAQ - -0.30 (-0.35;-0.25) -0.43 (-0.57;-29) -0.45 (-0.58;-
0.32)
0.17 (-0.32;-0.01)
MACTAR 8.1 (7.0;9.2) - - - -
PCS - 6.0 (4.9;7.2) 9.9 (7.1;12.7) 9.1 (6.1;12.1) 4.2 (0.2;8.1)
MCS 0.8 (-0.01;1.7) - - - -
*Adjusted for anti-citrullinated protein antibody (ACPA) status (positive/negative), sex (male/female), 
disease activity score (DAS) at baseline, Tender Joint Count and Swollen Joint count.
As fixed effects were entered: time (study visit at 4 months, 8 months and 1 year) and mean baseline 
score of the assessed patient reported outcome. HAQ and PCS were stratified for treatment group (early 
remission, arm1, arm 2, outside of protocol group) because of a significant interaction between treatment 
group and achieving remission.
CI, confidence interval; HAQ, Health Assessment Questionnaire; MACTAR, McMaster-Toronto Arthritis 




was more improvement after 1 year in arm 2 than in arm 1 (mean difference (95%CI) 13 (2;23)) 
and for the other VAS scores the improvement was comparable between the randomization 
arms (mean difference (95%CI) VASgh 7 (-2;16), VASpain 9 (-1;19) and VASms 5 (7;16). The OP 
group showed similar results as patients in arm 1 and 2.
association of Pros with achieving remission (das <1.6)
The analyses of the HAQ and the PCS were stratified for treatment group because there was 
an interaction between treatment group and achieving remission. The association between 
HAQ and achieving remission and between PCS and achieving remission was significant in 
all groups during the first year of the study.(table 3) The analyses for MACTAR and MCS were 
not stratified. In the total study group there was a significant association between MACTAR 
and achieving remission. There was also a significant association between MCS and achieving 
remission in the total study group, but after adjustment (for ACPA status (positive/negative), 
sex (male/female), DAS at baseline and Tender Joint Count and Swollen Joint count at base-
line, this association was no longer found.(table 3) Results were the same when we used the 
ACR/EULAR provisional remission definition (data not shown).
discussion
We assessed patient reported outcomes (PROs) of functional ability and health related 
quality of life (HRQoL) in patients with UA and early RA who were treated with the aim to 
achieve remission (DAS <1.6). Patients who achieved early remission after 4 months had the 
best PROs from baseline through the first year of the study and only in these patients PROs 
reached levels comparable with those measured in the general population. Patients who did 
not achieve early remission and were randomized to multiple DMARDs with prednisone or a 
combination of methotrexate with adalimumab had lower, and between arms comparable, 
PRO scores during the first year.
At baseline, the IMPROVED population with a mean age of 52 years scored lower on all 
domains of the physical HRQoL compared to healthy individuals of the Dutch population 
aged >70 years 12 and therefore it seems that the disease burden of early arthritis is substan-
tial. With treatment, the component score for physical HRQoL showed a clinically relevant 
improvement in all groups, with the most improvement in the early remission group during 
the first 4 months. The mental HRQoL remained stable around the population average during 
the first year of treatment, which suggests that the impact of early arthritis is mainly physical. 
This was also shown in previous published studies.1,16 However, improvement of physical 
HRQoL and HAQ to the population average in the first year after diagnosis in a remission 
steered treatment protocol, was not earlier reported.1,17
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It is generally accepted that remission is the optimal treatment target in rheumatoid arthri-
tis. Ideally, this would result in patients having no radiological joint damage progression, and 
no symptoms and no limitations, in other words ‘normality’, with functional ability and qual-
ity of life comparable to the general population. More than disease activity scores, patient 
reported outcomes show whether such improvement can be achieved if treatment is steered 
at achieving remission. The current results indicate that scores comparable with the general 
population can indeed be achieved, but mainly in patients who were in early remission after 
4 months of initial treatment. There is possibly a two-sided relationship between early re-
mission and better PRO scores, since patients who achieved early remission had better PRO 
scores at baseline than patients who did not. This indicates that maybe a predisposition to 
achieve remission determines the outcomes. Our results indicate that patients with a milder 
disease or better predisposition to achieve remission benefit from remission steered treat-
ment because this allows them to achieve normal levels of functional ability and quality of 
life, which may have a significant impact on their ability to work and personal and societal 
costs of having (rheumatoid) arthritis.18,19 The magnitude of the association between remis-
sion and the various PROs is actually bigger in arms 1 and 2 than in the early remission group, 
which had better PROs after 1 year, but also already better PROs at baseline than patients 
in arms 1 and 2. This suggests that regardless of baseline score, achieving remission itself is 
associated with PRO improvement.
One may argue that also without treatment arthritis in these patients would have regressed, 
with function and quality of life restored. However, previously we showed that patients who 
achieved remission were in majority ACPA positive, which makes spontaneous remission less 
likely.5
Although after 1 year significantly more patients in arm 2 achieved remission than in arm 
1, we found no significant differences in improvement of functional ability, HRQoL and VAS 
results between both arms. Only VAS disease activity, as estimated by the patient, improved 
more in arm 2 than in arm 1. Despite continued treatment adjustments targeted at remis-
sion, remission percentages in both arms remained lower than in the early remission group. 
Possibly as a consequence also functional ability and HRQoL in the physical domain did not 
achieve the same levels as the early remission group. In particular HAQ was higher in the 
randomization arms than in the early remission group and physical HRQoL did not reach 
levels found in the general population. Although we found that PROs were associated with 
achieving remission and significantly more patients in arm 2 achieved remission after 1 year 
than in arm 1, we found no significant differences in improvement of functional ability and 
HRQoL between both arms. Only improvement in VAS disease activity was significantly better 
in patients of arm 2 compared to patients in arm 1, which can be explained by a significantly 
lower mean DAS in arm 2 and it may also be related to higher patient expectations associ-
ated with earlier introduction of subcutaneous TNF-inhibitor, adalimumab, in this treatment 
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To assess if baseline characteristics in patients with undifferentiated or early rheumatoid 
arthritis affect the possibility to achieve drug free remission after one year (DFR1year) of early 
remission induction therapy.
methods
We included 375 patients participating in the IMPROVED study, who achieved remission 
(DAS<1.6) after four months (early remission) and were by protocol able to achieve DFR1year. 
Having started with methotrexate (MTX) plus prednisone, patients tapered prednisone to 
zero after 4 months. After 8 months, those still in remission tapered MTX to zero, while those 
not restarted prednisone. Characteristics of patients achieving and not achieving DFR1year 
were compared. Logistic regression was performed to identify predictors of DFR1year.
results
After one year, 119 patients (32%) were in DFR. Presence of Rheumatoid Factor (RF), fulfilling 
the 2010 criteria for RA and a low tender joint count were associated with achieving DFR1year, 
whereas presence of ACPA was not. None of the baseline characteristics were independently 
associated with DFR1year. DFR1year was sustained for 4 months in 65% patients. ACPA positive pa-
tients less often had sustained DFR than ACPA negative patients (58% versus 80%, p=0.013).
conclusions
After 1 year of remission steered treatment, 32% of the patients who had achieved early re-
mission after 4 months, were able to taper medication and achieved DFR. Neither presence of 
ACPA nor other baseline characteristics were independently associated with achieving DFR 
after 1 year but in ACPA positive patients DFR was less often sustained.
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With the current treatment strategies, remission has become a realistic goal in patients with 
rheumatoid arthritis (RA).1-3 It remains to be seen whether achieving drug free remission 
(DFR) after tapering medication is also a realistic goal. In recent cohort studies and clinical 
trials in patients with RA, DFR rates vary between 17 and 29% 4-6 and DFR was sustained 
for 1-4 years in 9-16%.4-7 Previously reported independent predictors for sustained DFR are 
absence of Anti-Citrullinated Protein Antibodies (ACPA), Rheumatoid Factor (RF) and shared 
epitope, short symptom duration and low disease activity until remission.6,7
In the IMPROVED study, patients with recent onset RA or undifferentiated arthritis (UA) 
clinically suspected for RA received initial treatment with a combination of MTX and a tapered 
high dose of prednisone. If remission (DAS <1.6) was achieved after 4 months, medication 
was stepwise tapered until DFR could be achieved already after 1 year (DFR1year).
We previously reported that 61% of the patients achieved early remission after 4 months. 
Surprisingly, these patients were more often ACPA positive than the patients who did not 
achieve early remission.8 Here, we aimed to assess whether ACPA status also influenced the 
likelihood to achieve DFR1year and to identify possible other determinants of achieving DFR1year.
methods
Patients, study design and outcomes
IMPROVED is a multi-center clinical trial in 122 patients with undifferentiated arthritis (UA) 
and 479 patients with recent onset rheumatoid arthritis (RA, 2010 criteria), treated according 
to a tight controlled, remission (DAS <1.69) steered protocol. Details on in- and exclusion 
criteria were previously published.10 Initially, all patients were treated with MTX 25 mg/week 
plus prednisone 60 mg/day tapered in 7 weeks to 7.5 mg/day, continued up to 4 months. 
Patients not in remission after 4 months by protocol could not achieve DFR1year because they 
had to take additional treatment steps before tapering was possible, and thus were left out 
of the current analysis. Patients who achieved remission after 4 months (early remission) first 
tapered prednisone to zero in 4 weeks and, if still in remission after 8 months, also tapered 
MTX to zero in 2 months. Patients who lost remission while still on MTX restarted prednisone 
and patients who already discontinued MTX restarted MTX. DFR1year was defined as having a 
DAS<1.6 from 4 months to 1 year while both prednisone and methotrexate (MTX) were sub-
sequently tapered and stopped. Because DFR1year was only achieved about 2 months before 
the end of year 1, we included 16 months follow up data to see if DFR could be sustained. 




Clinical, radiological and laboratory variables during the first year were compared between 
patients achieving and not achieving DFR1year using the students T test, Mann Whitney U test 
and Chi Square test. All available baseline clinical, demographic and laboratory characteristics 
were entered as covariates in univariate logistic regression analyses, with DFR1year as binomial 
dependent variable. Using a significance level of 0.10, univariate significant variables were 
entered in a multivariate model to identify independent predictors.
results
After 4 months, 375 (61%) patients achieved early remission, of which 291 (78%) fulfilled the 
2010 classification criteria for RA. Compared to patients not in early remission, patients in early 
remission had lower mean baseline DAS and HAQ levels, more were ACPA positive and fewer 
were female.8 After one year, 119 (32%) patients were in DFR and 245 (65%) were not, although 
138 (56%) of those were in remission but on medication. Eleven patients had insufficient data. 
Whether patients fulfilled the 1987 12 and/or the 2010 classification criteria for RA 10 did not sig-
nificantly affect the DFR1year rate (DFR1year was achieved by 51 (28%) patients who fulfilled both 
classification criteria, 33 (34%) who fulfilled the 2010 but not the 1987 criteria and 21 (37%) 
who fulfilled neither (p=0.4)). Similar proportions of patients in DFR1year and not in DFR1year were 
ACPA positive (66 (55%) versus 150 (61%) respectively, p=0.2). There were no differences in 
baseline DAS, symptom duration and percentage of females between patients in and not in 
DFR1year. Patients in DFR1year were more often RF negative, and after 4 months as well as after 1 
year, they had lower mean DAS and HAQ values than patients not in DFR1year. (table 1)
Results of the univariate regression analyses are shown in table 2. Baseline DAS and HAQ 
values, ACPA status, age, male sex and symptom duration were not associated with achieving 
DFR1year. RF positivity, high baseline TJC and fulfilling the 2010 criteria for RA were predictive 
for less often achieving DFR1year. In a multivariate regression model none of these variables 
were independently predictive for less often achieving DFR1year (adjusted OR (95%CI) RF 
positivity 0.6 (0.4-1.1), baseline TJC 0.9 (0.9-1.0), fulfilling the 2010 criteria for RA 0.9 (0.5-1.8)). 
After leaving out the least significant variable, fulfilling the 2010 criteria for RA (p=0.8), odds 
ratio’s did not change importantly, although RF positivity adjusted for TJC was significantly 
predictive for less often achieving DFR1year (data not shown).
Seventy seven (65%) patients in DFR1year were still in DFR after 16 months (DFR16mo), 36 (30%) 
were not and 6 patients had missing data. Those who lost remission were more often ACPA posi-
tive than those who sustained DFR (26 (72%) versus 36 (47%), p=0.01), and ACPA positive patients 
less often sustained remission than ACPA negative patients (36 (58%) versus 40 (80%), p=0.013). 
Regardless of achieving DFR1year, 107 (29%) patients achieved DFR16mo. Patients in DFR16mo were 
less often ACPA positive than those not in DFR16mo (47 (44%) versus 159 (67%), p<0.001).(figure 1)
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table 1: Baseline characteristics and clinical outcomes of patients who are and are not in drug free 






DAS 2.9±0.9 3.0±0.8 0.3
Swollen joint count 4 (2-10) 5 (3-9) 0.2
Tender joint count 5 (3-8) 6 (4-8) 0.1
VAS global health, mm 41±25 43±24 0.3
ESR mm/hr 21 (11-36) 24 (10-38) 0.5
HAQ 1.0±0.7 1.0±0.6 0.5
Age, years 52±13 51±14 0.5
Symptom duration, weeks 16 (8-30) 17 (9-32) 0.4
Female 67 (56) 158 (64) 0.1
RF positive 60 (50) 152 (62) 0.03
ACPA positive 66 (55) 150 (61) 0.2
Diagnosis RA(2010) 87 (74) 196 (80) 0.1
Diagnosis RA(1987) 61 (51) 138 (56) 0.4
SHS total score 0 (0-1) 0 (0-0) 0.08
Erosive 20 (17) 31 (13) 0.3
4 months follow up
DAS 0.8±0.4 1.0±0.4 <0.001
Swollen joint count 0 (0-0) 0 (0-0) 0.3
Tender joint count 0 (0-1) 0 (0-1) 0.07
VAS global health, mm 12±14 15±13 0.1
ESR mm/hr 6 (2-11) 7 (4-13) 0.08
HAQ 0.2±0.3 0.3±0.3 0.006
ACR/EULAR remission 57 (48) 86 (35) 0.006
1 year follow up
DAS 0.9±0.4 1.5±0.8 <0.001
Swollen joint count 0 (0-0) 0 (0-2) <0.001
Tender joint count 0 (0-0.5) 1 (0-3) <0.001
VAS global health, mm 12±15 25±22 <0.001
ESR mm/hr 6 (3-11) 9 (4-18) 0.01
HAQ 0.2±0.3 0.5±0.5 <0.001
DAS-remission 119 (100) 138 (56) <0.001
ACR/EULAR remission 64 (54) 54 (22) <0.001
Data are presented as means ± standard deviations (SD), medians and interquartile ranges (IQR), or 
numbers and percentages (%) when appropriate. Eleven patients had missing data after 1 year.
ACPA, anti-citrullinated protein antibodies; ACR/EULAR remission, remission according to the Boolean 
based ACR/EULAR provisional remission definition, based on 44 joint counts; DFR1year, drug free remission 
defined as DAS<1.6 and all medication tapered after 1 year; DAS, disease activity score; Erosive, number 
of patients having one or more erosions; DAS-remission, defined as a DAS<1.6; ESR, erythrocyte 
sedimentation rate; HAQ, Health Assessment Questionnaire; RA(2010), Rheumatoid Arthritis according to 
the 2010 ACR/EULAR classification criteria, RA(1987), RA according to the 1987 ACR classification criteria; 




In the IMPROVED study, 32% of the early arthritis patients who had achieved remission after 
4 months, were able to maintain remission and taper all medication to drug free remission 
after 1 year (DFR1year), regardless of fulfilling the 1987 and/or 2010 classification criteria for 
RA at study entrance. Baseline characteristics in the past associated with chronic and/or 
progressive disease, such as a positive RF and fulfilling criteria for RA, were associated with 
less often achieving DFR1year, although not independently of each other. Also a high tender 
joint count at baseline was, non-independently, associated with less often achieving DFR1year. 
ACPA status and symptom duration were not associated with DFR1year. In 65% of patients in 
DFR1year, DFR was sustained for 4 more months. Although DFR was achieved in ACPA positive 
patients as often as in ACPA negative patients, ACPA positive patients less often sustained in 
DFR than ACPA negative patients.
To our knowledge, IMPROVED is the first study in which DFR was a treatment goal. A DFR 
rate of 32% after 1 year is probably high, although 29% of the total IMPROVED population 
did not achieve early remission after 4 months and by protocol were not able to achieve DFR 
already after 1 year.
Given the fact that we included both RA and UA patients, clinically suspected to have RA 
but not fulfilling the criteria, we may have included and treated patients who might have 
remitted spontaneously. This was a reason why we introduced a rapid drug tapering scheme 
in our protocol. However, if the 32% mainly represented non-chronic types of arthritis, one 
table 2: Univariate logistic regression analyses with drug free remission after 1 year (yes/no) as 
dependent variable.
Baseline characteristics Crude OR 95%CI p-value
Age, years 1.0 0.99-1.0 0.3
Male sex 1.4 0.9-2.2 0.13
DAS 0.8 0.6-1.0 0.10
HAQ 0.9 0.6-1.2 0.5
TJC 0.9 0.9-1.0 0.08
SJC 0.99 0.95-1.0 0.6
ESR, mm/hr 0.996 0.99-1.0 0.4
Symptom duration, weeks 0.997 0.99-1.0 0.6
ACPA positivity 0.7 0.5-1.2 0.2
RF positivity 0.6 0.4-0.96 0.03
Diagnosis RA(2010) 0.6 0.4-1.1 0.099
ACPA, anti-citrullinated protein antibodies; 95% CI, 95% confidence interval; DAS, baseline disease 
activity score; ESR, baseline erythrocyte sedimentation rate (mm/hr); HAQ, baseline health assessment 
questionnaire; OR, odds ratio; RA(2010), rheumatoid arthritis according to the 2010 ACR/EULAR 
classification criteria; RF, rheumatoid factor; SJC, baseline swollen joint count; TJC, baseline tender joint 
count.
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would expect that these patients more often were auto-antibody negative, possibly had 
shorter disease duration or less often fulfilled the criteria sets for RA than patients not achiev-
ing DFR, which was not the case.
Interestingly, presence of ACPA was not associated with less DFR1year. Previously we re-
ported that presence of ACPA was associated with achieving more remission after 4 months 
in the IMPROVED study,8 which was in contrast with previous data indicating that presence of 
ACPA is associated with a less favorable disease course.13,14 In a study comparing DFR in the 
Leiden Early Arthritis Clinic and the BeSt study, absence rather than presence of ACPA was 
an independent predictor of sustained DFR.7 That ACPA positive patients achieve DFR1year in 
figure 1: Percentages ACPA positive patients achieving drug free remission after 1 year versus not, 
sustaining drug free remission up to 16 months versus not and achieving drug free remission after 16 
months versus not.
ACPA, anti-citrullinated protein antibodies; DFR 1 year, drug free remission after 1 year; DFR 16 months, 
patients in DFR after 16 months, regardless of being in DFR after 1 year; Sustained DFR, patients in DFR 
after 1 year and after 16 months.
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similar numbers as ACPA negative patients may be explained both by the initial combination 
with MTX and prednisone and the early remission steered treatment in the IMPROVED study.
However, after treatment was stopped 30% of patients lost remission and had to restart 
medication within 4 months after achieving DFR, and ACPA positive patients more often lost 
DFR than ACPA negative patients. This suggests that compared to ACPA negative patients, 
ACPA positive patients have a similar likelihood of achieving and maintaining remission, even 
while medication is tapered. But after having successfully tapered and discontinued medica-
tion, ACPA positive patients show more relapses in disease activity in the next 4 months, and 
this may even increase with follow up. Reasons why sustained DFR was achieved less often in 
ACPA positive patients may be that we have tapered medication too soon or too fast or have 
not used the optimal initial treatment within the optimal time frame. In the future we will 
also be able to see which patients who did not achieved early remission after 4 months, may 
achieve late DFR in the randomization arms and whether this is sustained over time.
In conclusion, 32% of patients with early arthritis who achieved remission after 4 months of 
initial combination therapy can taper medication until DFR is achieved after one year. Achiev-
ing DFR is possible regardless of ACPA status or other baseline disease characteristics, but 
DFR is sustained less often in ACPA positive than in ACPA negative patients.
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To assess depressive symptoms severity and dispositional optimism in patients with recent 
onset arthritis, both before and after 4 months treatment.
methods
Two-hundred-twenty-two patients with recent onset RA and undifferentiated arthritis (UA) 
in the IMPROVED study filled out the Beck Depression Inventory (BDI-II) to assess depressive 
symptoms severity and the Life Orientation Test Revised (LOT-R) to measure optimism before 
and after 4 months of treatment. All patients were treated with methotrexate (MTX) 25 mg/
week and prednisone 60 mg/day (tapered to 7.5 mg/day in seven weeks). Linear regression 
analysis was used to assess the association between the Disease Activity Score (DAS) and its 
components (Tender Joint Count, Visual Analogue Scale (VAS) Global Health, Swollen Joint 
Count and Erythrocyte Sedimentation Rate (ESR)) with the BDI-II an LOT-R scores.
results
In general, depressive symptoms were mild. The DAS was an independent predictor of 
depressive symptoms scores both at baseline and after 4 months follow-up, in particular 
Tender Joint Count and VAS Global Health. Disease activity was not associated with the level 
of optimism. Nevertheless, patients who achieved clinical remission improved significantly 
more in both depression score and optimism score than patients who did not.
conclusions
Patients with early arthritis report improvement in depressive symptoms and optimism with 
improvement in disease activity and achieving clinical remission. Depression scores are as-
sociated with pain and unwell being but not with swollen joint counts and inflammatory 
parameters.
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Depressive symptoms are more common in patients with rheumatoid arthritis (RA) com-
pared to healthy individuals.1-4 The etiology of the association between RA and depressive 
symptoms is poorly understood.2 Pain and disability may negatively affect mood (and vice 
versa), but inflammatory processes itself may also play a role in inducing depressive symp-
toms.5,6 Suppression of disease activity might improve depressive symptoms.3 However, 
anti-rheumatic treatment with oral corticosteroids, in particular in higher dosages, may also 
induce psychiatric disorders including depression, anxiety, delirium and (hypo)mania.7-10 
To investigate the relationship between disease activity and mood, we assessed levels of 
depressive symptoms and dispositional optimism 11 in patients with recent onset arthritis 
who were treated with methotrexate and a high tapered dose of prednisone with the aim to 
induce clinical remission in the IMPROVED study.
Patients and methods
study design
The IMPROVED study is a multicenter investigator driven clinical trial among patients with re-
cent onset arthritis, designed and conducted by rheumatologists in 12 cooperating hospitals 
in the Western part of the Netherlands. The Medical Ethics Committee of each participating 
center approved the study protocol and all patients gave written informed consent. Patients 
with undifferentiated arthritis (UA) and recent onset RA were included. Recent onset RA was 
defined according to the 2010 American College of Rheumatology (ACR)/European League 
Against Rheumatism (EULAR) 2010 classification criteria 12 with a duration of symptoms ≤2 
years. UA patients had at least 1 joint clinically assessed as ‘arthritis’ and at least 1 other tender 
joint, in the opinion of the rheumatologist clinically suspected to represent early RA but not 
fulfilling the 2010 ACR/EULAR criteria. All patients were recruited between March 2007 and 
September 2010, were at least 18 years old, disease modifying anti-rheumatic drug (DMARD) 
naïve and had a Disease Activity Score (DAS) ≥1.6. Exclusion criteria included pregnancy, 
malignancy within the last five years, bone marrow hypoplasia, elevated liver enzyme levels 
(AST and/or ALT >3 times normal value), serum creatinine level >150 umol/l or estimated cre-
atinine clearance of <75%, uncontrolled diabetes mellitus, uncontrolled hypertension, heart 
failure (NYHA class III/IV), alcohol or drug abuse, serious infections in the previous 3 months 
or chronic infectious disease, opportunistic infections within previous 2 months, active or 
latent hepatitis B, HIV infection or AIDS, lymphoproliferative diseases and multiple sclerosis.
All patients received initial treatment in the first 4 months with methotrexate 25 mg/week 




At baseline and after 4 months a trained assessor performed a full joint evaluation and calculated 
a DAS. Patients were asked to fill out a Visual Analogue Scale (VAS) for global wellbeing, the Health 
Assessment Questionnaire (HAQ) 14, and questionnaires on educational level, job-participation 
and productivity. Separate informed consent was obtained for additional questionnaires, the 
Beck Depression Inventory II (BDI-II) and the Life Orientation Test Revised (LOT-R).15,16
The BDI-II is a 21-item questionnaire to assess depressive symptoms severity according to 
the diagnostic criteria as stated by the DSM-IV. It is scored as the sum of scores (0-3). Missing 
values e.g. unanswered questions (12 questions in the baseline questionnaire, 15 questions 
in the 4-month questionnaire) were replaced with zero. This is the neutral answer in all ques-
tions; in case of the question about ‘sadness’, 0 means ‘I don’t feel sad’. Patients with a total 
score of 0-13 are defined as having minimal depressive symptoms, a score of 14-19 denotes 
mild depressive symptoms, 20-28 moderate depressive symptoms and 29-63 severe depres-
sive symptoms.15
Dispositional optimism was assessed by using the Life Orientation Test - Revised (LOT-R). 
The LOT-R is a 10-item continuous scale to measure optimism.16 The questionnaire consists of 
6 score items and 4 filler items, answered on a 0-4 Likert scale (0 strongly disagree, 4 strongly 
agree). Three items are keyed in a positive direction and three in a negative direction, and 
negatively worded items (i.e. items 3, 7 and 9) are reversely coded. The total score is cal-
culated as the sum of the score items (i.e. items 1, 3, 4, 7, 9, and 10), with a range between 
0 and 24 with higher scores indicating greater optimism. Low dispositional optimism has 
previously been defined as a total score <12 (often yielding ±20% of the subjects with the 
lowest scores).17 Missing values were replaced with the rounded mean of the remaining score 
items, if at least 4 of the 6 score items were filled out.18 Previously, college-students in the 
United States scored a mean (standard deviation (SD)) LOT-R score of 14.3 (4.3); patients after 
bypass surgery scored 15.2 (4.1).16
statistical analyses
Comparison between participants of IMPROVED who filled out the BDI-II and LOT-R and 
participants who did not, were analyzed using the independent t-test, the Wilcoxon rank sum 
tests and the Chi-squared test at the 5% level. Linear regression analysis was used to assess the 
relationship between DAS scores and depressive symptoms severity scores, both at baseline 
and at 4 months follow-up. We adjusted for age, gender and alcohol use (yes/no), because 
these characteristics are known to be related to depressive symptoms as well as (changes in) 
disease activity. Given the possible association between the questionnaire outcomes on the 
one hand and marital status (not married and living alone, not married and living together, 
married, divorced, widow(er)), having children (yes/no), level of education (highest level of edu-
cation; primary school, secondary education, vocational education or university), employment 
(yes/no) and tobacco use (yes/no) on the other hand, the analyses were repeated with these 
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covariates included in the model. The analyses to assess the relationship at follow-up were also 
adjusted for baseline disease activity and baseline questionnaire scores. Subsequently, sepa-
rate analyses were done for the components of the DAS: Tender Joint Count and patients’ sense 
of general wellbeing, measured with a VAS as subjective components, and Swollen Joint Count 
and Erythrocyte Sedimentation Rate (ESR) as objective components. Univariate and multivari-
ate analyses were done separately for Tender Joint Count and Swollen Joint count because of 
collinearity. The regression analyses were also done for the LOT-R questionnaire.
Finally, questionnaire outcomes were compared at baseline and after 4 months using the 
paired t-test at the 5% level. Differences in change scores of the BDI-II and LOT-R between 
patients who achieved remission (defined as a DAS<1.6 19) and those who did not were evalu-
ated with an ANCOVA model with remission achievement (yes/no) as factor and the baseline 
values of BDI-II or LOT-R as a covariate. Statistical analyses were conducted with SPSS for 
Windows version 17.0 (SPSS Inc., Chicago, Ill).
results
characteristics of participants
Six-hundred-and-ten patients were included in the IMPROVED study of whom 222 patients 
gave informed consent to fill out the questionnaires and filled out at least one of the ques-
tionnaires at baseline or after 4 months. Of these, 211 patients completed the LOT-R and 
215 patients the BDI-II both at baseline and follow-up. Patient characteristics are presented 
in table 1. Among patients who filled out the BDI-II and optimism questionnaires, a higher 
percentage was ACPA-positive (p=0.050) and had children (p=0.03), compared to those who 
did not fill out the questionnaires (table 1).
Eight of 610 patients (1.3%) reported having a depression in their medical history. None 
of these patients reported having ongoing symptoms, 3 reported using antidepressants and 
2 patients reported being under care of a psychologist/psychiatrist. Seven other patients re-
ported using antidepressants without mentioning having a depression in their medical history.
depressive symptoms severity over time
Disease activity was at both time points independently positively associated with depres-
sive symptoms severity (baseline beta 0.26, p<0.001 and 4 months beta 0.31, p<0.001). The 
results did not change after adjustment for marital status, having children, level of education, 
employment and tobacco use. At baseline the DAS-component VAS for global well-being and 
after 4 months both Tender Joint Count and VAS for global wellbeing, but not Swollen Joint 
Count or ESR, were independently associated with BDI-II score (table 2).
After 4 months of treatment with methotrexate and prednisone, there was a significant 
decrease in mean (SD) BDI-II score in the entire group from 8.5 (7.7) at baseline to 7.0 (7.2) 
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(95%CI -2.3;-0.6, p=0.001). Depressive symptoms after treatment were minimal, only 21/215 
(9.8%) had mild depressive symptoms (BDI-II score 14-19), 11/215 (5.1%) had moderate (BDI-
II score 20-28) and 5/215 patients (2.3%) had severe depressive symptoms (BDI-II>29). After 
four months, 138 (66%) patients had achieved clinical remission, with a mean (SD) DAS of 
0.9 (0.4). BDI-II scores after 4 months were significantly decreased in patients who achieved 
remission (mean (SD) 6.9 (6.4) to 4.8 (5.0), 95%CI -3.1;-1.2, p<0.001), but not in patients who 
did not achieve remission (mean (SD) 11.2 (8.9) to 11.0 (8.7), 95%CI -1.96;1.6, p=0.83). In 
patients who did achieve remission the mean change in BDI-II was 4.0 (SE 0.8) points lower 
than in patients who did not (p<0.001).(figure 1)
table 1. Baseline characteristics of patients who filled out BDI-II and optimism questionnaires compared 
to patients who did not.
Baseline Patients who filled out the BDI-II and 
LOT-R  
(n=222)*




Age (years) 51.4 ± 12.5 52.2 ± 14.7 0.45
Female sex 157 (71) 257 (66) 0.25
Married 143 (64) 237 (61) 0.40
Children 184 (83) 300 (77) 0.03
Higher education 73 (33) 177 (29) 0.12
Working 121 (55) 199 (51) 0.10
Disease characteristics
DAS 3.2 ± 0.9 3.2 ± 0.9 0.51
Duration of symptoms (weeks) 18 (9-36) 18 (9-32) 0.49
ACPA positive 134 (60) 199 (51) 0.050
ESR 24 (11-37) 25 (11-41) 0.21
Tender Joint count 6 (4-9) 6 (4-9) 0.96
Swollen joint count 6 (3-10) 5 (2-10) 0.38
VAS global health 44 ± 24 47 ± 23 0.10
HAQ 1.1 ± 0.7 1.2 ± 0.7 0.28
BDI-II 8.5 ± 7.7 - -
LOT-R 16.7 ± 4.0 - -
Health related factors
Smoking 63 (28) 114 (29) 0.79
Alcohol 130 (59) 232 (60) 0.67
*Data of patients who filled out at least one of the questionnaires, at one of the time points. Data are 
presented as means ± standard deviations (SD), medians and interquartile ranges (IQR), or numbers and 
percentages (%) when appropriate.
ACPA, Anti-Citrullinated Protein Antibodies; BDI-II, Beck Depression Inventory II; DAS, Disease Activity 
Score; ESR, Erythrocyte Sedimentation Rate; HAQ, Health Assessment Questionnaire; LOT-R, Life 
Orientation Test Revised; VAS, Visual Analogue Scale.
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At baseline, disease activity was not associated with optimism scores as assessed with the 
LOT-R (beta 0.001, p=0.99). After 4 months DAS score and LOT-R score (beta -0.14, p=0.02) 
were inversely associated, but this association disappeared after adjustment for age, gender, 
marital status, having children, level of education, employment and alcohol and tobacco use 
(beta 0.02, p=0.79).
At baseline, the optimism score was 16.7 and after 4 months 16.5 (95%CI -0.7;0.3, p=0.42) 
in the entire group. The LOT-R scores for optimism and BDI-II scores for depressive symp-
toms severity were significantly associated both at baseline and after 4 months (beta -0.51 
(p<0.001) at baseline and beta -0.44 (p<0.001) after 4 months). Patients with higher optimism 
scores had less depressive symptoms.
Of the 211 patients who filled out the questionnaire twice, 138 (65.7%) achieved remission 
after 4 months (mean (SD) DAS 0.9 (0.4)). LOT-R scores remained stable from baseline to 4 
months, whether remission was achieved (mean (SD) 17.0 (4.1) to 17.1 (3.5), 95%CI -0.4;0.7, 
p=0.08) or not (16 (3.9) to 15.2 (3.7), 95%CI -1.6;0.1, p=0.68). Yet, the mean change in LOT-R 
was 1.4 (SE 0.4) points higher than in the patients who did not achieve remission (p=0.001).( 
figure 1) In all patients, LOT-R scores were above the cut-off of 12.
table 2. The association between DAS-components and BDI-II, separately for tender joint count and 
swollen joint count.
Crude beta (p-value) Adjusted beta (p-value)
Baseline
Tender Joint Count 0.27 (<0.001) 0.12 (0.08)1
ESR -0.004 (0.96) 0.02 (0.75)1
VAS 0.33 (<0.001) 0.31 (<0.001)1
4 months follow up
Tender Joint Count 0.41 (<0.001) 0.14 (0.04)2
ESR 0.04 (0.53) 0.04 (0.57)2
VAS 0.47 (<0.001) 0.30 (<0.001)2
Baseline
Swollen Joint Count 0.11 (0.27) 0.04 (0.57)1
ESR -0.004 (0.96) 0.01 (0.85)1
VAS 0.33 (<0.001) 0.34 (<0.001)1
4 months follow up
Swollen Joint Count 0.14 (0.04) 0.04 (0.79)2
ESR 0.04 (0.53) 0.04 (0.54)2
VAS 0.47 (<0.001) 0.35 (<0.001)2
1.Beta adjusted for: age, gender, alcohol consumption yes/no. 2. Beta adjusted for: age, gender, alcohol 
consumption yes/no, Disease Activity Score at baseline, outcome BDI-II at baseline.




In patients with recent onset rheumatoid and undifferentiated arthritis disease activity 
showed a relationship with depressive symptoms severity. In patients who achieved clinical 
remission after 4 months of treatment with methotrexate and prednisone, both depression 
scores and optimism scores improved significantly more compared to patients who did not 
achieve remission.
Our intention was to monitor possible mood changes that might occur during treatment 
with the high tapered dose of prednisone used to try to induce remission of early arthritis in 
our patients. Depression, as well as mania, could be induced by corticosteroids.10 Although 
we do not have a control group to compare the effect of corticosteroids, the finding that 
none of the patients in the IMPROVED study expressed extreme values on either the depres-
sion or the optimism questionnaire, makes it unlikely that prednisone greatly influenced 
depressive symptoms or optimism. More likely, the changes in mood scores that we saw are 
related to a previously described association between rheumatoid arthritis and depression.4 
The patients in the current study had early and relatively mild arthritis and did not carry 
the extra burden of joint destruction and the comorbidity of advanced rheumatoid arthritis, 
which may explain why only few patients had more than minimal depressive symptoms.
It has previously been hypothesized that the occurrence of depressive symptoms in RA 
is related to inflammatory processes and immune activation. This was based on the finding 
that in patients with depression, increased serum levels of cytokines IL-1, IL-6 and TNF-alpha 













































P<0.001 for group difference
F (1, 214) = 26.1
P=0.001 for group difference





5–10 12–16 16–20 > 2010–15 15–20 20–25 25–30 > 30 ≤ 8 8–12
 
figure 1. Univariate regression lines of patients with and without remission.
The size of each square is proportional to the number of patients. P-values by analysis of covariance 
for the group difference, while adjusting for baseline values. Continuous values were used throughout 
the statistical analyses; categorization of baseline BDI-II and optimism scores was done for visualization 
purposes only.
BDI-II, Beck Depression Inventory II; LOT-R, Life Orientation Test Revised
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were found.5,6 In our study, it appears that the depressive symptoms depended mostly on 
the presence and extend of joint tenderness on examination and reported global wellbe-
ing as measured with a Visual Analogue Scale rather than on joint swelling and increased 
erythrocyte sedimentation rate as signs of inflammation. Therefore our results do not sup-
port the hypothesis on inflammation and depression but point into the direction of a relation 
between mood and pain.
This relation may be bidirectional, as already at baseline patients with more severe pain 
had more severe depressive symptoms, which is consistent with previous findings 20 while 
patients who have more severe depressive symptoms may also be more susceptible for and 
report more pain.21-23 Even if inflammation is well suppressed with prednisone and metho-
trexate, residual or non-inflammatory pain can prevent that the patient will be assessed as 
being in remission. This may explain why patients who did not achieve remission after 4 
months had higher depression scores. And this in turn may be related to the fact that patients 
who did not achieve remission had significantly higher depression scores at baseline than 
patients who did achieve remission. Since all patients knew that the treatment goal in the 
IMPROVED trial was to achieve remission, after which medication would be tapered and 
finally discontinued, it may be that not achieving remission and therefore having to intensify 
medication, also influenced feelings of depression.3
Changes in disease activity or arthritic symptoms in general were not related to level of 
optimism as measured with the LOT-R questionnaire, which did not significantly change over 
time. This is possibly related to the fact that optimism levels at baseline were above the cut-
off for low optimism in the majority of our patients. Also, in contrast to depressive symptoms, 
which are considered to be an affliction or reaction to events, optimism is a relative stable 
trait and one of the components of personality. Any differences in reported optimism over 
time appear to be limited and reverberate around what can be called an internal ‘thermostat’ 
of optimism.24 Although the level of optimism after treatment in general did not significantly 
change in our patients, increase in LOT-R score was significantly higher in those who achieved 
remission compared to those who did not. Therefore, there may be a small state component 
to dispositional optimism. Our results also suggest that optimistic patients suffered less from 
depressive symptoms which in turn were influenced by arthritis related symptoms, especially 
pain and unwell being. Also optimism influences pain and therefore possibly symptoms of 
arthritis. In general, baseline optimism has been related to slower disease progression and 
more efficient adjustment and coping strategies.18,25,26
A limitation of our study is that we chose self-report questionnaires to assess depressive 
symptoms severity and optimism because they are easy to answer and little time consuming. 
With the use of a structured psychiatric interview the assessment of depressive symptoms in 
relation to RA disease activity might have been more extensive. The BDI-II provides a numeri-
cal score what makes it easy to assess improvement or reduction of the severity of depressive 
symptoms over time, and a means to classify depressive symptoms severity. In view of the 
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generally minimal reported depressive symptoms, we believe that the results are of scientific 
interests rather than of clinical significance.
We looked at optimism as a different focus on mood, and chose the LOT-R to assess whether 
scores increase or decrease over time or in relation to changes in disease activity. However, 
although there are numerous reports on baseline optimism in relation to changes in aspects 
of (coping with) chronic illnesses, the literature on changes in repeated measurements of 
LOT-R scores in relation to changes in disease activity in patients with a chronic disease are 
scarce. Previous studies on dispositional optimism in rheumatoid arthritis had cross-sectional 
designs, which therefore could not analyze effects on optimism in time.27-29
In conclusion, among these patients with early RA, treated with methotrexate and a 
tapered high dose of prednisone, generally already minimal depressive symptoms severity 
decreased with lower disease activity and was significantly lower in patients who achieved 
remission than in patients who did not. This appears to be mostly due to the relationship of 
depression severity with symptoms of arthritis (pain and unwell being) rather than signs of 
inflammation. Dispositional optimism scores in general stay stable over time, although there 
appeared to be significantly more improvement in optimism when remission was achieved. 
Our data suggest that depressive symptoms in RA patients may improve if, by targeted treat-
ment, symptoms of RA are optimally suppressed.
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To assess whether metacarpal bone mineral density (BMD) loss after 4 months predicts 
radiological progression after 1 year of anti-rheumatic treatment in patients with early (rheu-
matoid) arthritis (RA).
methods
Metacarpal BMD was measured 4 monthly during the first year by digital X-ray radiogramme-
try (DXR-BMD) in patients participating in the IMPROVED study, a clinical trial in 610 patients 
with recent onset RA (2010 criteria) or undifferentiated arthritis (UA), treated according to a 
remission (disease activity score<1.6) steered strategy. With Sharp- van der Heijde progres-
sion ≥0.5 points after 1 year (yes/no) as dependent variable, univariate and multivariate 
logistic regression analyses were performed.
results
Of 428 patients with DXR-BMD results and progression scores available, 28 (7%) had radio-
logical progression after 1 year. Independent predictors for radiological progression were 
presence of baseline erosions (OR (95%CI) 6.5 (1.7-25)) and early DXR-BMD loss (OR (95%CI) 
1.5 (1.1-2.0)). In 366 (86%) patients without baseline erosions early DXR-BMD loss was the 
only independent predictor of progression (OR (95%CI) 2.0 (1.4-2.9)).
conclusions
In early (rheumatoid) arthritis patients, metacarpal BMD loss after 4 months of treatment is an 
independent predictor of radiological progression after 1 year. In patients without baseline 
erosions, early metacarpal BMD loss is the main predictor of radiological progression.
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Early treatment of patients with rheumatoid arthritis (RA) improves disease outcomes includ-
ing radiological joint damage.1-3 Identification of patients who will have a more severe disease 
course may steer early treatment strategies. Since predicting disease outcome is currently 
not possible in a reliable way for all patients, there is a need for new predictors to improve 
existing prediction models.4-7
Periarticular osteopenia is one of the earliest radiological manifestations in RA and may 
already be found in the phase of undifferentiated arthritis (UA).8,9 Metacarpal bone mineral 
density (BMD) loss may therefore be a potentially new predictor of disease outcome in pa-
tients with early (rheumatoid) arthritis. Previous research showed that metacarpal BMD loss 
is associated with disease activity 10 and metacarpal BMD loss in the first year after diagnosis 
is predictive for radiological damage up to five years in patients with early RA.11-13 For clinical 
practice however, any predictive value of metacarpal BMD loss would be greater if it can be 
measured earlier in the disease course.
Therefore we investigated whether metacarpal BMD loss after 4 months of treatment, as 
measured by digital X-ray radiogrammetry (DXR-BMD), may be a predictor of radiological 
joint damage progression after 1 year in patients with undifferentiated or early RA treated 
according to a tight control, remission steered treatment strategy.
Patients and methods
Patients and study design
Data from the IMPROVED study were used, a multicenter, randomized clinical trial in 610 
patients, including 479 (80%) patients with recent onset RA (according to the 2010 American 
College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classifica-
tion criteria for RA 14 with a symptom duration <2 years), 122 patients with UA (having at 
least 1 joint clinically assessed as ‘arthritis’ and 1 other painful joint, clinically suspected of 
having early RA, regardless of symptom duration) and 9 patients that could not be classified 
because of missing data. Patients were treated according to a tight control strategy, aimed at 
achieving remission, defined as a disease activity score (DAS) <1.6 (DAS-remission).15 All pa-
tients started with 4 months of methotrexate (MTX) 25 mg/week and prednisone 60 mg/day 
tapered to a stable dose of 7.5 mg/day in 7 weeks. Patients in DAS-remission after 4 months 
started tapering medication, if possible to drug free (early DAS-remission group). Patients not 
in early DAS-remission were randomized either to MTX 25 mg/week plus hydroxychloroquine 
(HCQ) 400 mg/day, sulfasalazine (SSZ) 2000 mg/day and prednisone 7.5 mg/day (arm 1) or to 
MTX 25 mg/week plus adalimumab (ADA) 40 mg/2weeks (arm 2). Some patients who were 
not in DAS-remission after 4 months, were not randomized and treated outside of protocol 
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(Outside of Protocol (OP) group). Full details about the IMPROVED study protocol were previ-
ously published.16,17
In the current analysis we included all patients participating in the IMPROVED study whose 
radiological progression data after 1 year and at least 1 DXR-BMD result during the first year 
were available.
demographic and clinical variables
At baseline the following variables were collected: age, gender, symptom duration, body 
mass index, current smoking status and alcohol use, calcium intake, postmenopausal status, 
previous fractures, family history on osteoporosis, anti-citrullinated protein antibodies (ACPA) 
and rheumatoid factor (RF) status. At baseline and every 4 months, the following clinical and 
laboratory variables were collected: DAS, including Ritchie Articular Index (RAI), swollen 
joint count, erythrocyte sedimentation rate (ESR, mm/hr) and visual analogue scale (VAS) 
for global health, and C-reactive protein (CRP). During the first year, X-rays of hand and feet 
were made 4 monthly by digital radiography in all patients. Radiological progression, scored 
using the Sharp/van der Heijde scoring method, was assessed by two independent readers 
blinded for patient identity and time order of the radiographs.18 Progression was defined 
as an increase in Sharp-van der Heijde Score (SHS) of ≥0.5 points. Details on inter-reader 
reliability were previously published.17
metacarpal bmd measurements
Suitable routine digital X-rays of both hands were used to measure metacarpal BMD us-
ing Digital X-ray Radiogrammetry (DXR-BMD) measured by DXR-online (Sectra, Linköping, 
Sweden), a computerised method that automatically recognises three regions of interest on 
the second, third and fourth metacarpal bones. At each region, DXR-BMD is estimated from 
multiple measurements of cortical thickness, bone width and porosity.19 The mean value of 
both hands was used in all analyses to avoid bias induced by hand dominance. ‘DXR-BMD 
loss’ was defined as a loss in DXR-BMD of ≥1.5 mg/cm2/4months.10
statistical analysis
Almost half of the available X-rays were found unsuitable for DXR-measurements. This re-
sulted in missing DXR-BMD values in 141/428 patients (33%) at baseline, 73/428 (17%) after 
4 months, 148/428 (35%) after 8 months and 140/428 (33%) after 1 year. To avoid possible 
bias induced by missing data and to increase power, multiple imputation was performed. 
Ten datasets were created in which missing DXR-values were imputed based on a linear 
regression model fitting available patient and disease characteristics and DXR-values.20 Esti-
mates obtained from regression analyses were automatically pooled by SPSS, other multiple 
estimates were averaged.
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Median (IQR) DXR-BMD changes are shown because of a skewed distribution. Mann 
Whitney U test was used for comparisons of DXR-BMD changes between patients with and 
without radiological progression. To identify independent predictors of radiological progres-
sion, we performed univariate followed by multivariate regression analyses. From previous 
literature, the following potential predictors for (rapid) radiological progression were 
identified and entered in a univariate logistic regression model with radiologic progression 
(yes/no) as dependent variable: presence of ACPA and/or RF, baseline swollen joint count, 
baseline ESR and CRP levels, baseline total SHS, baseline erosion score and treatment.4,6,7 In 
addition, we selected age, gender, fulfilling the 2010 ACR/EULAR criteria for RA and achieving 
DAS-remission after 4 months. Next to baseline erosion score we also entered presence of 
erosions, defined as ≥1 erosions, as covariate. Because only 28 (7%) patients had radiological 
progression, multivariate regression in the total study population was powered for about 
three variables.21,22 Therefore, in addition to DXR-BMD loss from baseline to 4 months, we 
selected the 2 univariate significant predictors (using a significance level of 0.10) with the 
highest effect size for multiple regression. As radiological progression was present in <10% of 
the patients and therefore can be classified as ‘rare’, we argued that Odds Ratios (OR) obtained 
from all logistic regression analyses can be interpreted as relative risks (RR).23
All statistical analyses were conducted with SPSS for Windows version 20.0.
results
clinical characteristics
We included 428 patients in the current analyses. Baseline characteristics of these patients 
did not differ significantly from those participating in the IMPROVED study where no SHS 
or DXR data were available (data not shown). Twenty-eight (7%) patients had radiological 
progression after 1 year and 400 (93%) had no radiological progression. For those with ra-
diological progression, the median (IQR) progression score was 0.5 (0.5-1.4). One patient had 
rapid radiological progression (progression score ≥5 points) 24 after 1 year (18 points).
Compared to patients without progression, patients with progression were older, more 
often postmenopausal and ACPA positive, and more often fulfilled the 2010 criteria for RA. 
Furthermore, they had more often ≥1 erosions at baseline and a higher median total baseline 
SHS and, only at 8 months, a slightly higher DAS. (table 1)
dXr-bmd change
Table 2 shows absolute DXR-BMD values and DXR-BMD changes during the first year. Com-
pared to patients without radiological progression after 1 year, patients with radiological 
progression had lower absolute DXR-BMD values at baseline and after 4, 8 and 12 months 
follow up. From baseline to 4 months, median DXR-BMD changes were significantly larger 
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table 1: Clinical characteristics at baseline and during one year follow up of the total study group and 
separate for patients with and without radiological progression.
Radiologic progression
Total population Yes No p-value
Baseline n=428 n=28 n=400
Age, years, mean±SD 52 ± 13 58 ± 11 52 ± 13 0.01
Female, no (%) 294 (69) 22 (79) 272 (68) 0.2
BMI, kg/m2, mean±SD 26 ± 4 25 ± 4 26 ± 4 0.6
Current smoking, no (%) 127 (30) 11 (39) 116 (29) 0.3
Current alcohol use, no (%) 250 (58) 17 (61) 233 (58) 0.9
Postmenopausal status, no (%), n=294 156 (53) 17 (89) 139 (58) 0.01
Previous fractures, no (%) 142 (33) 8 (29) 134 (34) 0.7
Familial osteoporosis, no (%) 72 (17) 6 (21) 66 (17) 0.5
Calcium intake, mg/day, median (IQR) 800 (600-1050) 875 (725-1069) 778 (600-1030) 0.2
25(OH) Vitamine D, nmol/l, median (IQR) 55 (38-75) 46 (25-75) 55 (39-75) 0.3
DAS (mean±SD) 3.2 ± 0.9 3.3 ± 0.9 3.2 ± 0.9 0.8
RA(2010), no (%) 344 (80) 26 (93) 318 (80) 0.04
Symptom duration, weeks, median (IQR) 18 (9-33) 20 (9-47) 18 (9-32) 0.5
ACPA positive, no (%) 247 (58) 23 (82) 224 (56) 0.008
RF positive, no (%) 241 (56) 18 (64) 223 (56) 0.2
ACPA and RF positive, no (%) 205 (48) 19 (68) 186 (47) 0.04
SHS total score 0 (0-0) 0.5 (0-4.5) 0 (0-0) <0.001
Presence of erosions, no (%) 62 (14) 11 (39) 51 (13) <0.001
4 months follow up
DAS (mean±SD) 1.5 ± 0.9 1.5 ± 0.8 1.5 ± 0.9 0.9
Remission, no (%) 275 (64) 17 (61) 258 (65) 0.7
Early remission Group, no (%) 281 (66) 17 (61) 264 (66) 0.6
Arm 1 MTX+SSZ+HCQ+pred, no (%) 60 (14) 4 (14) 56 (14) 0.97
Arm 2 MTX+adalimumab, no (%) 57 (13) 5 (18) 52 (13) 0.5
Outside of Protocol Group, no (%) 30 (7) 2 (7) 28 (7) 0.98
8 months follow up
DAS (mean±SD) 1.5 ± 0.8 1.8 ± 1.0 1.5 ± 0.8 0.05
Remission, no (%) 246 (57) 12 (43) 234 (61) 0.1
1 year follow up
Use of Bisphosphonate, no (%) 129 (30) 9 (32) 120 (30) 0.8
Use of Calcium and/ or Vitamine D, no (%) 204 (48) 16 (57) 180 (45) 0.2
DAS (mean±SD) 1.6 ± 0.9 1.6 ± 0.9 1.6 ± 0.9 0.7
Remission, no (%) 235 (55) 16 (57) 219 (55) 0.8
SHS progression 0 (0-0) 0.5 (0.5-1.4) 0 (0-0) <0.001
ACPA, Anti-Citrullinated Protein Antibodies; arm 1, patients not in early remission who were randomized 
to arm 1; arm 2, patients not in early remission who were randomized to arm2; BMI, Body Mass Index (kg/
m2); DAS, Disease Activity Score; Early remission group, patients who were in remission after 4 months 
and started tapering medication; HCQ, hydroxychloroquine; IQR, interquartile range; MTX, methotrexate; 
no, number; Outside of Protocol group, patients not in early remission but not randomized and 
treated outside the protocol; Presence of erosions, defined as ≥1 erosions; pred, prednisone; RA(2010), 
rheumatoid arthritis according to the ACR/EULAR 2010 classification criteria for RA; RF, Rheumatoid 
Factor; remission, defined as DAS<1.6; SD, standard deviation; SHS, Sharp- van der Heijde Score; SSZ, 
sulfasalazine.
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in patients with radiological progression (median (IQR) -9.6 (-15.2;-2.7) mg/cm2) than in pa-
tients without (-2.0 (-7.2;2.5) mg/cm2, p=0.007). Twenty-four (86%) patients with radiological 
progression had DXR-BMD loss within the first 4 months, compared to 212 (53%) patients 
without radiological progression (p=0.01). One patient with rapid radiological progression 
(18 points after 1 year) had a change in DXR-BMD within the first 4 months of -27.4 mg/cm2.
treatment steps
Seventeen (61%) patients with radiological progression after 1 year had been in early 
DAS-remission after 4 months and subsequently had started tapering prednisone to zero, 
9 (32%) had not achieved early remission and were randomized, and 2 were treated outside 
of protocol. Of the 17 in early DAS-remission, 5 patients relapsed after tapering prednisone 
and restarted it, whereas 12 remained in remission and started tapering MTX to zero. Six 
patients relapsed after tapering MTX and restarted it and 6 did not relapse and were in drug 
free remission after 1 year. The median (IQR) early DXR-BMD change of all 17 patients was 
-10.9 (-14.5;-2.5) mg/cm2 (corresponding to -2.7 (-3.6;-0.6 mg/cm2/month)), compared to 
-1.8 (-7.3;2.4) mg/cm2 (corresponding to -0.5 (-1.8;0.6 mg/cm2/month)) in 258 patients who 
achieved early DAS-remission and had no radiological progression after 1 year (p=0.02). DXR-
BMD loss after 4 months was present in 14/17 (82%) patients in early DAS-remission who had 
radiological progression after 1 year, compared to 134 (52%) patients in early DAS-remission 
without radiological progression after 1 year (p=0.053).
table 2: Metacarpal bone mineral density measured by digital X-ray radiogrammetry during the 
first study year of the total study population and separate for patients with and without radiological 
progression.
Time point SHS progression
(months) Total n=428 Yes: n=28 No: n=400 p-value
DXR-BMD
g/cm2, median (IQR)
0 0.593 (0.527-0.640) 0.558 (0.501-0.601) 0.597 (0.529-0.642) 0.03
4 0.590 (0.526-0.637) 0.546 (0.486-0.587) 0.593 (0.529-0.640) 0.008
8 0.590 (0.525-0.639) 0.544 (0.482-0.589) 0.593 (0.528-0.642) 0.009
12 0.585 (0.522-0.636) 0.541 (0.472-0.586) 0.588 (0.524-0.638) 0.008
Change in DXR-BMD 
mg/cm2, median 
(IQR)
0 - 4 -2.4 (-7.6 ; 2.2) -9.6 (-15.2 ; -2.7) -2.0 (-7.2 ; 2.5) 0.007
4 - 8 -1.1 (-6.0 ; 3.2) -2.2 (-8.1 ; 3.9) -1.1 (-5.8 ; 3.1) 0.5
8 -12 -3.1 (-9.0 ; 1.3) -4.5 (-14.0 ; 0.05) -3.1 (-8.7 ; 1.5) 0.3
0 - 12 -5.7 (-15.4 ; 0.6) -15.8 (-27.4 ; -2.3) -5.4 (-14.2 ; 0.9) 0.007
Change in DXR-
BMD, % from 
baseline
0 - 4 -0.4 (-1.3 ; 0.4) -1.7 (-2.9 ; -0.5) -0.3 (-1.2 ; 0.4) 0.007
4 - 8 -0.2 (-1.1 ; 0.5) -0.4 (-1.5 ; 0.7) -0.2 (-1.0 ; 0.5) 0.5
8 -12 -0.5 (-1.5 ; 0.2) -0.8 (-2.7 ; 0.008) -0.5 (-1.5 ; 0.2) 0.2
0 - 12 -1.0 (-2.7 ; 0.1) -2.8 (-4.9 ; -0.4) -0.9 (-2.4 ; 0.2) 0.006
DXR-BMD, metacarpal bone mineral density measured by digital X-ray radiogrammetry; IQR, inter quartile 
range; SHS progression, defined as progression after 1 year ≥0.5 points.
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table 3a: Univariate logistic regression analysis with radiological progression (yes/no) as dependent 
variable in the total study population.
Univariate Logistic regression
Crude OR 95%CI R2
RA according to 2010 criteria 6.5 0.9-48.8 0.04
Presence of baseline erosions 4.4 2.0-10.0 0.07
ACPA/RF
Both negative ref 0.04
One positive 2.6 0.6-11.3
Both positive 3.9 1.1-13.2
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.8 0.13
Female gender 1.7 0.7-4.4 0.01
Erosion score at baseline 1.1 0.99-1.1 0.01
Baseline total SHS 1.1 0.996-1.0 0.02
Age, years 1.0 1.0-1.1 0.04
Baseline ESR 1.0 0.999-1.0 0.02
Baseline CRP 1.0 0.997-1.0 0.01
Baseline TJC 0.97 0.9-1.1 0.003
Treatment Group
Early remission group ref 0.003
Arm 1 MTX+SSZ+HCQ+pred 1.1 0.4-3.4
Arm 2 MTX+adalimumab 1.5 0.5-4.2
Outside of Protocol group 1.1 0.2-5.1
Early DAS-remission 0.8 0.4-1.9 0.001
ACPA, anti-citrullinated protein antibodies; arm 1, patients not in early remission who were randomized 
to methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ) and low dose prednisone; arm 
2, patients not in early remission who were randomized to MTX plus adalimumab; CI, confidence 
interval; CRP, C-reactive protein; DXR-BMD, metacarpal bone mineral density measured by digital X-ray 
radiogrammetry; Early DXR-BMD loss, change in DXR-BMD between baseline and 4 months; Early 
remission group, patients who were in remission after 4 months and started tapering medication; Early 
DAS-remission, remission (DAS<1.6) after 4 months; Erosion score, Sharp-van der Heijde erosion score; 
ESR, erythrocyte sedimentation rate in mm/hr; OR, odds ratio; Outside of protocol group, patients 
not in early remission but not randomized and treated outside the protocol; Presence of baseline 
erosions, defined as ≥1 erosions at baseline; RA, rheumatoid arthritis according to the 2010 ACR/EULAR 
classification criteria; RF, rheumatoid factor; ref, reference category; SHS, Sharp-van der Heijde Score; TJC, 
tender joint count.
table 3b: Multivariate logistic regression with radiologic progression (yes/no) as dependent variable in 
the total study population.
Multivariate logistic regression Adjusted OR 95%CI
Presence of baseline erosions 3.9 1.6-9.5
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.7
RA according to 2010 criteria 4.9 0.6-37
CI, confidence interval; DXR-BMD, metacarpal bone mineral density measured by digital X-ray 
radiogrammetry; Early DXR-BMD loss, change in DXR-BMD between baseline and 4 months; OR, odds 
ratio; Presence of baseline erosions, defined as ≥1 erosions, RA, rheumatoid arthritis according to the 2010 
ACR/EULAR classification criteria.
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Predictors of radiological progression
Univariate predictive variables for radiologic progression after 1 year were: fulfilling the 
2010 criteria for RA (p=0.07), presence of baseline erosions (yes/no) (p<0.001), presence of 
both ACPA and RF (p=0.03), early DXR-BMD loss after 4 months (p=0.008), baseline total SHS 
score (p=0.07), age (p=0.01), baseline ESR (p=0.06) and baseline tender joint count (p=0.05). 
Female gender, presence of either ACPA or RF, symptom duration, baseline erosion score, CRP 
level and treatment group were not predictive. Achieving DAS-remission after 4 months was 
also not predictive for radiological progression after 1 year.(table 3a)
Together with early DXR-BMD loss, presence of baseline erosions and fulfilling the 2010 cri-
teria for RA were selected for inclusion in the multivariate regression analysis. Both presence of 
baseline erosions and early DXR-BMD loss were predictive for radiological progression after one 
year independent of each other and independent of fulfilling the 2010 criteria for RA.(table 3b).
In an additional multivariate model including early DXR-BMD loss, presence of baseline 
erosions and presence of both ACPA and RF, presence of both ACPA and RF was not an 
independent predictor of radiological progression, whereas DXR-BMD loss and presence of 
baseline erosions both were (data not shown).
After leaving out the one patient with rapid radiological progression, the results above did 
not significantly change (data not shown).
Patients without baseline erosions
In 366 (86%) patients no baseline erosions were present. Of these 366 patients, 17 patients (5%) 
showed radiological progression after 1 year (61% of all 28 patients with radiological progres-
sion) and 349 (95%) did not. Median DXR-BMD change from baseline to 4 months was -11.8 
(-16.7;-4.7) mg/cm2 in patients with progression and -2.0 (-7.0;2.4) mg/cm2 in patients without 
progression (corresponding to -2.9 (-4.2;-1.2) and -0.5 (-1.7;0.6) mg/cm2/months, respectively). 
Univariate significant predictors for progression after 1 year in patients without baseline ero-
sions were age (p=0.004), baseline total SHS (in these patients reflecting baseline joint space 
narrowing) (p=0.009), baseline ESR level (p=0.096) and early DXR-BMD loss (p=0.02).(table 4a)
Early DXR-BMD loss and total baseline SHS were selected for inclusion in the multivariate 
regression analysis. Early DXR-BMD loss was predictive for radiological progression after 1 
year independent of baseline total SHS in patients without baseline erosions.(table 4b)
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table 4a: Univariate logistic regression analysis with radiological progression (yes/no) as dependent 
variable in patients without baseline erosions.
Univariate Logistic regression
Crude OR 95%CI R2
RA according to 2010 criteria 4.1 0.5-31.3 0.02
ACPA/RF
Both negative ref 0.03
One positive 3.0 0.5-17
Both positive 3.2 0.7-15
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.9 0.13
Female gender 2.1 0.6-7.5 0.01
Baseline total SHS 1.3 1.1-1.6 0.06
Age, years 1.1 1.0-1.1 0.08
Baseline ESR, mm/hr 1.0 0.997-1.0 0.02
Baseline CRP 1.0 0.99-1.0 0.002
Baseline TJC 0.97 0.9-1.1 0.004
Treatment Group
Early remission group ref 0.01
Arm 1 MTX+SSZ+HCQ+pred 1.6 0.4-5.9
Arm 2 MTX+adalimumab 1.7 0.5-6.6
Outside of Protocol group 1.8 0.4-8.8
Early DAS-remission 0.6 0.2-1.7 0.007
ACPA, anti-citrullinated protein antibodies; arm 1, patients not in early remission who were randomized 
to methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ) and low dose prednisone; arm 
2, patients not in early remission who were randomized to MTX plus adalimumab; CI, confidence 
interval; CRP, C-reactive protein; DXR-BMD, metacarpal bone mineral density measured by digital X-ray 
radiogrammetry; Early DXR-BMD loss, change in DXR-BMD between baseline and 4 months; Early 
remission group, patients who were in remission after 4 months and started tapering medication; Early 
DAS-remission, remission (DAS<1.6) after 4 months; ESR, erythrocyte sedimentation rate in mm/hr; OR, 
odds ratio; Outside of protocol group, patients not in early remission but not randomized and treated 
outside the protocol; RA, rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria; RF, 
rheumatoid factor; ref, reference category; SHS, Sharp-van der Heijde Score; TJC, tender joint count.
table 4b: Multivariate logistic regression with radiologic progression (yes/no) as dependent variable in 
patients without baseline erosions
Multivariate logistic regression Adjusted OR 95%CI
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.8
Baseline total SHS 1.3 1.0-1.6
CI, confidence interval; DXR-BMD, metacarpal bone mineral density measured by digital X-ray 
radiogrammetry; Early DXR-BMD loss, change in DXR-BMD between baseline and 4 months; OR, odds 
ratio; SHS, Sharp-van der Heijde Score.
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In patients with early rheumatoid or undifferentiated arthritis, metacarpal BMD loss measured 
by DXR after four months of treatment with MTX and a tapered high dose of prednisone is 
predictive for future joint damage after 1 year of remission steered treatment. In patients 
without baseline erosions (86%), metacarpal BMD loss was the main predictor of future joint 
damage.
These data suggest that DXR measurements over a period of 4 months from baseline can 
help to decide which patients with early arthritis should start anti-rheumatic treatment to 
prevent joint damage or damage progression, one of the main goals in the treatment of 
RA.25 Early treatment and suppression of disease activity has been shown to be associated 
with better suppression of radiological damage progression.1-3 To facilitate this, in 2010 new 
classification criteria for RA were formulated.14 In the IMPROVED trial we included not only 
patients with RA (according to the 2010 classification criteria) but also patients with UA, who 
were judged to represent RA in an early phase of the disease by the treating rheumatologist. 
Starting treatment so early in disease course carries the risk of overtreatment of patients 
who are misdiagnosed as RA, but a treatment delay means risking irreversible joint damage 
progression.
To individualize treatment, predictive factors for damage progression have been identified 
and prediction models built.4,6,7 But in particular in patients without baseline damage, pre-
dicting which patients will develop joint damage may be difficult. We predicted metacarpal 
BMD loss since this was linked with both disease activity and joint damage progression in 
patients with early and established RA, and metacarpal BMD loss after 1 year has been shown 
to have predictive value additional to known predictors.11,12 Our paper is the first to report 
metacarpal BMD changes already after 4 months, and we found that changes do occur.
Ideally, an outcome predictor can be identified already at baseline. In this early arthritis 
population, presence of baseline erosions was the only independent baseline predictor of 
radiological progression after 1 year besides metacarpal BMD loss after 4 months. Another 
obvious outcome after 4 months, remission yes or no, was not predictive of radiological pro-
gression after 1 year. Some patients who had radiological joint damage after 1 year even were 
in remission throughout the whole year and tapered all medication according to the study 
protocol. Our results indicate that after 4 months, a strong predictor of progression may help 
to decide if adjustments of the chosen treatment strategy should be made in patients with 
early arthritis.
One limitation of this study is the fact that, due to the inclusion of patients with early and 
relatively mild disease, progressively treated with the aim of achieving remission, only a few 
patients had radiological damage progression. Our results however reached statistical sig-
nificance, although we acknowledge that the damage scores are hardly of clinical relevance 
this early in the disease phase. But as RA treatment more and more aims at achieving total 
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disease and damage control in an early phase of the disease, we think that our findings may 
be relevant for daily practice.
Another limitation was that we found many of the ‘routinely’ acquired radiographs to be 
unsuitable for DXR. To handle missing metacarpal BMD data, we performed multiple imputa-
tion 20 to account for potential bias caused by data ‘missing at random’, meaning that miss-
ingness depends on other observed patient characteristics rather than on the fact whether 
metacarpal BMD measurements were possible or not.
A third possible limitation may be that, as DXR-measurements in this study were done in 
retrospect on X-rays taken in 12 different hospitals using imaging protocols not adjusted to 
DXR, precision of the method may be lower than previously published. DXR-BMD has been 
shown to have a very high short and long term precision in both in vitro cadaver studies 
(coefficients of variation (CV) of 0.22 to 1%) and in one cohort study and one clinical trial (CV 
of 0.25 to 0.46%).26-29 However, supported by the consistency of our results, precision in this 
study may still be considered as high.
If metacarpal BMD is to be applied in clinical practice using the DXR online method, neither 
low precision nor missing values may be problematic, as X-rays will then be taken according 
to a predefined protocol (Sectra, Sweden). Precision may reach values described above, and 
in case of mal positioning, direct feedback will be given, which makes it more suitable for use 
in clinical practice.
In conclusion, we showed that loss of metacarpal bone mineral density measured by DXR 
after the first 4 months of treatment is an independent predictor of future bone damage 
in patients with early (rheumatoid) arthritis. This suggests that 4 monthly metacarpal BMD 
measurements can help to guide treatment decisions in individual patients or may be added 
to improve the predictive value of existing prediction models for disease outcome in RA.
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To investigate possible determinants of localized bone loss in patients with early arthritis.
methods
Of 610 patients with early arthritis in the IMPROVED study, 442 had ≥1 measurements of 
metacarpal bone mineral density (BMD) by Digital X-ray Radiogrammetry (DXR-BMD) during 
year 1 of remission (Disease Activity Score <1.6) steered treatment. Initial treatment consisted 
of methotrexate and a tapered high dose of prednisone. If remission was achieved medica-
tion was tapered, if not, patients were randomized to combination therapy including low 
dose prednisone or adalimumab. DXR-BMD loss (≥1.5 mg/cm2/4 months, ≥4.6 mg/cm2/year) 
or gain (≥4.6 mg/cm2/year) was compared between treatment and patient groups. Predictors 
for DXR-BMD loss were assessed.
results
DXR-BMD loss occurred in 246 (56%) and 243 (55%) patients after 4 months and 1 year, DXR-
BMD gain in 60 (14%) patients after 1 year. Of patients with DXR-BMD loss after 4 months, 32 
(13%) regained the total loss within 1 year. Age and postmenopausal status were indepen-
dent predictors of DXR-BMD loss after 1 year. Randomized patients less often showed DXR-
BMD loss after 1 year than patients who achieved early remission (52 (44%) versus 170 (59%), 
p=0.02). Based on small numbers, patients treated with adalimumab showed the smallest 
loss and most often gain (14 (54%)).
conclusions
After 1 year of remission steered treatment, metacarpal BMD loss occurs in more than half of 
patients with early arthritis. Our data may suggest that although initial combination therapy 
including a tapered high dose of prednisone may induce remission in a large proportion of 
patients, it may have at least a temporary negative effect on localized BMD.
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Bone loss is a clinical feature in patients with rheumatoid arthritis (RA) and occurs general-
ized as well as localized around inflamed joints.1 Generalized bone loss may be caused by 
prolonged disease activity, immobility by functional impairment and anti-rheumatic medica-
tion such as corticosteroids.2-5 Earlier in the disease course of RA localized bone loss occurs, 
possibly due to localized inflammatory processes.1,6 In an earlier study we have shown that 
in RA patients who were in clinical remission for at least 1 year, an increase in localized bone 
mineral density (BMD) can occur. This was not found in patients who had high or even low 
disease activity.7 Measuring localized bone loss in patients with early (rheumatoid) arthritis 
in association with treatment and treatment response may be helpful to understand pos-
sible determinants of bone loss in rheumatoid arthritis. To investigate this, we performed 
four-monthly metacarpal BMD measurements by Digital-X-ray Radiogrammetry (DXR, Sectra, 
Linköping, Sweden) during the first year in patients participating in the IMPROVED study, 
a remission steered clinical trial in 610 patients with undifferentiated arthritis (UA) or early 
RA.8,9
methods
Patients and study design
IMPROVED is a multicentre, randomized clinical trial in 479 (79%) patients with recent onset 
RA (according to the 2010 classification criteria for RA 10 with a symptom duration <2 years) 
and 122 (20%) UA patients (having at least one arthritic and one other painful joint and clini-
cally suspected to represent early RA, regardless of symptom duration). Patients were treated 
according to a tight control strategy, aimed at achieving remission, defined as a Disease 
Activity Score (DAS) <1.6.11 All patients started with 4 months of methotrexate (MTX) 25 mg/
week and prednisone 60 mg/day, tapered to a stable dose of 7.5 mg/day in 7 weeks. Patients 
in remission after 4 months (early remission) started tapering medication, if possible to drug 
free. Patients who did not achieve early remission were randomized either to MTX 25 mg/
week plus hydroxychloroquine (HCQ) 400 mg/day, sulphasalazine (SSZ) 2000 mg/day and 
prednisone 7.5 mg/day (arm 1) or to MTX 25 mg/week plus adalimumab 40 mg/2weeks (arm 
2). Thirty-one patients who did not achieve early remission were not randomized and treated 
outside of protocol. Full details on the IMPROVED study protocol were previously published.9
demographic and clinical variables
At baseline and every 4 months, the following clinical and laboratory variables were collected: 
DAS, including Ritchie Articular Index (RAI), swollen joint count, erythrocyte sedimentation 
rate (ESR, mm/hr) and visual analogue scale (VAS, mm) for global health,12 and C-reactive 
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protein (CRP). Use of calcium and/or vitamin D supplements and bisphosphonates was as-
sessed after one year.
metacarpal bmd measurements
At baseline, 4 months, 8 months and 1 year, digital plain radiographs of hands and feet were 
made according to the protocol of the local hospitals’ radiology departments. No moulds 
or positioning devices were used, no specific technical adaptions were applied. Metacarpal 
BMD was measured on X-rays of both hands using Digital X-ray Radiogrammetry (DXR-
BMD) by dxr-online (Sectra, Linköping, Sweden). Three regions of interest are automatically 
recognized on the second, third and fourth metacarpal bone. At each region, DXR-BMD is 
estimated from multiple measurements of cortical thickness, bone width and porosity.13 The 
mean value of both hands was used in all analyses to maximize precision and avoid bias 
induced by hand dominance. Previously, DXR-BMD measurements have been shown to have 
a very high short and long term precision in both in vitro cadaver studies (coefficients of 
variation (CV) of 0.22 to 1%) and in one cohort study and one clinical trial (CV of 0.25 to 
0.46%).14-17 However, because measurements in this study were done in retrospect, precision 
may be lower than previously published.
Absolute values of DXR-BMD were expressed in g/cm2, changes in DXR-BMD in mg/
cm2/4months or mg/cm2/year. ‘DXR-BMD loss’ was defined as a decrease in DXR-BMD ≥1.5 
mg/cm2/4months or ≥4.6 mg/cm2/year and ‘BMD-DXR gain’ as an increase in DXR-BMD ≥1.5 
mg/cm2/4months or ≥4.6 mg/cm2/year.7
Of the 610 patients included, 442 patients had least one DXR-BMD measurement during the 
first year. Of the other patients, four-monthly radiographs were available but found unsuit-
able for DXR-measurements by Sectra,18 as were baseline radiographs in 148 patients (33%), 
4 months-radiographs in 78 patients (18%), 8 months-radiographs in 155 patients (35%) and 
1 year radiographs in 148 patients (33%) of the 442 patients included in the current analysis.
statistical analysis
Median (IQR) DXR-BMD (change) values were shown because of skewed distributions. Be-
cause of missing DXR-BMD values multiple imputation was performed.19 Ten datasets were 
created in which missing DXR-values were imputed based on a linear regression model fitting 
available patient and disease characteristics and DXR-values. Estimates obtained from regres-
sion analyses were automatically pooled by SPSS, other multiple estimates were averaged.
All DXR-BMD changes and percentages loss and gain were obtained from the imputed 
dataset. Because of the small number of patients, separate values for arm 1 and 2 were ob-
tained from the original dataset. Non-parametric test were used for comparisons of DXR-BMD 
changes between various patient groups. Absolute DXR-BMD levels over time were compared 
between various patient groups by linear mixed models, performed on the original dataset, 
with time (study visit) and fulfilling of the 2010 classification criteria for RA (yes/no) or having 
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achieved early remission (yes/no) or being in continuous remission throughout the first study 
year (yes/no) as fixed effects, in an unstructured covariance structure. Regression analyses 
were performed on the imputed dataset with DXR-BMD loss (yes/no) as binomial dependent 
variable. Statistical analyses were conducted with SPSS for Windows version 20.0.
results
baseline and follow up clinical characteristics
Of the 442 patients selected for the current analysis, 355 (80%) patients fulfilled the 2010 cri-
teria for RA at baseline, 82 (19%) did not (UA) and 5 patients had missing data. Compared to 
RA patients, UA patients had a lower disease activity (mean DAS (SD) 2.7 (0.7) versus 3.3 (0.9), 
p<0.001), were less often female (47/82 (57%) versus 247/355 (70%), p=0.2) and female pa-
tients less often were in a postmenopausal state (21/82 (41%) versus 134/355 (54%), p=0.03). 
Furthermore, 3 UA patients were anti-citrullinated protein antibodies (ACPA) positive and 3 
rheumatoid factor (RF) positive, compared to respectively 246 (69%) and 244 (69%) of the RA 
patients (p<0.001). After 4 months, early remission was achieved in 55 UA patients (67%) and 
226 RA patients (64%) (p=0.6).(table 1)
changes in dXr-bmd
From baseline to 4 months, median (IQR) DXR-BMD loss in all patients was -2.6 (-8.1;2.2) mg/
cm2 (with a maximum of -40.3 mg/cm2 and a minimum of 44.0 mg/cm2), -1.5 (-7.3;3.7) mg/
cm2 in UA patients and -2.8 (-8.6;2.1) mg/cm2 in RA patients (p=0.2). DXR-BMD loss, defined 
a decrease ≥1.5 mg/cm2, was present in 246 (56%) patients, 41 (50%) UA and 205 (58%) RA 
patients (p=0.3). DXR-BMD gain, defined as an increase ≥1.5 mg/cm2, was present in 129 
(29%) patients, 27 (33%) UA and 102 (29%) RA patients (p=0.5).
From baseline to 1 year, median (IQR) DXR-BMD loss in all patients was -6.4 (-16.1;0.6) mg/
cm2 (with a maximum of -80.0 mg/cm2 and a minimum of 39.8 mg/cm2), -4.1 (-13.1;2.9) mg/
cm2 in UA patients and -6.9 (-16.6;0.1) mg/cm2 in RA patients (p=0.08). (table 2) DXR-BMD loss 
after 1 year, defined as a decrease ≥4.6 mg/cm2, was present in 243 (55%) patients, 40 (49%) 
UA patients and 203 (57%) RA patients (p=0.2). DXR-BMD gain after 1 year, defined as an 
increase ≥4.6 mg/cm2, was present in 60 (14%) patients, 15 (18%) UA patients and 45 (13%) 
RA patients (p=0.3).
To investigate whether DXR-BMD loss from baseline to 4 months was regained in the fol-
lowing months, we evaluated changes in DXR-BMD from 4-12 months in the 246 patients 
with DXR-BMD loss from baseline to 4 months. In these patients, the additional median 
(IQR) DXR-BMD loss from 4-12 months was -3.1 (-12.0;2.5) mg/cm2. In 123 (50%) patients the 
additional DXR-BMD loss was ≥3.1 mg/cm2/8months, 56 (23%) patients had DXR-BMD gain 
≥3.1 mg/cm2/8months and 67 (27%) patients had a stable DXR-BMD (loss or gain <3.1 mg/
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cm2/8months). Only 32 (13%) patients regained all the DXR-BMD loss (or more) that occurred 
from baseline to 4 months.
Table 3 shows results of the univariate regression analyses with DXR-BMD loss after 4 
months and 1 year as dependent outcomes. Of tested baseline variables, age and postmeno-
pausal status were predictors for DXR-BMD loss after 4 months (respectively OR (95%CI) 1.03 
(1.01-1.05), p=0.002 and 2.9 (1.6-5.2), p=0.001), although not independently of each other. 
DAS at 4 months was not associated with DXR-BMD loss after 4 months (0.96 (0.7-1.3), nor 
table 1: Demographic, clinical and laboratory characteristics at baseline and follow up of the total study 
population and separate for patients with undifferentiated arthritis and rheumatoid arthritis (according to 










Age, years, mean±SD 52 ± 14 52 ± 15 52 ± 13 0.8
Female, no (%) 303 (69) 47 (57) 247 (70) 0.2
BMI, kg/m2, mean±SD 26 ± 4 26 ± 4 26 ± 5 0.98
Current smoking, no (%) 132 (30) 18 (22) 112 (32) 0.1
Current alcohol use, no (%) 259 (59) 47 (57) 209 (59) 0.8
Postmenopausal status, no (%), n=268 women** 159 (59) 21 (41) 134 (54) 0.03
Calcium intake, mg/day, median (IQR) 800 (600-1050) 825 (725-1075) 800 (600-1050) 0.2
25(OH) Vitamine D, nmol/l, median (IQR) 55 (37-75) 52 (39-74) 56 (37-76) 0.7
DAS (mean±SD) 3.2 ± 0.9 2.7 ± 0.7 3.3 ± 0.9 <0.001
Symptom duration, weeks, median (IQR) 18 (9-33) 17 (8-28) 18 (9-34) 0.2
ACPA positive, no (%) 253 (57) 3 (4) 246 (70) <0.001
RF positive, no (%) 251 (57) 3 (4) 244 (71) <0.001
SHS total score, median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) 0.9
Presence of erosions, no (%) 62 (14) 7 (9) 54 (15) 0.1
Follow up
Remission after 4 months, no (%) 284 (64) 55 (67) 226 (64) 0.6
Remission after 1 year, no (%) 240 (54) 48 (59) 189 (53) 0.3
Calcium and/or vitamin D suppletion during year 1, no (%) 210 (48) 36 (44) 172 (48) 0.5
Bisphosphonate use year 1, no (%) 135 (31) 28 (34) 106 (30) 0.5
Treatment groups
Early remission group, no (%) 289 (65) 57 (70) 229 (65)
Arm 1: MTX+SSZ+HCQ+prednisone, no (%) 60 (14) 13 (16) 47 (13)
Arm 2: MTX+adalimumab, no (%) 57 (13) 7 (9) 48 (14)
Outside of protocol group, no (%) 31 (7) 4 (5) 27 (8)
*Five patients could not be classified according to the 2010 classification criteria for RA because of missing 
data. **35 women had missing data on postmenopausal status.
ACPA, anti-citrullinated protein antibodies; BMI, body mass index; DAS, disease activity score; IQR, 
inter quartile range; no, number; RA, rheumatoid arthritis (2010 ACR/EULAR classification criteria); RF, 
rheumatoid factor; SD, standard deviation; SHS, Sharp-van der Heijde Score; UA, undifferentiated arthritis.
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table 2: Metacarpal bone mineral density measured by digital X-ray radiogrammetry during the first year 












0 0.592 (0.528-0.640) 0.599 (0.538-0.647) 0.590 (0.527-0.638) 0.6
4 0.590 (0.528-0.637) 0.602 (0.535-0.653) 0.589 (0.527-0.634) 0.4
8 0.590 (0.585-0.639) 0.598 (0.537-0.645) 0.589 (0.525-0.636) 0.5
12 0.585 (0.523-0.637) 0.589 (0.525-0.649) 0.585 (0.522-0.635) 0.4
Change in DXR-BMD
mg/cm2, median (IQR)
0 - 4 -2.6 (-8.1 ; 2.2) -1.5 (-7.3 ; 3.7) -2.8 (-8.6 ; 2.1) 0.2
4 - 8 -1.4 (-6.5 ; 3.3) -1.5 (-6.5 ; 3.0) -1.4 (-6.6 ; 3.4) 0.6
8 -12 -2.9 (-8.9 ; 1.8) -1.4 (-7.8 ; 3.1) -3.5 (-9.1 ; 1.6) 0.2
0 - 12 -6.4 (-16.1 ; 0.6) -4.1 (-13.1 ; 2.9) -6.9 (-16.6 ; 0.1) 0.08
DXR-BMD loss ≥4.6 mg/cm2 after 1 year, no (%) 243 (55) 40 (49) 203 (57) 0.2
DXR-BMD gain ≥4.6 mg/cm2 after 1 year, no 
(%)
60 (14) 15 (18) 45 (13) 0.3
DXR-BMD, bone mineral density measured by digital X-ray radiogrammetry; IQR, interquartile range; 
no, number; RA, rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria; UA, 
undifferentiated arthritis.
table 3: Univariate regression analyses with metacarpal bone mineral density loss after 4 months and 1 
year (yes/no) measured by digital X-ray radiogrammetry as dependent variable.
4 months DXR-BMD loss 1 year DXR-BMD loss
Univariate regression analyses Crude OR 95% CI Crude OR 95% CI
Age 1.03 1.01-1.05 1.07 1.04-1.09
Female gender 0.9 0.6-1.4 1.09 0.7-1.8
Postmenopausal status 2.9 1.6-5.2 7.2 3.5-14.8
Baseline DAS 1.03 0.8-1.3 1.03 0.8-1.4
Baseline DXR-BMD (g/cm2) 0.7 0.02-24.2 0.02 0.001-0.4
Presence of ACPA 1.5 0.9-2.6 1.3 0.9-2.0
Presence of RF 1.0 0.6-1.8 1.02 0.6-1.7
Fulfilling 2010 criteria for RA 1.3 0.7-2.4 1.4 0.8-2.3
Symptom duration 1.003 0.99-1.01 0.996 0.985-1.006
Baseline TJC 0.97 0.93-1.02 0.97 0.92-1.01
Baseline SJC 1.02 0.98-1.1 1.009 0.96-1.06
Baseline ESR 1.01 0.995-1.02 1.01 1.001-1.02
Baseline CRP 1.0 0.99-1.02 1.01 1.001-1.02
Baseline SHS 1.1 0.98-1.2 1.2 1.006-1.3
Baseline erosions (yes/no) 0.7 0.4-1.3 0.8 0.4-1.5
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS, disease activity score; DXR-BMD, 
bone mineral density measured by digital X-ray radiogrammetry, ESR, erythrocyte sedimentation rate; RA, 




was achieving remission after 4 months (0.96 (0.6-1.5)). Univariate predictors for DXR-BMD 
loss after 1 year were age (1.07 (1.04-1.09), p<0.001), postmenopausal status (7.2 (3.5-14.8, 
p<0.001), baseline DXR-BMD (0.02 (0.001-0.4), p=0.012), both baseline ESR (1.01 (1.001-1.02), 
p=0.03) and CRP (1.01 (1.001-1.02), p=0.03) and baseline Sharp-van der Heijde Score (SHS) 
(1.2 (1.006-1.3), p=0.04). Of these, again only age and postmenopausal status were indepen-
dent predictors of DXR-BMD loss after 1 year (respectively 1.04 (1.003-1.07), p=0.03 and 3.3 
(1.4-7.9), p=0.008). Regression analyses performed on the original dataset showed similar 
trends (data not shown).
early remission versus randomization
To evaluate how early remission and subsequent tapering of prednisone affects DXR-BMD, 
we compared the results of the 289 (65%) patients who achieved early remission (of whom 
277 tapered and stopped prednisone) with the 117 (26%) patients who did not achieve early 
remission and were randomized to either MTX, SSZ, HCQ and low dose prednisone (arm 1, 60 
patients) or MTX plus adalimumab (arm 2, 57 patients).
At baseline, patients who achieved early remission had a lower baseline disease activity 
than randomized patients and after 1 year they more often achieved remission than random-
ized patients. Also, fewer patients in early remission were female. On the other hand, more 
patients in early remission were ACPA and RF positive and they less often used bisphospho-
nates than randomized patients.(table 4) Overall during the first year, absolute DXR-BMD 
levels were higher in patients who had achieved early remission than in patients who were 
randomized, although the difference was not significant (mean difference 10.3 (-6.4;26.9), 
p=0.2, randomized patients set as reference).
After 1 year, patients in early remission had a larger median (IQR) DXR-BMD loss than 
randomized patients (-7.2 (-16.3;-0.1) versus -3.4 (-13.3;2.4), p=0.051).(table 5) DXR-BMD loss 
≥4.6 mg/cm2 after 1 year occurred in 170 (59%) patients who had been in early remission 
and in 52 (44%) patients who were randomized (p=0.02). DXR-BMD gain ≥4.6 mg/cm2 after 
1 year was present in 36 (12%) patients who achieved early remission and 22 (19%) patients 
who were randomized (p=0.2). In the original data set, DXR-BMD gain ≥4.6 mg/cm2/year was 
present in 7/33 (21%) patients in arm 1 and 14/26 (54%) in arm 2 (p=0.015).
The smallest DXR-BMD loss during the first year was seen between 4-8 months, both in pa-
tients who achieved early remission and in randomized patients (median (IQR) -2.0 (-7.1;3.0) 
and -0.3 (-5.0;4.3) mg/cm2 respectively, p=0.07). (table 5) In the original data set, the median 
(IQR) DXR-BMD change from 4-8 months in arm 1 (MTX+SSZ+HCQ+low dose prednisone) 
was -0.8 (-4.6;1.3) mg/cm2 and in arm 2 (MTX+adalimumab) 2.0 (-3.1;3.6) mg/cm2 (p=0.16).
continuous remission versus no continuous remission
Over year 1, 132 (30%) patients were in continuous remission, 285 (64%) were not (in 25 
patients remission data were missing on ≥1 time points). Patients in continuous remission 
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had a lower baseline disease activity (DAS 2.9 (0.8) versus 3.4 (0.9), p<0.001) and included 
fewer females (74 (56%) versus 212 (74%), p<0.001), compared to patients not in continuous 
remission. On the other hand, patients in continuous remission used less often calcium and 
vitamin D supplements (53 (40%) versus 150 (53%), p=0.007) and bisphosphonates (29 (22%) 
versus 104 (36%), p=0.003) during the first year. Median baseline DXR-BMD levels of patients 
in continuous remission were 0.603 (0.546-0.659) mg/cm2 and of patients not in continuous 
remission 0.589 (0.521-0.637) mg/cm2 (p=0.09). Over the first year, absolute DXR-BMD levels 
were higher in patients in continuous remission than in patients not in continuous remission, 
although not significantly (mean difference 12.0 (28.3;4.4) mg/cm2, patients not in continu-
ous remission set as reference, (p=0.15)).
table 4: Demographic and clinical characteristics and treatment steps at 8 months of patients in 







Age, years, mean±SD 52±14 51±14 0.3
Female, no (%) 181 (63) 92 (79) 0.002
Postmenopausal status, no (%), n=241 women** 92 (58) 47 (57) 0.9
DAS, mean±SD 3.1±0.9 3.5±0.9 <0.001
Symptom duration, weeks, median (IQR) 18 (9-32) 19 (8-34) 0.97
ACPA positive, no (%) 179 (62) 57 (49) 0.008
RF positive, no (%) 173 (60) 58 (50) 0.08
SHS total score, median (IQR) 0 (0-0.25) 0 (0-0) 0.6
Presence of erosions, no (%) 44 (15) 18 (15) 0.96
Baseline DXR-BMD g/cm2, median (IQR) 0.603 (0.532-0.650) 0.582 (0.540-0.627) 0.2
Treatment steps at 8 months follow up
Restarting prednisone (7.5 mg/day) 62 (21) -
Tapering MTX 158 (55) -
Tapering SSZ, HCQ and prednisone (arm 1, n=60) - 20 (33)
Switching to adalimumab (arm 1, n=60) - 25 (42)
Tapering adalimumab (arm 2, n=57) - 16 (28)
Increasing adalimumab dose (arm 2, n=57) - 24 (42)
No or other steps 69 (24) 32 (27)
1 year follow up
Remission, no (%) 194 (67) 36 (31) <0.001
ACPA, anti-citrullinated protein antibodies; arm 1, randomized to treatment with 
MTX+SSZ+HCQ+prednisone; arm 2: randomized to treatment with MTX+adalimumab; DAS, disease 
activity score; DXR-BMD, bone mineral density measured by digital X-ray radiogrammetry; HCQ, 
hydroxychloroquine; IQR, inter quartile range; mg, milligram; MTX, methotrexate; no, number; RF, 
rheumatoid factor; SHS, Sharp-van der Heijde Score; SSZ, sulfasalazine; SD, standard deviation.
CHAPTER 9
128
Median (IQR) DXR-BMD loss and percentages patients with DXR-BMD loss ≥4.6 mg/cm2/
year after 1 year were comparable between patients in continuous remission and patients 
who were not (-6.3 (-14.8;0.1) compared to -6.4 (-16.6;0.6) mg/cm2, p=0.5 and 72 (55%) versus 
157 (55%), p=0.5). DXR-BMD gain was present in 16 (12%) patients who were in continuous 
remission and in 40 (14%) patients who were not in continuous remission.
discussion
We investigated metacarpal BMD loss in patients with early (rheumatoid) arthritis, treated 
initially with MTX and a tapered high dose of prednisone, with subsequent treatment ad-
justments aiming at remission. This is the first clinical trial in which metacarpal BMD was 
monitored this intensively and this early in the disease course of RA, while disease activity was 
effectively suppressed in the majority of patients by the current treatment strategy. However, 
we are aware that results were obtained from frequent measurements and imputed data and 
that observed differences generally were small. Future studies are needed to demonstrate 
the relevance of our results.
Our data suggest that the annual decrease in metacarpal BMD in patients with early ar-
thritis may be somewhat lower than previously found in patients with early RA (varying from 
9 to 22 mg/cm2/year).15,20-22 However, still more than half of the early arthritis patients had 
metacarpal BMD loss after 4 months of treatment with MTX and a tapered high dose of pred-
nisone. In subsequent months, only 13% of the patients regained this DXR-BMD loss. Patients 
who had achieved early remission and tapered medication, showed more metacarpal BMD 
loss than patients who were randomized to extended combination therapy either including 
low dose prednisone or adalimumab. Although based on small numbers, we observed that 
table 5: Changes in metacarpal bone mineral density measured by digital X-ray radiogrammetry during 
the first year, separate for patients who achieved early remission and patients who were randomized.







0 - 4 -2.7 (-8.4;2.2) -2.2 (-7.2;2.7) 0.4
4 - 8 -2.0 (-7.1;3.0) -0.3 (-5.0;4.3) 0.07
8 -12 -3.2 (-8.6;1.8) -2.2 (-8.7;2.7) 0.4
0 - 12 -7.2 (-16.3;-0.1) -3.4 (-13.3;2.4) 0.051
DXR-BMD loss ≥4.6 mg/cm2 after 1 year, no (%) 170 (59) 52 (44) 0.02
DXR-BMD gain ≥4.6 mg/cm2 after 1 year, no (%) 36 (12) 22 (19) 0.2
DXR-BMD, bone mineral density measured by digital X-ray radiogrammetry; Early remission, remission 
after 4 months of treatment with MTX and a tapered high dose of prednisone; IQR, inter quartile range; 
no, number; randomized, patients who did not achieve early remission and were randomized to either 
MTX, sulphasalazine, hydroxychloroquine and low dose prednisone or MTX plus adalimumab.
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patients treated with adalimumab showed the smallest loss in metacarpal BMD and most 
often showed gain after 1 year (54%, compared to 21% in patients randomized to combina-
tion therapy including prednisone and 12% of early remission patients).
Our finding that metacarpal BMD loss after 4 months may be present in more than half of 
the patients with early arthritis, may be due to initial disease activity, the use of prednisone 
or both. The effect of the initial treatment cannot be elucidated since in the first 4 months 
all patients receive the same medication. However, results from the regression analyses may 
suggest that metacarpal BMD loss after 4 months was not dependent of baseline or 4 months 
disease activity, but only on age and postmenopausal status. This may indicate that the use 
of a tapered high dose of prednisone initially causes metacarpal BMD loss, a loss that was 
regained during the subsequent months in only a minority of the patients. Longer follow up 
data are needed to see whether more patients may regain the loss in the second year or later.
The finding that patients not achieving remission after 4 months who were randomized, 
may have less metacarpal BMD loss after 1 year and more gain than patients who did achieve 
early remission, may be explained by the intensive combination treatment that randomized 
patients received, either including low dose prednisone or adalimumab. Previously, treat-
ment with anti-TNF-alpha or low dose prednisone has been shown to reduce hand BMD loss 
in patients with early RA.15,23,24 However, the possibly larger metacarpal BMD loss in the early 
remission group might also be explained by the finding that randomized patients more often 
used bisphosphonates.
Despite small patients numbers, our results may suggest that patients treated with com-
bination therapy including adalimumab had even less hand BMD loss and more gain than 
patients treated with a combination of DMARDs with low dose prednisone. Previously, TNF 
blockers have been shown to reduce joint damage progression,25 and generalized as well as 
hand bone mineral density loss.23,26-28 It has been suggested that this reduction may occur 
independently of the clinical response to TNF blockers.28,29
We found no differences in metacarpal BMD loss or gain between patients who were in 
continuous remission during the first year and patients who were not. In an earlier study in 
patients with recent onset RA, who had achieved sustained remission for at least one year, 
metacarpal BMD gain was found in 32% of patients.7 These patients however achieved sus-
tained remission for at least 1 year and later in the course of treatment after prolonged low 
disease activity, which may enable metacarpal BMD gain.
We found no differences in metacarpal BMD loss between UA and RA patients, although UA 
patients had a lower baseline disease activity at inclusion. This might be related to the similar 
symptom duration at study entrance and the fact that with the current treatment strategy 
disease activity was equally well suppressed during the first year in both groups.
A limitation of this study is the large amount of missing data. Radiographs were taken 
before we planned to measure DXR-BMD, and not for this purpose. To deal with this problem, 
we used multiple imputation, which is considered as a highly valid method to impute missing 
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data.19 Results from the original dataset, although based on small numbers, showed similar 
trends.
In conclusion, during 1 year of remission steered therapy in patients with undifferentiated 
or early RA, metacarpal BMD loss seemed not to be influenced by disease activity, classifi-
cation as RA or antibody status, but depends largely on age and postmenopausal status. 
Initial loss during treatment with a combination of methotrexate and a tapered high dose 
of prednisone may be substantial, and despite high remission rates and overall low disease 
activity, metacarpal BMD loss may only partially be recovered in the subsequent 8 months. 
These results may suggest that although initial combination therapy including a tapered 
high dose of prednisone may induce low disease activity and (sustained) remission in a large 
proportion of early arthritis patients, it may have at least a temporary negative effect on 
localized BMD.
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To date, only limited evidence is available to answer the question whether starting treatment 
already in the phase of undifferentiated arthritis (UA) is more effective than waiting until a 
patient meets classification criteria for rheumatoid arthritis (RA). As shown in chapter 2, the 
available evidence is not only limited, but there is also a huge heterogeneity in performed 
treatments and treatment strategies and in outcomes. Furthermore, the follow up duration of 
all trials is restricted and long term effects of the applied treatment strategies are not known.
The IMPROVED study, in which both patients with early RA and patients with UA were 
included, provides a valuable addition to the limited evidence for the beneficial effect of 
treating patients in early phases of RA, even before classification criteria are met.
the imProVed study: an oVerView of outcomes
In the IMPROVED study, patients with in an early phase of RA are intensively treated with 
combination treatment, introduced as early as in the phase of UA or early RA, and treatment 
is subsequently steered at the stringent goal of achieving remission. If remission was not 
achieved, medication was extended, either by adding more synthetic disease modifying anti-
rheumatic drugs (DMARDs) to the initial treatment of prednisone and methotrexate (MTX), 
or by replacing prednisone with the biologic agent adalimumab. If remission was achieved 
medication was tapered, even until patients were in drug free remission. As early as one year 
after starting therapy, this goal was achieved in 20% of the patients. More than 50% of all 
patients were in remission and radiological damage progression was found in only 5% of the 
patients after one year. Also patient reported outcomes concerning functional ability and 
health related quality of life improved, and in a proportion of the patients even normalized, 
during the first year.
study PoPulation
inclusion
By protocol, DMARD-naïve patients with UA, defined as having at least one joint clinically 
diagnosed as arthritis and one other painful joint, not fulfilling the 1987 classification criteria 
for RA but in the opinion of the treating rheumatologist clinically suspect of early RA, and 
patients with early RA according to the 1987 criteria 1 and with a symptom duration of less 
than 2 years, were included. In chapter 3 is shown that, compared to previous clinical trials in 
patients with early RA, 2-5 we included patients with a relatively mild baseline disease activity 
(mean Disease Activity Score (DAS) 3.2), short symptom duration (median symptom duration 
18 (9-32) weeks) and almost no radiological damage present (median baseline Sharp-van 
der Heijde Score (SHS) 0 (0-0) and 12% of the patients had erosions). Mean age (52 years) 
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and percentages female and rheumatoid factor (RF) positive patients (respectively 70% and 
56%) were comparable with previous trials. The percentage of patients with a positive test for 
anti-citrullinated protein antibodies (ACPA) (55%) was also comparable with previous trials, 
although in most previous trials ACPA status was not known at baseline, but measured after-
wards. As ACPA nowadays can be routinely measured in the Netherlands, rheumatologists 
were often aware of the ACPA status of patients they included in the IMPROVED study. This 
may explain why the percentage of ACPA positive patients was higher than one might expect 
in patients with early arthritis.
reclassification
As in 2010 new ACR/EULAR classification criteria for RA were introduced,6 we reclassified all 
patients participating in the IMPROVED study according to these new criteria. The new criteria 
aim to classify patients earlier in the disease course and give a lot of weight to the presence 
of ACPA and/or the presence of many arthritic joints. In chapter 3 we showed that 60% of the 
total study population fulfilled the 1987 classification criteria for RA and 40% were included 
as UA. Based on the new criteria 79% were classified as RA and 20% remained classified as UA. 
Thus, 19% of the patients were classified as RA by the 2010 criteria but not (yet) by the 1987 
criteria. Compared to patients who were classified as RA according to the 1987 criteria,1 these 
19% had a comparable symptom duration, but they had a slightly lower baseline disease 
activity (mean DAS 3.3 versus 3.5), mainly due to a lower median swollen joint count (7 (3-11) 
versus 8 (4-12)) and a somewhat lower median erythrocyte sedimentation rate (ESR) level (26 
(12-41) versus 29 (15-45). Other clinical variables were comparable.
In conclusion, compared to using the 1987 criteria, reclassification using the 2010 criteria 
did not result in identifying patients with a shorter symptom duration, but in classifying 
patients with a lower disease activity. Other studies, performed in early arthritis cohorts, 
showed similar results.7,8 These findings seem to challenge some of the intentions of the new 
criteria.
undifferentiated versus early rheumatoid arthritis
Although we expected that UA patients we included would have a shorter symptom dura-
tion than RA patients, this was not the case, as was shown in chapter 3. UA and RA patients 
had a median symptom duration of respectively 16 (8-28) and 18 (9-34) weeks. Included 
UA patients had lower baseline disease activity than RA patients (mean baseline DAS 2.7 
(0.7) versus 3.3 (0.9)), and only a few UA patients were ACPA and/or RF positive compared 
to almost 70% of the RA patients. Another difference was apparent in the distribution of 
affected joints. Sixty-eight percent of UA patients and 73% of RA patients had involvement 
of large joints, but 6% of the UA patients had involvement of only large joints compared to 










rheumatic diseases than RA, such as osteoarthritis or spondylarthropathy, in particular when 
ACPA and RF were negative.
ACPA negative patients who were still classified as RA differed from ACPA positive RA 
patients. To meet the 2010 classification criteria, ACPA negative RA patients had to have a 
higher disease activity than ACPA positive patients, mainly based on more affected joints. At 
time of classification, ACPA negative RA patients also had a longer symptom duration than 
ACPA positive RA patients.
main outcomes of the first study year
remission, drug free remission and joint damage progression
In chapter 3 we showed that, after 4 months of remission induction therapy with MTX and 
a tapered high dose of prednisone, as many as 61% of patients with early arthritis achieved 
remission (early remission, defined as DAS<1.6 9), regardless of fulfilling the 2010 criteria. 
Ninety percent of patients had no radiological progression and in those who had progression 
it was minimal (median progression score 1(1-1)). In chapter 4 we demonstrated that after 
one year of remission steered treatment, 54% of patients in the IMPROVED study were in 
remission and only 5% of the patients had radiological damage progression of more than 
0.5 SHS points. Remission was most often achieved in patients who achieved early remission 
after four months (68%) and 32% of these patients were able to taper all medication and 
achieved drug free remission as soon as after one year. Patients who did not achieve early 
remission and were randomized, less often achieved remission after one year. Those random-
ized to treatment with MTX and adalimumab, with an increased dose of adalimumab as pos-
sible next step, more often achieved remission after one year (40%) than patients who were 
randomized to the extended combination of DMARDs with continued low dose prednisone, 
reserving adalimumab as possible next step (25%). Radiographic progression and functional 
ability were similar between randomization arms.
Compared to previous trials in patients with early RA, percentages of patients achieving 
remission during the first year of the IMPROVED study were high and joint damage was more 
effectively suppressed.2,3,5,10,11 In other studies reporting similar high remission percentages 
after 1 year medication was not tapered.11 On the other hand, these studies included patients 
with early or established RA with a higher baseline disease activity than patients in the 
IMPROVED study. Drug free remission was previously reported in 17-29% in clinical trials,12-14 
but never as soon as after one year. These results may be explained by the treatment strategy 
we used, starting early in disease course with combination therapy consisting of MTX 25 
mg/week and a tapered high plus continued low dose of prednisone, followed by extending 
medication in those who did not achieve remission. Previously the beneficial effect of low 
dose corticosteroids compared to placebo was shown,15 and several trials showed the benefit 
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of DMARD combination including prednisone compared to DMARD mono therapy.2,3,5 In the 
recently published CAMERAII trial, a randomized placebo controlled trial in patients with 
early RA aimed at achieving remission, treatment with MTX was compared with MTX plus low 
dose prednisone. After 2 years of remission steered therapy, patients treated with MTX plus 
low dose prednisone had less radiological damage progression and more often and sooner 
achieved remission than patients treated with MTX alone. Remission percentages in this trial 
were comparable with percentages we found in the IMPROVED study, although in contrast 
with the IMPROVED study, there was no ability to taper medication as soon as remission was 
achieved.16
However, other explanations for the high (drug free) remission rates and nearly absence of 
radiological damage progression in the IMPROVED study may also be possible, such as the 
fact that early arthritis patients with a low disease activity at baseline may not have damage 
progression (yet) and may easier achieve the treatment goal of a DAS < 1.6. Also, some UA 
patients and patients who fulfilled the 2010 classification criteria may have had self-limiting 
forms of early arthritis, that would have gone into spontaneous remission without the use of 
medication.
Compared to the DAS-remission criteria that we used to steer treatment adjustments in the 
IMPROVED study, the Boolean based ACR/EULAR preliminary definition published in 2011 17 
appeared to be a more stringent definition, as fewer patients achieved remission according 
to this definition after 4 months (26%) and after 1 year (24%). In patients who were in DAS-
remission but did not fulfill the Boolean based remission definition, this was most often due 
to a VAS global health ≥ 10. Recently, similar results were observed in the DREAM study,18 in 
which also was shown that residual disease activity was only present in the minority (32%) of 
these patients. Thus, although the Boolean based definition is more stringent, the question 
raises whether it may be too stringent, resulting in patients in clinical remission not fulfilling 
this definition.
never achieving remission during the first year
Results of chapter 4 showed that despite of the progressive treatment strategy aiming at 
remission, still 16% of patients did not achieve remission during the first year of treatment. 
Also, 5% of the patients had radiological damage progression after 1 year, although with a 
limited progression rate (median progression score of 1 and only one patient had rapid ra-
diological progression of 18 SHS points). Patients who never achieved remission throughout 
the first year were characterized by a higher mean baseline disease activity (mean DAS 3.7 
(0.9) versus 3.2 (0.9)), a longer symptom duration (24 (12-44) versus 17 (8-31) weeks) and 
included more females (89% versus 63%) compared to patients who achieved remission at 
least once. It is possible that these patients might have benefitted from starting treatment 










therapy with other biologic therapies than adalimumab might have been more effective in 
these patients.19
Patient reported outcomes
In chapter 5 we showed that patient reported outcomes (PROs) at baseline, such as func-
tional ability measured by the Health Assessment Questionnaire (HAQ) and McMaster 
Toronto Arthritis questionnaire (MACTAR) and health related quality of life measured by the 
Short Form-36 (SF-36), were lower in this population of early arthritis patients than in the 
general population. Only mental health, measured by the mental component score (MCS) of 
the SF-36, seemed not to be affected, since mean MCS in the IMPROVED study participants 
were comparable to the general population throughout the first year. During the first year, 
functional ability and physical health improved, with the greatest improvement occurring 
in the first four months. Improvement was largest in patients who achieved early remission. 
In this group, mean or median values of the HAQ and SF-36 after one year returned to levels 
comparable to those in the general population. In randomized patients, no differences were 
seen between treatment arms. In all patients, achieving remission during the first year was 
associated with better functional ability and health related quality of life than not achieving 
remission. These results suggest that with the current treatment strategy, PROs reflecting 
functional ability and physical health improve, and in part of the patients even normalize 
within one year after diagnosis. Achieving early remission after four months and achieving 
remission throughout the whole year improved PROs most.
Results of chapter 7 showed that minimal depressive symptoms were present among 
patients participating in the IMPROVED study. Depressive symptoms severity decreased 
with lower disease activity and was significantly lower in patients who achieve remission 
than in patients who did not. Mostly, this was due to symptoms of arthritis, such as pain and 
unwell being, rather than signs of inflammation, suggesting that depressive symptoms in RA 
patients may improve if symptoms of RA are optimally suppressed.
metacarpal bone mineral density
In chapter 9 we explored changes in metacarpal bone mineral density (BMD) loss during the 
first year of remission steered treatment. The IMPROVED study is the first clinical trial in which 
metacarpal BMD was monitored this intensively and this early in the disease course of RA. 
These data however have to be interpreted with care, because they were imputed because 
of many missing values and most differences found were small. The data suggested that over 
half of the patients had metacarpal BMD loss after 4 months after 1 year (respectively 56% 
and 55%), and some patients might even have metacarpal BMD gain after 1 year (14%).
Our finding that more than half of these patients early arthritis, having a relatively mild 
disease activity and being treated intensively, may have had metacarpal BMD loss after 4 
months, may be due to the initial treatment with a tapered high dose of prednisone. Only 
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a minority (13%) of the patients seem to totally regain this metacarpal BMD loss during the 
subsequent months. Longer follow data are needed to see whether this loss may be regained 
in the other patients in the second year or later. Another explanation may be the initial dis-
ease activity, although in these data, baseline disease activity was not found to be predictive 
of metacarpal BMD loss after 4 months.
The data may also suggest that patients who had achieved early remission and tapered 
medication, showed more metacarpal BMD loss than patients who were randomized to 
extended combination therapy. This may be explained by the intensive combination therapy 
randomized patients achieved, either including low dose prednisone or adalimumab. On the 
other hand, the fact that patients who achieved early remission tapered medication and that 
part of them lost remission, might also explain this possible difference. Although based on 
small numbers, the original data may furthermore suggest that patients treated with adalim-
umab may show the smallest loss in metacarpal BMD and most often metacarpal BMD gain 
after 1 year (54%, compared to 21% in patients randomized to combination therapy includ-
ing prednisone and 12% of early remission patients). This is in line with previous research, 
showing that anti-TNF alpha inhibitors may reduce generalized as well as localized bone loss 
in patients with RA.20-23
adverse events
Adverse events were reported in 56% of the patients during the first 4 months, as was shown 
in chapter 3. Most adverse events were mild and temporary, but in 3% of the patients seri-
ous adverse events occurred including the death of two patients, one of a pneumonia left 
untreated by wish of the patient and one of a myocardial infarction later found to be caused 
by a giant cell arteriitis. None of the serious adverse events were suspected unexpected seri-
ous adverse events (SUSARs). In general, initial combination therapy with MTX and a tapered 
high and continued low dose of prednisone appears to be safe on the short term. However, 
fourteen of sixteen serious adverse events (infections, cardiovascular disease, femoral head 
necrosis, diabetic complications) might have been related to the use of prednisone. Further 
follow up will show whether there are long term consequences of this induction therapy. 
Previous data of the COBRA trial, in which the same tapered high dose of prednisone was 
used, suggest that a tapered high dose of prednisone, in combination with MTX and SSZ, 
can be used safely.2,24 Previously, no evidence has been found for long term complications of 
short term use of low dose prednisone.15
In chapter 4 we showed that from 4 months two one year adverse events were reported 
in 57% of the patients. The lowest percentage of adverse events was reported in the early 
remission group (53%) and adverse events were reported in similar percentages in the 
randomization arms (74% in arm 1 and 68% in arm 2). Adverse were generally mild. Serious 
adverse events were reported in 4% of the patients, including 3 patients who died; one of a 










2) and one of an ovarian carcinoma (OP group). Serious adverse events that were possibly 
related to the use of adalimumab were: pneumonia, cerebral tumor, percutaneous coronary 
intervention for myocardial infarction, exacerbation of chronic obstructive pulmonary 
disease and cerebrovascular accident. None of the serious adverse events were SUSARs. In 
summary, also after 1 year, adverse events were generally mild and combination treatment 
with multiple DMARDs and low dose prednisone seemed to be equally safe as treatment with 
MTX and adalimumab.
limitations of the imProVed study
no control group
To avoid the need of excessive patient numbers, no control group was included in the 
IMPROVED study to verify the superiority of the initial combination treatment. Instead of 
finding the best initial treatment, we decided to use a combination of two drugs, proven very 
effective as initial treatment for patients with active RA,2,3 in all patients and focus on identify-
ing the best follow up treatment when the initial treatment did not result in remission. This 
means we also do not know how many UA and RA patients would actually have achieved 
remission spontaneously and thus which part achieved remission and drug free remission 
due to the applied therapy.
single blind study
This study was a single blind study. For practical reasons, only research nurses who did 
the four monthly assessments were blinded, while patients and doctors were aware of 
the allocated treatment. Several years after the introduction of biological agents, patients 
participating in the BeSt study were shown to have a preference for combination therapy 
including infliximab and disliked taking prednisone.35 In the IMPROVED study, patients might 
also have had a preference for combination therapy including a biological agent, in this case 
adalimumab, which might have biased our results. However, almost none of the patients 
randomized to the combination of multiple DMARDs and low dose prednisone refused to 
start with this therapy.
definition of remission: das <1.6
Remission was defined as a DAS <1.6 and treatment was steered at this definition. In the 
past, it has been shown to correspond well to the 1981 ACR preliminary criteria for clini-
cal remission.9,36 However, because this definition allows for one or two swollen or painful 
joints, some say that it reflects low disease activity rather than remission. Recently two new 
definitions for remission have been proposed.37 In the IMPROVED study, the Boolean based 
definition for remission 17 appeared to be more stringent than the DAS-definition. In future, 
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one of the provisional definitions may best be used to reach uniformity among clinical trials. 
However, it remains questionable whether the various remission definitions are associated 
with significant differences in clinical and radiological outcomes.38
Protocol deviations
Protocolized treatments adjustments in the IMPROVED study were integrated in daily prac-
tice, which led to a considerable amount of protocol deviations for several reasons. Some-
times the treating rheumatologist disagreed with the required treatment step or with the 
DAS evaluation by the research nurse. For example, a DAS might have been high due to an 
elevated ESR or painful joints due to other reasons than RA activity. In this case rheumatolo-
gist deviated from the protocol because the patient was clinically in remission. Also, the fact 
that we steered at remission defined as a DAS <1.6 might have caused protocol deviations. 
When for example the DAS was 1.6 or just >1.6, treatment had to be intensified according to 
the protocol but sometimes rheumatologists hesitated to do so. Or sometimes they might 
have hesitated to taper medication when the DAS was <1.6 but they felt there still was some 
residual disease activity.
In 50 patients who did not achieve remission after 4 months, the protocol was not fol-
lowed and patients were not randomized (Outside of Protocol group, OP group). In 17 of 
these patients prednisone was tapered, probably because these patients were estimated by 
the rheumatologist to be in clinical remission, but the DAS was >1.6 due to other reasons. In 
other patients several other treatment steps were taken for different reasons. In most cases 
treatment remained steered at remission, but this was clinical rather than DAS-remission. 
After 1 year, outcomes of the patients in the OP group were similar to patients who had been 
randomized to arm 1, suggesting that following the current treatment strategy may lead to 
better disease outcomes than treatment outside of protocol.
ua Versus ra
We included UA patients ‘clinically suspect for RA’ because we expected that these patients 
would represent RA patients with a shorter disease duration than classifiable RA patients and 
might achieve remission in a higher rates. This would support the window of opportunity 
theory.25,26 Our results in chapter 3 however showed that UA patients did not have shorter 
symptom duration at inclusion of the study than RA patients (median (IQR) 16 (8-28) versus 
18 (9-34) weeks, respectively). It is thought that the first twelve weeks after symptom onset 
offer the best opportunity to stop or reverse the disease process that otherwise may become 
chronic and destructive. This means that for 64% of the UA patients as well as for 66% of the 











UA patients also may have had a favorable outlook compared to the RA patients because on 
average they were included with a lower disease activity, and almost all were auto-antibody 
negative, possibly including patients with self-limiting forms of arthritis. However, as shown in 
chapters 3 and 4, we found no differences between UA and RA patients in percentages (drug 
free) remission, functional ability or radiological joint damage progression after 4 months or 
1 year. Besides having missed the window of opportunity, some UA patients may not have 
had self-limiting arthritis but rather a type of rheumatic disease that did not respond to the 
given therapy (for example osteoarthritis or spondylarthropathy).
Presence Versus absence of anti-citrullinated Protein antibodies
The presence of ACPA is known as a factor associated with a higher disease activity, more 
functional disability and more radiological damage progression in patients with RA.27-29 
Therefore we were surprised to find that after one year in the IMPROVED study, as described 
in chapter 6, ACPA positive patients achieved remission and drug free remission equally 
often as ACPA negative patients and also functional ability and radiological damage progres-
sion both were similar in ACPA positive and negative patients. After the initial combination 
therapy of MTX and a tapered high dose of prednisone, ACPA positive patients even achieved 
remission more often than ACPA negative patients. This might suggest that ACPA positive 
patients responded better to the initial combination therapy than ACPA negative patients. 
Previously, results of the PROMPT study showed that in ACPA negative UA patients MTX was 
not superior to placebo treatment, while in ACPA positive patients MTX resulted in suppres-
sion of progression to classifiable RA and suppression of joint damage progression.30,31 This 
suggests that ACPA negative UA responds less well to anti-inflammatory treatment than 
ACPA positive UA, and therefore may be driven by different disease pathways.
Furthermore, results of chapter 6 showed that of those patients who achieved early re-
mission, and by protocol of the IMPROVED study were able to achieve drug free remission 
(DFR) after 1 year, 32% actually achieved DFR after 1 year. Of those, 55% were ACPA positive, 
compared to 61% of the patients who achieved early remission but not DFR after 1 year (no 
significant difference). Patients in DFR after 1 year were less often RF factor positive than 
patients not achieving DFR (50% versus 62%).
In the following 4 months, 30% of the patients who had achieved DFR after 1 year, lost it. 
These patients were more often ACPA positive than patients who did not lose DFR (72% versus 
47%), and ACPA positive patients less often sustained DFR than ACPA negative patients (58% 
versus 80%). This suggests that compared to ACPA negative patients, ACPA positive patients 
have a similar likelihood of achieving and maintaining remission, even while medication is 
tapered. But after having successfully tapered and discontinued medication, ACPA positive 
patients show more relapses in disease activity in the next 4 months.
CHAPTER 10
144
Prediction of disease outcome by metacarPal bone mineral 
density
We showed in chapter 8 that metacarpal bone mineral density (BMD) loss in the first 4 months 
after diagnosis was predictive for radiological damage progression after 1 year of remission 
steered treatment in the IMPROVED study, independent of several known predictors. The 
presence of baseline erosions was found to be the only other predictor, but 86% of the total 
study group had no erosions at baseline and 17 (5%) still developed radiological progression 
(63% of all 27 patients with radiological progression). In patients without baseline erosions 
no predictors other than metacarpal BMD loss after 4 months were found.
Preferably, an outcome predictor would be present at baseline. But with the lack of base-
line predictors, especially in patients without baseline erosions, and with achieving remission 
after 4 months also not being predictive for future joint damage, metacarpal BMD loss after 4 
months may be a useful new predictor in patients with early arthritis.
Furthermore, several known predictors of (rapid) radiological progression, such as ACPA 
and/or RF positivity and baseline CRP or ESR level, were not found to be predictive of progres-
sion in this population with almost no progression present after 1 year. This may be explained 
by the treatment strategy we applied, starting early in disease course with combination treat-
ment and steering at remission, which may have prevented progression of radiological dam-
age. But it may also be possible that radiological progression would, also without medication, 
hardly be present in this early arthritis population with a relatively low disease activity.
In conclusion, early metacarpal BMD loss may be used in clinical practice or may be added 
to known prediction models of disease outcome in patients with RA 32-34 to steer early treat-
ment decisions with the ultimate goal of preventing radiological joint damage.
future PersPectiVes
Data in this thesis suggest that, with the treatment strategies applied in the IMPROVED study, 
disease outcomes have indeed been further improved in early phases of RA. Remission and 
even drug free remission can be achieved in higher proportions of patients and earlier in 
disease course than before. Future results of the IMPROVED study will show for how long and 
in which patients remission and drug free remission can be sustained, if tapering of medica-
tion and achieving drug free remission is also possible in patients who were randomized, 
how many and which patients will have radiological progression, and what will be the best 
follow up treatment strategy in patients who did not achieve remission within the first year. 
After one year, remission was achieved in approximately half of the patients, of which about 
one third were in drug free remission. To achieve these goals in the majority, or ultimately 










Even including results of the IMPROVED study, the current evidence of treating patients 
in the stage of undifferentiated arthritis is limited and very heterogeneous. Further research 
has to elucidate the optimal period to start treatment and the optimal treatment strategy. 
Starting therapy within twelve weeks after symptom onset may further improve outcomes, 
but may also increase overtreatment of patients with a self-limiting type of arthritis. In these 
patients, tapering medication as soon as remission is achieved may further minimize the risk 
of side effects.
Targeting treatment to low disease activity has been shown to benefit patients with RA and 
our results as well as data from the FINRA-Co and NEORA-Co study suggest that remission 
as treatment target may be even better. However, a randomized trial with a head to head 
comparison of the same treatment strategy aiming either at low disease activity or at remis-
sion has not been done. Until such as trial has been performed, no definitive statement can 
be made on the superiority of remission over low disease activity as treatment goal.
Adding short term prednisone to one or more DMARDs may become a new cornerstone 
in the treatment of RA. It has been shown to suppress disease activity and radiological 
damage as effectively as combination therapy including a biologic agent, but may offer a 
less expensive alternative. However, the optimal dosage and duration of therapy has still to 
be determined and future research has to ensure that short and long term side effects are 
indeed acceptable.
In patients who do not achieve remission on initial DMARD therapy in combination with 
prednisone, follow up treatment with early introduction of a biological agent seems to result 
in more patients achieving remission. Whether drug free remission is also achieved more 
often en whether damage progression is more effectively suppressed still has to be deter-
mined. If this is the case, exchanging prednisone for a biologic agent in these patients may 
be the best next step in their treatment strategy.
There is an ongoing search for new predictors to further optimize current prediction mod-
els for disease outcome in patients with RA. Early bone loss may be a candidate for further 
improvement of predicting the disease course in individual patients. To improve prediction 
even more, future research has to reveal more new predictor candidates. Being able to ac-
curately predict disease outcome in all patients with RA will offer the best opportunity to 
choose the most advantageous treatment strategy for all individual patients.
In conclusion, the current treatment strategy, including early start of combination therapy 
and steering treatment at remission, may have contributed to the high remission and drug 
free remission rates and the nearly absence of radiological damage progression after one 
year in patients with early arthritis. However, current treatment strategies still need further 
optimization with the ultimate goal of achieving these outcomes in the future in every pa-
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Verbetering Van ziekte-uitkomsten in een Vroege fase Van 
reumatoïde artritis
Reumatoïde artritis (RA) is een potentieel invaliderende auto-immuunziekte die geken-
merkt wordt door symmetrische gewrichtsontstekingen waarbij hand- en voetgewrichten 
meestal betrokken zijn. De behandeling van RA heeft de afgelopen decennia een enorme 
verandering doorgemaakt. Vele onderzoeken hebben aangetoond dat het behandelen van 
patiënten vroeg in het ziektebeloop, zo snel mogelijk na het stellen van de diagnose, betere 
ziekte-uitkomsten geeft. In 2010 hebben de European League Against Rheumatism (EULAR) 
en de American College of Rheumatology (ACR) gezamenlijk nieuwe classificatie criteria 
voor RA ontworpen, met als doel patiënten vroeger in het ziektebeloop te classificeren, 
zodat behandeling eerder kan worden gestart. Ook het behandelen met een combinatie 
van middelen in plaats van monotherapie heeft geleid tot een snellere onderdrukking van 
ziekteverschijnselen, minder gewrichtsschade en minder invaliditeit. Verder heeft de ontdek-
king van relatief nieuwe middelen, biologicals genaamd, bijgedragen aan de verbetering van 
ziekte-uitkomsten. Tot slot is gebleken dat het streven naar lage of geen meetbare ziekte 
activiteit, door patiënten intensief te vervolgen en medicatie zo nodig aan te passen (‘tight 
control’), heeft bijgedragen aan deze vooruitgang.
Het gevolg is dat de ziekte RA, voorheen bekend als een chronische en invaliderende aan-
doening, steeds minder vaak een chronisch beloop kent en dat symptomen steeds beter en 
vroeger in het ziektebeloop onderdrukt kunnen worden in het merendeel van de patiënten. 
Het behalen van remissie en zelfs medicatie vrije remissie zijn haalbare behandeldoelen 
geworden die in toenemende aantallen patiënten worden bereikt.
Deze enorme verbetering in prognose roept echter de vraag op of de ziekte niet nóg beter, 
nóg eerder en in nóg meer patiënten kan worden onderdrukt. Mogelijk leiden behandeling 
in het stadium dat patiënten nog niet aan de classificatie criteria voor RA voldoen, sturen 
van behandeling op remissie in plaats van op lage ziekte activiteit en combinatie behande-
ling met prednison of een biological vroeg in het ziekte-beloop, tot een verdere verbetering 
van ziekte-uitkomsten. De ultieme vraag is zelfs of, met de juiste behandeling op het juiste 
tijdstip, genezing kan worden bereikt.
In dit proefschrift, waarin resultaten van het eerste jaar van de Induction therapy with 
Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED) 
studie worden getoond, hopen we een stap dichter bij de beantwoording van bovenstaande 




behandeling Van ongedifferentieerde artritis
Het wetenschappelijk bewijs voor het effect van behandeling in het stadium van ongedif-
ferentieerde artritis (UA) is nog maar zeer beperkt, zo blijkt uit een systematische review van 
studies over behandeling van patiënten met UA (hoofdstuk 2). Het aantal studies is klein, 
onderzochte behandelingen of behandelstrategieën en uitkomsten zijn zeer heterogeen, en 
de effecten van behandeling zijn uitsluitend op korte termijn geëvalueerd.
Met de IMPROVED studie, waarin zowel patiënten met vroege RA als patiënten met UA 
geïncludeerd zijn, wordt zeer waardevolle kennis toegevoegd aan het beperkt aanwezige 
bewijs dat starten van behandeling nog voordat patiënten voldoen aan de classificatie crite-
ria voor RA zinvol is.
de imProVed studie
De IMPROVED studie is een gerandomiseerde klinische studie waarin patiënten met UA en 
met vroege RA zijn geïncludeerd. RA is gedefinieerd als voldoend aan de ACR 1987 clas-
sificatie criteria voor RA, UA als hebbende op zijn minst één gewricht met artritis en één 
ander pijnlijk gewricht, zonder aanwijzingen voor een andere reumatologische aandoening. 
Patiënten zijn behandeld volgens een ‘tight control’ strategie, waarbij behandeling gestuurd 
is op remissie, gedefinieerd als een ziekteactiviteit score (‘Disease Activity Score’, DAS) < 1.6. 
Alle patiënten werden initieel behandeld met methotrexaat (MTX) 25 mg/week en prednison 
60 mg/dag, in 7 weken afgebouwd tot 7.5 mg/dag. Patiënten die met deze initiële behande-
ling remissie bereikten, bouwden eerst prednison geheel af. Patiënten die hierna remissie 
behielden, bouwden 4 maanden later ook MTX geheel af. Binnen een jaar na het starten 
van medicatie kon zo medicatie vrije remissie worden bereikt. Patiënten die remissie niet 
behielden na het afbouwen van prednison, herstartten prednison 7.5 mg/dag.
Patiënten die geen remissie bereikten na de initiële behandeling, werden gerandomiseerd 
in twee armen. In arm 1 werden twee anti-reumatische middelen (‘Disease Modifying Anti-
Rheumatic Drugs’, DMARDs), sulfasalazine (SSZ) en hydroxychloroquine (HCQ), toegevoegd 
aan MTX en prednison; in arm 2 werd prednison vervangen door de biological adalimumab 
en werd MTX gecontinueerd.
De belangrijkste ziekte-uitkomsten zijn remissie, medicatie vrije remissie en progressie van 
gewrichtsschade. Andere uitkomsten zijn onder andere patiënt gerapporteerde uitkomsten 












In totaal zijn 610 patiënten geïncludeerd in de IMPROVED studie, waarvan 60% voldeed 
aan de 1987 criteria voor RA (hoofdstuk 3). Na publicatie van de ‘nieuwe’ 2010 criteria zijn 
patiënten opnieuw geclassificeerd, waarbij 79% voldeed aan de 2010 classificatie criteria (RA 
patiënten) en 20% niet (UA patiënten) (1% van de patiënten was niet classificeerbaar door 
missende waarden). UA patiënten bleken niet, zoals verwacht, een kortere symptoomduur te 
hebben, maar hadden ten tijde van de inclusie een lagere ziekteactiviteit dan RA patiënten. 
Ook waren reumafactoren (RF) en antistoffen tegen gecitrullineerde eiwitten (‘Anti-Citrullina-
ted Protein Antibodies’, ACPA) in slechts enkele UA patiënten aanwezig, vergeleken met 70% 
aanwezigheid van deze antistoffen in RA patiënten.
remissie, medicatie vrije remissie en schade progressie
Na 4 maanden behandeling met MTX en prednison bereikten 61% van de patiënten remissie 
(vroege remissie), waarbij de remissie percentages niet verschilden tussen RA en UA patiën-
ten (hoofdstuk 3). Negenentwintig procent van de patiënten bereikten geen vroege remissie 
en werden gerandomiseerd, 83 in arm 1 (MTX, SSZ, HCQ en lage dosering prednison) en 78 
in arm 2 (MTX en adalimumab), en 50 (8%) patiënten bereikten geen remissie maar werden 
niet gerandomiseerd volgens het studieprotocol (hoofdstukken 3 en 4). Zeventien van deze 
patiënten waren volgens de reumatoloog klinisch in remissie, waarna werd gestart met het 
afbouwen van prednison. In de overige patiënten werd het protocol om verschillende andere 
redenen niet gevolgd.
Na een jaar waren van alle patiënten 54% in remissie en 20% zelfs in medicatie vrije remis-
sie. In slechts 5% van de patiënten was radiologische progressie aanwezig. Met een mediane 
Sharp van der Heijde progressie score (SHS) van 1 was de mate van progressie minimaal. 
Slechts 1 patiënt had een progressie score ≥ 5 (18 punten). Er waren geen verschillen tus-
sen patiënten met UA en RA. Patiënten die na 4 maanden remissie bereikten, waren na 1 
jaar het meest frequent in remissie (68%). Van hen behaalden 32% medicatie vrije remissie. 
Patiënten die gerandomiseerd waren voor behandeling met MTX en adalimumab bereikten 
vaker remissie na 1 jaar dan patiënten die gerandomiseerd waren voor MTX, SSZ, HCQ en 
lage dosering prednison (41% versus 25%). De hoeveelheid radiologische schade na 1 jaar 
verschilde niet tussen de randomisatie armen.
Vergeleken met eerder onderzoek worden remissie en medicatie vrije remissie in het eerste 
jaar van de IMPROVED studie in hoge percentages bereikt en wordt radiologische progressie 
zeer goed onderdrukt. In enkele voorgaande studies zijn vergelijkbaar hoge remissie percen-
tages bereikt, maar medicatie is in deze studies niet afgebouwd dan wel gestopt. Wel zijn 
over het algemeen patiënten met een hogere ziekte activiteit geïncludeerd. Medicatie vrije 
remissie is in eerdere studies beschreven in 17-29%, maar nooit eerder zijn deze percentages 
binnen 1 jaar na het starten van medicatie bereikt.
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De resultaten kunnen worden verklaard door de intensieve, remissie gestuurde behande-
ling, die patiënten in de IMPROVED studie al vroeg in het ziektebeloop hebben gekregen. In 
voorgaand onderzoek zijn de positieve effecten van behandeling met lage dosering predni-
son ten opzichte van placebo in RA patiënten aangetoond, evenals de positieve effecten van 
combinatie therapie met lage dosering prednison ten opzichte van monotherapie. De recent 
gepubliceerde, gerandomiseerde en placebo gecontroleerde CAMERAII studie toont tevens 
aan dat remissie gestuurde behandeling met MTX en lage dosering prednison superieur is 
aan MTX monotherapie, waarbij het bereikte percentage remissie na 2 jaar vergelijkbaar is 
met het behaalde percentage remissie na 1 jaar in de IMPROVED studie.
Maar er zijn meerdere verklaringen mogelijk voor onze resultaten. Omdat patiënten vroeg 
in het ziektebeloop en met een relatief lage ziekte activiteit zijn geïncludeerd, wordt het 
behandeldoel remissie (ofwel een DAS < 1.6) wellicht makkelijker bereikt en is schade pro-
gressie misschien nog nauwelijks aanwezig. Ook kan de vroege inclusie hebben geleid tot 
deelname van patiënten die ook spontaan remissie zouden hebben bereikt, zonder enige 
vorm van behandeling.
In 2011 is door de ACR en EULAR een voorstel gedaan voor nieuwe remissie criteria in kli-
nische trials, omdat er tot dan toe geen uniforme definitie voor remissie voorhanden was en 
omdat een aantal huidige definities eerder lage ziekteactiviteit dan remissie vertegenwoor-
digen. Een van de twee voorgestelde definities is de zogenaamde ‘Boolean based’ definitie. 
In de IMPROVED studie bereikten na 4 maanden en na 1 jaar respectievelijk 26% en 24% 
van de patiënten remissie volgens deze definitie (hoofdstukken 3 en 4). Het merendeel van 
de patiënten die in remissie waren volgens de DAS definitie maar niet volgens de Boolean 
based definitie, bereikten geen remissie omdat de visueel analoge schaal (VAS) voor globale 
ziekte activiteit als enig criterium verhoogd was ( ≥ 10 mm op een schaal van 100 mm). Ver-
gelijkbare resultaten zijn recentelijk ook in de DREAM studie gezien, waarbij een deel van 
deze patiënten klinisch wel in remissie bleken te zijn. De Boolean based definitie lijkt dus een 
striktere definitie te zijn dan de DAS definitie, maar is wellicht te strikt, waardoor een deel van 
de patiënten die klinische in remissie zijn, wellicht volgens deze definitie niet in remissie zijn.
geen remissie tijdens het eerste studie jaar
Ondanks goede resultaten in het merendeel van de patiënten, bereikten 16% van de pa-
tiënten op geen enkel moment tijdens het eerste studie jaar remissie, zoals beschreven in 
hoofdstuk 4. Deze patiënten werden gekenmerkt door een hogere ziekte activiteit aan het 
begin van de studie (gemiddelde DAS 3.7 (0.9) versus 3.2 (0.9)), een langere symptoomduur 
(mediane duur 24 (12-44) versus 17 (8-31) weken) en ze waren vaker vrouw (89% versus 63%) 
vergeleken met patiënten die een of meerdere keren remissie bereikten. Wellicht hadden 
deze patiënten baat gehad bij het starten van behandeling in een vroegere fase of bij andere 











Resultaten in hoofdstuk 5 laten zien dat het dagelijks functioneren (gemeten met de Health 
Assessment Questionnaire, HAQ) en de ziekte gerelateerde kwaliteit van leven (gemeten met 
de Short Form-36, SF-36) in deze populatie met vroege artritis lager is dan in de normale 
populatie. Ziekte gerelateerde kwaliteit van leven kan onderverdeeld worden in mentale en 
fysieke gezondheid, waarbij alleen de fysieke component aangedaan bleek te zijn in patiën-
ten in de IMPROVED studie. Na 1 jaar behandeling waren zowel het dagelijks functioneren 
als de fysieke gezondheid in de totale studie groep verbeterd. De grootste verbetering vond 
plaats in patiënten die vroege remissie bereikten, waarbij na 1 jaar gemiddelde waarden 
gemeten werden die vergelijkbaar waren met die in de normale populatie. In gerandomi-
seerde patiënten werd geen verschil gezien tussen de randomisatie armen. Het bereiken van 
remissie gedurende het eerste jaar was geassocieerd met beter dagelijks functioneren en 
betere ziekte gerelateerde kwaliteit van leven. Concluderend leidt het bereiken van remissie 
en in het bijzonder van vroege remissie, tot de grootste verbetering en in een deel van de 
patiënten zelfs tot normalisatie van dagelijks functioneren en ziekte gerelateerde kwaliteit 
van leven in patiënten met vroege RA.
Resultaten in hoofdstuk 7 laten zien dat patiënten met vroege artritis weinig depressieve 
symptomen hebben. De ernst van depressieve symptomen daalde wanneer patiënten een 
lagere ziekte activiteit hadden en het behalen van remissie resulteerde in significant minder 
depressieve klachten. Depressieve klachten traden voornamelijk op door symptomen van 
artritis, zoals pijn en malaise. Dit suggereert dat depressieve symptomen het beste kunnen 
worden tegengegaan door het optimaal behandelen van symptomen van artritis.
afname van metacarpale botdichtheid
Viermaandelijkse metingen van botmineraaldichtheid (BMD) in de metacarpalen tijdens 
het eerste jaar van de IMPROVED studie suggereren dat ruim de helft van de patiënten een 
afname van metacarpale BMD had (metacarpaal BMD verlies) na 4 maanden en na 1 jaar 
(respectievelijk 56% en 55%) (hoofdstuk 9). Mogelijk was er bij sommige patiënten ook sprake 
van een toename van metacarpaal BMD na 1 jaar (14% van de patiënten). Aangezien deze 
resultaten gebaseerd zijn op geïmputeerde data en de geobserveerde verschillen soms klein 
zijn, dienen ze met voorzichtigheid geïnterpreteerd te worden.
Het feit dat mogelijk ruim de helft van de patiënten met vroege artritis, ondanks een 
relatief lage ziekte activiteit, metacarpaal BMD verlies had na 4 maanden van vroege en 
intensieve behandeling, kan wellicht verklaard worden door de tijdelijke hoge dosering 
prednison waarmee ze behandeld zijn. Slechts een kleine deel van de patiënten (13%) leek 
het totale verlies (of meer) tijdens de daarop volgende maanden weer te herwinnen. Uit data 
met een langere follow up duur zal duidelijk moeten worden of het metacarpaal BMD verlies 
zich ook bij de overige patiënten nog hersteld. Ook de initiële ziekte activiteit kan hebben 
bijgedragen aan het hoge percentage patiënten met metacarpaal BMD verlies, hoewel de 
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resultaten suggereren dat ziekte activiteit bij aanvang van de studie geen voorspeller is van 
metacarpaal BMD verlies na 4 maanden.
Patiënten die na 4 maanden vroege remissie bereikten en medicatie afbouwden, leken na 1 
jaar meer metacarpaal BMD verlies te hebben dan patiënten die werden gerandomiseerd. Dit 
kan verklaard worden door de intensieve combinatie therapie met lage dosering prednison 
dan wel met adalimumab, waarmee gerandomiseerde patiënten werden behandeld. Maar 
ook het feit dat patiënten die vroege remissie bereikten medicatie afbouwden, en dat een 
deel van hen remissie verloor, kan hebben bijgedragen.
Hoewel gebaseerd op kleine aantallen patiënten, suggereren de resultaten dat met ada-
limumab behandelde patiënten het kleinste metacarpaal BMD verlies hadden en het meest 
frequent een toename van metacarpale botdichtheid na 1 jaar (54%, vergeleken met 21% 
van de gerandomiseerde patiënten behandeld met combinatie therapie met lage dosering 
prednison en 12% van de patiënten in vroege remissie). Dit is in lijn met eerder onderzoek, 
waaruit is gebleken dat behandeling met anti-TNF-α middelen mogelijk gegeneraliseerde en 
lokale afname van botdichtheid remt.
bijwerkingen
Na 4 maanden behandeling met MTX en prednison werden in 56% van de IMPROVED 
patiënten bijwerkingen gerapporteerd (hoofdstuk 3). De meeste bijwerkingen waren mild 
en tijdelijk van aard, maar in 3% van de patiënten was er sprake van ernstige bijwerkingen. 
Twee patiënten overleden, een ten gevolge van een pneumonie (waarvoor patiënte niet 
behandeld wenste te worden) en een ten gevolge van een myocard infarct, dat bij obductie 
veroorzaakt bleek te zijn door een reuscel arteriitis van de coronair arteriën. Veertien van 
de 16 ernstige bijwerkingen werden mogelijk veroorzaakt door prednison (infecties, hart en 
vaat ziekten, kopnecrose van de heup, diabetische complicaties).
Na 1 jaar behandeling in de IMPROVED werden in 57% van de patiënten bijwerkingen ge-
rapporteerd (hoofdstuk 4). In patiënten die vroege remissie bereikten en vervolgens medica-
tie afbouwden, werden de minste bijwerkingen gerapporteerd (53%). Er werd geen verschil 
gezien in bijwerkingen tussen de randomisatie armen (74% in arm 1 and 68% in arm 2). In 
4% van de patiënten vonden ernstige bijwerkingen plaats. Drie patiënten overleden, allen 
ten gevolgen van een maligniteit: een plaveiselcel carcinoom van de tong (vroege remissie 
groep), een hersentumor (arm 2: MTX+adalimumab) en een ovariumcarcinoom (in vroege 
remissie maar niet gerandomiseerd volgens protocol). Ernstige mogelijk aan prednison ge-
relateerde bijwerkingen waren: pneumonie, hersentumor, percutane coronaire interventie in 
verband met een hartinfarct, exacerbatie van ‘chronic obstructive pulmonary disease’ (COPD) 
op basis van een luchtweginfectie en een cerebrovasculair accident (CVA).
Concluderend lijkt de initiële behandeling met MTX en prednison op korte termijn veilig te 
zijn. In het vervolg van de IMPROVED studie zullen ook lange termijn gevolgen van prednison 










termijn complicaties laten zien van kortdurende behandeling met lage dosering prednison. 
Verder suggereren de resultaten dat er geen verschil in bijwerkingen is tussen behandeling 
met een combinatie van DMARDs met een lage dosering prednison en behandeling met MTX 
in combinatie met adalimumab.
bePerkingen Van de imProVed studie
Om de grootte van de studie te beperken, is er in de IMPROVED studie geen controle groep 
geïncludeerd om uitkomsten van de initiële behandeling met MTX en prednison te kunnen 
vergelijken met placebo. In voorgaand onderzoek is aangetoond dat combinatie behande-
ling met MTX en prednison zeer effectief is in patiënten met RA. Daarom is ervoor gekozen 
om de optimale vervolg strategie te onderzoeken in een gerandomiseerde vervolg fase van 
het onderzoek. Door het ontbreken van een controle groep kan er geen uitspraak worden 
gedaan over hoeveel patiënten zonder behandeling remissie zouden hebben bereikt.
Wegens praktische redenen zijn alleen de onderzoeksverpleegkundigen, die viermaande-
lijkse uitkomsten zoals DAS en HAQ evalueerden, geblindeerd voor de gegeven behandeling. 
Artsen en patiënten waren zich hiervan wel bewust. Kort na de introductie van biologicals 
is in de BeSt studie beschreven dat patiënten een voorkeur hadden voor behandeling met 
een biological en een afkeur tegen prednison. Resultaten van de IMPROVED studie zouden 
dus vertekend kunnen zijn door het feit dat patiënten en artsen op de hoogte waren van de 
gegeven behandeling. Patiënten weigerden echter zelden de medicatie waarvoor zij geloot 
hadden.
In de IMPROVED studie is remissie gedefinieerd als een DAS <1.6. Voorgaand onderzoek 
heeft aangetoond dat deze definitie correspondeert met de in 1981 door de ACR opge-
stelde criteria voor klinische remissie. Er wordt echter gedacht dat een DAS <1.6 eerder lage 
ziekteactiviteit dan remissie representeert, omdat patiënten die aan deze definitie voldoen 
maximaal twee gezwollen of pijnlijke gewrichten kunnen hebben. De in 2011 voorgestelde 
nieuwe definities voor remissie zijn na het starten van de IMPROVED studie gepubliceerd. In 
de toekomst is meer onderzoek nodig naar de validiteit van de nieuwe definities en zal moe-
ten blijken of de verschillende definities gepaard gaan met verschillen in ziekte-uitkomsten 
zoals dagelijks functioneren en radiologisch schade progressie.
Tot slot is tijdens het eerste jaar van de IMPROVED studie relatief frequent afgeweken van 
het studieprotocol. Dit is waarschijnlijk veroorzaakt door het feit dat de geprotocolleerde 
behandeling van studie patiënten is geïntegreerd in de dagelijkse klinische praktijk. De 
behandelende reumatologen waren het soms oneens met de DAS verricht door de onder-
zoeksverpleegkundige, of beoordeelden dat de DAS verhoogd was door een andere oorzaak 
dan ziekteactiviteit van RA. In dat geval weken ze af van het studie protocol omdat de patiënt 
klinisch in remissie was. Ook het feit dat behandeling gestuurd werd op een DAS <1.6 kan 
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hebben geleid tot protocol afwijkingen, bijvoorbeeld omdat een arts aarzelde om medicatie 
aan te passen als de DAS slechts minimaal hoger of lager dan 1.6 was.
Vijftig patiënten zijn na 4 maanden niet in een behandelgroep worden ingedeeld omdat 
ze geen remissie bereikten maar ook niet volgens protocol gerandomiseerd werden. Ze zijn 
daarom als aparte groep geanalyseerd. Ziekte-uitkomsten in deze groep patiënten waren 
na 1 jaar vergelijkbaar met patiënten in arm 1 (DMARDs en een lage dosering prednison), 
maar waren wellicht beter geweest wanneer deze patiënten wel volgens protocol waren 
behandeld.
ua Versus ra
Naar verwachting hebben UA patiënten een kortere symptoomduur en bereiken ze vaker 
remissie dan patiënten met vroege RA. De symptoomduur van UA en RA patiënten ten tijde 
van inclusie in de IMPROVED was echter vergelijkbaar (mediane duur 16 (8-28) versus 18 
(9-34) weken). Vierenzestig procent van de UA patiënten en 66% van de RA patiënten hadden 
een symptoomduur langer dan 12 weken. Volgens de zogenaamde ‘window of opportunity’ 
theorie kan de juiste behandeling tijdens de ‘window of opportunity’, waarvan is geopperd 
dat deze de eerste 12 weken na het ontstaan van klachten beslaat, voorkomen dat klachten 
chronisch worden en de ziekte destructief wordt.
Ondanks het feit dat UA patiënten bij inclusie een lagere ziekteactiviteit hadden vergele-
ken met RA patiënten en dat autoantistoffen in bijna alle UA patiënten afwezig waren, waren 
er geen verschillen in percentages remissie, medicatie vrije remissie en radiologische schade 
progressie na 1 jaar (hoofdstukken 3 en 4). Naast het feit dat de ‘window of opportunity’ in de 
meeste patiënten wellicht gemist is, kunnen sommige UA patiënten ook andere reumatische 
aandoeningen hebben gehad die niet op de gegeven therapie reageerden.
antistoffen tegen gecitrullineerde eiwitten
De aanwezigheid van ACPA in patiënten met RA is geassocieerd met een hogere ziekteacti-
viteit, meer beperkingen in het dagelijks functioneren en meer gewrichtsschade. Daarom is 
het verrassend dat patiënten met en zonder aanwezigheid van ACPA even frequent remissie 
en medicatie vrije remissie na 1 jaar bereikten (hoofdstuk 6). Ook waren er geen verschillen 
in dagelijks functioneren en radiologische schade progressie. Na 4 maanden behandeling 
met MTX en prednison bereikten ACPA positieve patiënten zelfs vaker remissie dan ACPA 
negatieve patiënten (hoofdstuk 3). Dit zou kunnen betekenen dat ACPA positieve patiënten 
meer baat hebben bij deze behandeling. Eerder hebben resultaten van de PROMPT studie het 










tieve UA patiënten. Alleen in ACPA positieve patiënten werd de progressie naar RA uitgesteld 
en radiologische schade progressie onderdrukt. Dit zou kunnen betekenen dat verschillende 
pathologische mechanismen ten grondslag liggen aan de gewrichtsontstekingen in ACPA 
positieve en negatieve patiënten.
Van de patiënten die na 4 maanden remissie bereikten, en volgens het protocol na een jaar 
medicatie vrije remissie konden bereiken, bereikten 32% dit ook daadwerkelijk (hoofdstuk 
6). Hiervan was 55% ACPA positief, vergeleken met 61% van de patiënten in vroege remissie 
die geen medicatie vrije remissie bereikten na 1 jaar (geen significant verschil). Wel waren 
patiënten die medicatie vrije remissie na 1 jaar bereikten minder vaak RF positief (50% versus 
62%). In de 4 maanden na het bereiken van medicatie vrije remissie, verloren 30% van de 
patiënten (medicatie vrije) remissie. Deze patiënten waren vaker ACPA positief dan patiënten 
die medicatie vrije remissie behielden (72% versus 47%), en ACPA positieve patiënten waren 
minder vaak in staat medicatie vrije remissie 4 maanden te behouden dan ACPA negatieve 
patiënten (58% versus 80%). Deze resultaten kunnen betekenen dat, met de huidige be-
handelstrategie, ACPA positieve en negatieve patiënten even frequent remissie bereiken en 
tijdens het afbouwen van medicatie remissie even goed behouden, maar dat ACPA positieve 
patiënten medicatie vrije remissie minder goed behouden dan ACPA negatieve patiënten.
metacarPaal bmd Verlies als VoorsPeller Van radiologische 
schade
Het voorspellen van de ernst van het ziektebeloop van patiënten met RA kan de keuze van 
behandeling beïnvloeden. Hiermee kan zowel overbehandeling, met onnodige bijwerkingen 
als gevolg, als onderbehandeling met onnodige gewrichtsschade als gevolg, voorkomen 
worden. Het is tegenwoordig echter nog niet mogelijk om bij alle patiënten een nauwkeurige 
voorspelling van het ziektebeloop te geven. Daarom is er vraag naar nieuwe voorpellers van 
ziektebeloop die al in een vroege fase aanwezig zijn.
De mate van metacarpaal BMD verlies tijdens de eerste 4 maanden van de IMPROVED studie 
was voorspellend voor radiologische schade progressie na 1 jaar (hoofdstuk 8). Radiologische 
schade progressie na 1 jaar was aanwezig in 28 (7%) patiënten van de onderzochte subgroep 
uit de IMPROVED studie. Patiënten met radiologische progressie na 1 jaar hadden vaker me-
tacarpaal BMD verlies in de eerste 4 maanden dan patiënten zonder schade progressie na 1 
jaar (86 versus 53%). Naast metacarpaal BMD verlies tijdens de eerste 4 maanden was ook de 
aanwezigheid van erosies bij aanvang van de studie voorspellend voor gewrichtsschade. In 
86% van de patiënten waren echter geen erosies bij aanvang van de studie aanwezig, terwijl 
17 van deze patiënten na 1 jaar wel radiologische schade progressie bleken te hebben (63% 
van de 28 patiënten met schade progressie na 1 jaar). In deze patiënten is metacarpaal BMD 
verlies na 4 maanden de enige voorspeller voor schade.
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Bij voorkeur is een voorspeller zo vroeg mogelijk in het ziektebeloop aanwezig, het liefst 
reeds op het moment dat de diagnose wordt gesteld. Voorheen bekende voorspellers, zoals 
de aanwezigheid van ACPA, RF en een verhoogde bezinking of C-reactive protein (CRP), 
bleken in deze populatie met vroege artritis echter niet voorspellend te zijn voor toekom-
stige schade, evenmin als het behalen van remissie na 4 maanden. Dit kan worden verklaard 
doordat radiologische schade goed onderdrukt werd door de huidige behandelstrategie of 
doordat in deze vroege populatie überhaupt nog weinig schade progressie aanwezig was. 
Dus ondanks het feit dat metacarpaal BMD verlies pas na 4 maanden wordt bepaald, kan het 
in de klinische praktijk een toegevoegde waarde hebben in het voorspellen van gewrichts-
schade in patiënten met vroege RA. Toevoeging van deze voorspeller aan bestaande predic-
tie modellen zou deze kunnen verbeteren, met als doel om in de toekomst beslissingen ten 
aanzien van behandeling vroeg in het ziektebeloop te kunnen sturen.
toekomstPersPectieVen
De resultaten in dit proefschrift suggereren dat met de huidige behandelstrategie ziekte-
uitkomsten daadwerkelijk zijn verbeterd in een vroege fase van RA. Meer patiënten bereik-
ten remissie en medicatie vrije remissie vroeger in het ziektebeloop dan ooit te voren en 
radiologische schade progressie deed zich nauwelijks voor. Toekomstige resultaten van de 
IMPROVED studie geven antwoord op de vragen of en hoe lang medicatie vrije remissie kan 
worden behouden, of medicatie vrije remissie ook kan worden bereikt in patiënten die geen 
vroege remissie behaalden, of radiologische schade progressie ook na een langere periode 
nagenoeg afwezig blijft en wat de beste vervolg behandeling is voor patiënten die geen 
remissie bereikten na 1 jaar.
Na het eerste studie jaar bereikten ruim de helft van de patiënten remissie, en ruim 20% 
was zelfs in medicatie vrije remissie. Om deze uitkomsten in het merendeel, of zelfs in alle 
patiënten te bereiken, behoeven de huidige behandelstrategieën verdere optimalisatie. 
Toekomstig onderzoek zal moeten uitwijzen wat het optimale tijdstip is om te starten met 
behandeling. Wellicht bevindt dit tijdstip zich al binnen twaalf weken na aanvang van symp-
tomen. Zo vroeg starten met behandeling brengt echter het risico van overbehandeling met 
zich mee. Afbouwen van medicatie zodra remissie is bereikt kan het risico op schade door 
overbehandeling zo veel mogelijk reduceren.
Over het algemeen wordt aangenomen dat remissie als behandeldoel leidt tot betere 
uitkomsten dan lage ziekteactiviteit als behandeldoel, wat lijkt te worden te onderschreven 
door de resultaten in dit proefschrift. Er is echter nooit een gerandomiseerde studie gedaan 
waarin streven naar beide doelen met elkaar is vergeleken. Totdat een dergelijk onderzoek 
is gedaan kan een definitieve uitspraak over eventuele voordelen van sturen op remissie ten 










Het tijdelijk toevoegen van prednison aan behandeling met een of meerdere DMARDs kan 
de nieuwe hoeksteen worden van de behandeling van RA. Eerder onderzoek heeft laten zien 
dat combinatie behandeling met prednison even effectief is als combinatie behandeling met 
een biological, maar prednison is een veel goedkoper alternatief met wellicht een lagere 
kans op bijwerkingen. De optimale dosering en duur van de prednison behandeling is echter 
nog niet vastgesteld. Ook zal toekomstig onderzoek uitvoeriger moeten bevestigen dat 
de lange termijn bijwerkingen van kortdurende behandeling met lage dosering prednison 
waarschijnlijk verwaarloosbaar zijn.
De huidige resultaten suggereren dat patiënten die geen remissie bereiken na de initiële 
behandeling met MTX en prednison, frequenter remissie bereiken wanneer vervolg behan-
deling met adalimumab direct wordt gestart dan wanneer adalimumab pas wordt gestart 
na falen op een uitbreiding van DMARDs. Of ook medicatie vrije remissie frequenter wordt 
bereikt en radiologische schade progressie minder frequent optreed, moet nog worden be-
zien. Mocht dit het geval zijn, dan zou combinatie behandeling met adalimumab de optimale 
vervolg stap zijn in patiënten die geen remissie bereiken na initiële behandeling met MTX en 
prednison.
Om het ziekte beloop van zoveel mogelijk patiënten adequaat te kunnen voorspellen, 
gaat de zoektocht naar nieuwe voorspellers van ziekte-uitkomsten onverminderd door. 
Metacarpaal BMD verlies kan bijdragen aan een betere voorspelling van het ziekte beloop 
en hierdoor ook aan het vinden van de best passende behandeling voor iedere individuele 
patiënt.
Concluderend suggereren de resultaten in dit proefschrift dat de huidige behandelstrate-
gie, waarin combinatie behandeling vroeg in het ziektebeloop wordt gestart en behande-
ling gestuurd wordt op remissie, heeft bijgedragen aan de hoge percentages remissie en 
medicatie vrije remissie en het nagenoeg afwezig zijn van radiologische schade na 1 jaar in 
patiënten met vroege (reumatoïde) artritis. Er blijft echter ruimte voor verbetering van de 
huidige behandelstrategieën, met als ultiem doel om deze uitkomsten in de toekomst te 
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